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 This thesis dissertation research has aimed to develop novel protein therapeutics 
with potential to treat neurological diseases for which there are currently limited available 
treatments and no cures including Parkinson’s disease and neuronopathic Gaucher’s 
disease.  Although the individual chapters of this thesis had varied goals, all involved 
designing and expressing recombinant proteins, purifying the proteins, facilitating 
targeted and efficient protein delivery, and demonstrating in vitro activity. 
The effective targeting of neuronal cell types requires effective delivery 
strategies.  As a result, initial thesis work focused on the evaluation of cell-penetrating 
peptides (CPPs) and receptor-dependent neuronal membrane binding proteins to improve 
protein delivery.  This work led to the discovery of a novel protein delivery vector, Tat-
Tetanus Toxin Fragment C (Tat-TTC), a highly neuron-specific domain capable of 
dramatically enhancing the binding and internalization of recombinant proteins.  Both 
fluorescent microscopy and quantitative fluorimetry were utilized to demonstrate that, 
with Tat-TTC, model protein GFP was bound and internalized by neuronal cell types at 
least an order of magnitude better than Tat-GFP or TTC-GFP alone.  Since the Tat-TTC 
protein delivery vector was endocytosed, this research project addressed the issue of 
endosomal entrapment of cargo protein.  Photochemical internalization (PCI) was used to 
facilitate the endosomal release of Tat-TTC-linked cargo presenting the option of using 
the delivery vector to target endosomes/lysosomes or cytosolic or nuclear intracellular 
targets.   
 Cell-penetrating peptide Tat and PCI were next utilized in the design, production, 
and delivery of recombinant transcription factors Mash1, Lmx1a, and Nurr1 intended for 
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neuronal differentiation.  These transcription factors had been shown to transdifferentiate 
human fibroblasts to dopaminergic neurons (Caiazzo et al., 2011), the cell type lost in 
Parkinson’s disease (PD) (Thomas, 2010).  We hypothesized that direct protein delivery 
of Tat-linked transcription factors had the potential to generate dopaminergic neurons 
that would be safe for clinical cell-replacement therapy.  Four transcription factors, Tat-
Mash1, Tat-Mash1-GFP, Tat-Lmx1a, and Tat-Lmx1a-GFP were successfully expressed 
and purified from insoluble HEK293F cell lysate.  The transcription factors were 
delivered to cells and endosomal escape was facilitated with PCI.  Induction of promoter-
reporter constructs with purified protein was limited, a finding which led us to question 
the bioactivity of the resolubilized factors.  To address this issue, a cell-free mammalian 
expression system capable of producing high concentrations of soluble transcription 
factor was identified.  In the future, this strategy could prove invaluable for transcription 
factor production.  
 Research into novel PD therapies led to my strong interest in Gaucher’s disease 
(GD).  Mutations in the GBA1 gene encoding lysosomal enzyme glucocerebrosidase 
(GCase), leading to GD, has recently been shown to represent the greatest genetic risk 
factor for PD (Siebert et al., 2014).  There is currently no available treatment for the 
neuronopathic type 2 and type 3 forms of GD.  I aimed to develop a neuron-targeted 
recombinant GCase with the potential to cross the blood-brain barrier (BBB).  Since the 
target for delivered protein was the lysosome, protein delivery vectors taken up by 
endocytosis were predicted to work well for GCase delivery, without any need for PCI.  
Seventeen GCase variants were designed and expressed in combination with a variety of 
protein delivery vectors.  Cell-based assays using a GCase-knockout neuronal cell line 
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facilitated the identification of a rabies-derived peptide (RDP) linked GCase utilizing an 
IgA hinge linker region to remove steric hindrance by GCase on RDP.  RDP-IgAh-GCase 
was shown to target GCase-knockout neurons ~2.5X better than Tat-GCase.  Both RDP-
IgAh-GCase and Tat-GCase reduced substrate glucosylsphingosine accumulation to wild-
type levels with 72 hours of protein treatment, indicating the enzymes were appropriately 
trafficked to lysosomes and functional.    
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Thesis Committee Chair: Dr. Kevin Yarema 
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Chapter 1: Introduction 
 Derived from, or consisting of living entities, biologics are under widespread 
development for therapeutic use in the pharmaceutical industry.  Contrary to traditional 
small molecule drugs, biologics are considerably less well-defined.  They are a diverse 
class that can include gene therapeutic agents, proteins, or live cells.  Recombinant proteins 
constitute most of the FDA-approved biologics.  While direct protein delivery can have a 
powerful effect on phenotype, the effects are not permanent.  As a result, protein delivery 
is widely considered to be safer than gene or cell-based approaches.   
 The motivation for this doctoral research was the development of recombinant 
proteins to enable new therapeutic strategies for diseases affecting the brain.  With this goal 
in mind, I describe the design, development, and delivery of a novel neuronal cell type-
specific protein delivery vector, a set of purified transcription factors for cell 
differentiation, and a neuron-targeted recombinant glucocerebrosidase (GCase) enzyme for 
neuronopathic Gaucher’s disease (GD) treatment.  While numerous challenges associated 
with the development of recombinant proteins exist, delivery was a major focus for each 
of the above research endeavors.  Furthermore, design, production, and purification were 
addressed for each of the individual research goals.  These three parameters had variable 
impacts on a protein-specific basis that will be discussed.  
 The highest profile, and most recent, achievement of this thesis research was the 
development of rabies derived-peptide (RDP) linked GCase containing a linker region from 
the IgA hinge domain (RDP-IgAh-GCase), the first neuron-targeted glucocerebrosidase.  
Although this recombinant enzyme neither utilized Tat-Tetanus Toxin Fragment C (Tat-
TTC, Chapter 2) nor faced the challenges associated with transcription factor delivery 
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(Chapter 3), its development was successful as a result of experience gained in those two 
projects.  The discovery of Tat-TTC provided a base that was extensively built upon during 
the screening of GCase variants employing numerous receptor-independent cell-
penetrating peptides and receptor-dependent toxin and virus-derived protein delivery 
vectors.  The goal set out in Chapter 3, to create a collection of recombinant Tat-linked 
transcription factors to promote neuronal differentiation, was never fully achieved.  
However, the assay development work to test transcription factor biological activity later 
served as the primer for some of the GCase functionality testing.   
1.1. Protein Delivery Vectors 
Protein delivery vectors can be both receptor-independent and receptor-dependent 
and serve to target cargo proteins to a large variety of cellular compartments.  Both classes 
of these vectors have been used in neuronal delivery although their mechanism, specificity, 
and capacity differ considerably.   
1.1.1 Cell-penetrating peptides 
Cell-penetrating peptides (CPPs) are short cationic peptides capable of penetrating 
the cell membrane in a receptor-independent manner (DeShayes et al., 2005).  CPPs have 
been derived from a number of naturally occurring biological sources.  The mechanism of 
CPP uptake has been extensively debated, especially whether or not the process is energy-
dependent.   
The first CPP discovered was Tat, an arginine and lysine-rich peptide derived from 
the HIV protein Tat (trans-activator of transcription).  Frankel and Pabo, at The Johns 
Hopkins School of Medicine, unexpectedly discovered the membrane-penetrating ability 
of the intact purified Tat protein when attempting to develop a trans-activation assay for 
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Tat itself.  When Tat was added to the extracellular medium of HL3T1 cells, expression of 
a reporter gene increased linearly with Tat dose, an unexpected result. This result was 
surprising because Tat were not predicted to enter the cell at all.  Uptake was enhanced by 
lysosomotrophic agent chloroquine, indicating that membrane disruption increased the 
efficiency of the process (Frankel et al., 1988).  The implications of this discovery for 
protein delivery were quickly identified and research began to determine exactly how much 
and what portion of the 86 amino acid Tat protein was necessary for membrane 
translocation.  Initially, it was found that Tat amino acids 35-62 contained the region of 
interest (Anderson et al., 1993).  Soon after, Fawell and colleagues recommended amino 
acids 37-72 for optimal delivery, although they found that regions 37-58 and 47-58 were 
also sufficient (Fawell et al., 1994).  Other research groups confirmed that either 47-58 
(Pepinsky et al, 1994) or 48-60 (Vivès et al, 1997) were effective.  In the 48-60 sequence, 
it was found that any changes to the basic amino acids reduced membrane translocation 
potential (Vivès et al, 1997).  It was later determined that amino acids 49-57, peptide 
sequence RKKRRQRRR, represented the shortest Tat-based peptide useful for cellular 
uptake.  Although charge alone was not enough to reproduce this effect, polyarginine (R9) 
was found to be a very efficient CPP (Wender et al., 2000).  The Tat CPP was shown to 
deliver proteins in a cell-type independent manner.  β-galactosidase, a 120 kDa protein, 
was delivered across the blood-brain barrier (BBB) using Tat (Schwarze et al., 1999).   
Over the years, the mechanism for Tat uptake has been controversial.  It was 
initially reported that Tat and polyarginine were taken up directly into the cytosol by an 
energy-independent and unknown mechanism.  However, it was later determined that even 
mild cell fixation led to artifactual uptake and that live cell imaging showed endosomal 
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Tat-linked cargo protein distribution (Richard et al., 2003).  It is now generally accepted 
that Tat interacts electrostatically with cell surface proteoglycans (Heitz et al., 2009) and 
is internalized by receptor-independent lipid raft-dependent macropinocytosis (Kaplan et 
al., 2004; Wadia et al., 2004).   
Although Tat and polyarginine are the most common CPPs used for protein 
delivery, a number of other protein-derived CPPs exist including transportan, penetratin, 
and VP22.  Transportan is a 27 amino acid synthetic CPP consisting of a 13 amino acid N-
terminal fragment of neuropeptide galanin and a 14 amino acid fragment of mastoparan, a 
wasp venom peptide toxin (Pooga et al., 1998).  Penetratin is a 16 amino acid portion of 
the homeodomain of Antennapedia that is also capable of crossing the cell membrane.  The 
16 amino acid portion was found to be the minimal region capable of exhibiting the same 
penetrating properties as the entire 60 amino acid homeodomain (Derossi et al., 1994).  
VP22 is a 38 kDa structural protein of herpes simplex virus type 1 that can also freely 
penetrate the cell membrane; the C-terminal 34 amino acids were shown to be the critical 
portion of the molecule (Elliot et al., 1997).  Although these are the more commonly used 
CPPs, numerous others that have been naturally derived or engineered exist, including 
Koposi FGF, Syn B1, FGF-4, nuclear localization signals (NLS), anthrax toxin derivative 
254-amino acids peptide, diphtheria toxin binding domain, MPG, pep-1, WR peptide, and 
endotoxin A (Chauhan et al., 2007).   
Upon discovery, transportan, penetratin, and VP22 were reported to be taken up 
directly by energy-independent mechanisms (Derossi et al., 1994; Deshayes et al., 2005; 
Elliot et al., 1997; Pooga et al., 1998).  However, these early studies used cell fixation in 
their analysis; as a result, the internalization mechanisms may need to be revisited.  In live 
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cell imaging Penetratin was found to be taken up through macropinocytosis (Jones et al., 
2005; Maiolo et al., 2005).  It is possible that, even for a specific CPP, the mechanism of 
cellular uptake could differ with the presence of cargo.  It was found that, with live cell 
imaging, a R7 CPP could be taken up at 4ºC and observed as a diffuse signal in the cell, 
indicating that uptake could be direct.  However, with a cargo peptide, internalization was 
almost totally through endocytosis (Maiolo et al., 2005).   
Internalization of CPPs takes place quickly with maximum concentrations being 
reached in 1-3 hours, however, this can be slowed by the inclusion of cargo proteins (Jones 
et al., 2005; Zorko et al.; 2005).  There have been some quantitative comparisons of CPP 
internalization in which magnitude of uptake was affected by a peptide cargo.  In one study 
using FACS, the magnitude of uptake was compared with and without a cargo peptide.  
With the cargo peptide, polyarginine and transportan were taken up most efficiently, 
followed by penetratin and Tat.  Without the peptide cargo the order was polyarginine = 
penetratin > Tat = transportan.  However, penetratin and Tat were the least toxic, indicating 
that there are multiple factors to consider.  As anticipated based on the mechanism, uptake 
of all peptides studied was found to be cell-type independent (Jones et al., 2005).   
1.1.2 Receptor-dependent neuronal protein delivery vectors 
Tat and other CPPs have been used to deliver cargo proteins to neuronal cell types 
because they don’t require any specific receptor to bind.  The lack of receptor can be a 
disadvantage if the intent is to specifically target neurons.  Three neuronal protein delivery 
vectors have been utilized in this thesis: tetanus toxin fragment C (TTC), Tet1, and rabies-
derived peptide (RDP).  These delivery vectors vary in their size, binding affinity, and 
potential for in vivo delivery.   
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TTC is by far the largest of the neuronal binding domains, but it is also the best 
characterized.  TTC is the non-toxic 50 kDa binding domain derived from the C-terminus 
of the heavy chain of tetanus toxin.  It has been shown that TTC can enhance neuronal 
delivery of a cargo protein up to 1000x while retaining the retrograde transport and 
transsynaptic transport properties of tetanus toxin.  As a result, delivery of proteins to the 
CNS with TTC leads not only to better binding, but to better distribution as well (Francis 
et al., 2004).   
Gangliosides are sialic acid-containing glycosphingolipids that are present in 
neuronal membranes in high concentrations.  It has long been known that tetanus toxin 
binding to neuronal membranes was mediated by complex gangliosides, especially tri- and 
tetra-siaylated gangliosides such as GT1b (Rogers et al., 1981).  Many neuroblastoma cell 
lines, with the exception of N18-RE-105 and PC12, bind tetanus toxin poorly because they 
only express monosialogangliosides to which the toxin does not bind well (Walton et al., 
1988).  Tetanus toxin binds gangliosides in two binding pockets, the “W” lactose-binding 
site and the “R” sialic acid-binding site.  The Trp1289 and the Arg1226 are the key amino 
acids involved in the W and R binding pockets respectively (Chen et al, 2009).  In early 
research, it was hypothesized that tetanus toxin might also have a protein receptor; these 
receptors were much later found to be both the SV2A/B receptors (Yeh et al., 2010) and 
P15 (Calvo et al., 2012; Miana-Mena et al., 2002).  After cell binding with ganglioside and 
protein receptors, TTC is thought to be taken up via clathrin-mediated endocytosis (Calvo 
et al., 2012).  In fact, when TTC-GFP is delivered to neuronal cells, all fluorescent signal 
(if observed) is entrapped in vesicles and therefore not distributed throughout the cytosol 
(Gillmeister et al., 2011; Gramlich et al., 2013).   
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While the 50 kDa TTC is non-toxic, its large size has the potential to decrease 
protein expression.  Most importantly, TTC would be highly immunogenic as most 
individuals are immunized to tetanus toxin.  The Boulis Laboratory recognized a need for 
shorter peptides capable of mimicking TTC’s binding affinity.  Using a phage display 
assay, the 12 amino acid Tet1 peptide sequence HLNILSTLWKYR, was identified for its 
ganglioside-binding properties.  Tet1 does not have any direct homology to TTC.  The Tet1 
peptide has been found to bind trisialoganglioside GT1b and can mediate retrograde 
transport to the neuronal cell body.  Tet1 was found to bind differentiated PC12 cells, 
primary motor neurons, and dorsal root ganglion cells (Federici et al., 2007).  
Tet1 has only been used for neuronal targeting of cargo in a few applications.  The 
first application developed used Tet1-polyethylenimine (Tet1-PEI) to deliver nucleic acids 
to neuronal cells (Park et al., 2007).  Tet1 was also successfully used to deliver 
polymersomes to nerves in the inner ear (Zhang et al., 2012b).  To date, very limited protein 
delivery has been done using Tet1, although one recent paper investigated the feasibility 
of in vivo Tet1-mediated protein delivery using model protein GFP (Kassa et al., 2013).  
The Fishman laboratory was the first group to compare Tet1 protein delivery to TTC; 
unpublished results show that Tet1-GFP is bound and internalized significantly less than 
TTC-GFP (Mello et al., in preparation).  The most recent Tet1 application integrated Tet1 
into the capsid of an adenoviral vector, which improved transduction of motor neurons, 
decreased transduction of non-neuronal cells, and improved retrograde transport (Davis et 
al., 2015).   
RDP is the neuronal delivery vector derived from the rabies virus glycoprotein 
(RVG) that was found to be most useful for the neuron-targeting of glucocerebrosidase in 
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this thesis.  RVG is a 505 amino acid protein component of the rabies viral envelope that 
mediates neuron binding and internalization.  The full-length glycoprotein after translation 
is 524 amino acids but the first 19 amino acids constituting the signal peptide are removed 
during post-translational processing (Maillard et al., 2002).  All references to RVG amino 
acid sequences in the literature refer to the 505 amino acid glycoprotein.  RVG has two 
nerve binding regions consisting of amino acid sequences 189-214 and 330-357 (Fu et al., 
2013a).   
References to RDP peptides in the literature can be confusing, because effective 
delivery peptides have been derived from both of the aforementioned neuron-binding 
sequences.  To date, RVG-based delivery domains have been derived from amino acids 
175-203 (Kumar et al., 2007; Liu et al., 2009; Gao et al., 2014; Gong et al., 2012; Xiang et 
al., 2011) and amino acids 330-356 (Fu et al., 2012; Fu et al., 2013a; Fu et al., 2013b).  
These RVG-derived peptides vary for a number of parameters including the nerve-binding 
region used, the presence of a nine-arginine sequence, and the application.   
The first RVG-derived peptide was 41 amino acids long; it consisted of 29 amino 
acids derived from RVG sequence 175-203 and a R9 sequence connected by a 3 glycine 
linker.  The R9 sequence was included to facilitate siRNA binding.  Delivery of siRNA led 
to gene silencing in the brain, showing that this first RVG-derived peptide mediated 
delivery across the BBB (Kumar et al., 2007).  The specific RVG-derived sequence was 
inspired by a 1990 paper that demonstrated the peptide could inhibit bungarotoxin binding 
to the nicotinic acetylcholine receptor (nAChR) (Lentz et al., 1990).  The RVG-peptide 
alone was capable of crossing the BBB but because this peptide cannot bind siRNA, no 
comparison between delivery of RVG and RVG-R9 was done (Kumar et al., 2007).  The 
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RVG-derived 29 amino acid peptide was utilized without the R9 peptide for nanoparticle-
based gene delivery.  While it was originally assumed that RVG uptake was nAChR-
mediated, the nanoparticle delivery work showed that the GABA receptor also plays an 
important role.  Uptake of the nanoparticles was found to be energy-dependent and 
facilitated by a clathrin- and caveolae-mediated endocytosis (Liu et al., 2009).  Additional 
publications have also used this 29 amino acid RVG-derived peptide with (Gong et al., 
2012) and without (Gao et al., 2014) the R9 peptide to deliver nucleic acids to the brain.  
A 43 amino acid peptide has been used to deliver protein β-galactosidase (Xiang et al., 
2011). 
Literature references to the RDP peptide all come from one research group and refer 
to a 39 amino acid sequence consisting of 27 amino acids derived from RVG, a 3 glycine 
linker region, and a 9 arginine peptide.  The 27 amino acid peptide is RVG sequence 330-
356 (Fu et al., 2012).  RDP has been used to deliver several recombinant proteins including 
β-galactosidase, luciferase, brain-derived neurotrophic factor (BNDF) (Fu et al., 2012), 
GFP, and glial cell-derived neurotrophic factor (GDNF) (Fu et al., 2013b).  All RDP-linked 
proteins were constructed with a flexible GGGSGGGS linker region (Fu et al., 2012; Fu et 
al., 2013b).  Although not indicated in these publications, results in this thesis indicate that 
the linker region in RDP fusion proteins may be critical to biological activity (Chapter 4).  
RDP has also been used to deliver nucleic acids across the BBB (Fu et al., 2013a).  
Although the mechanism is not fully understood, RDP linked cargo proteins are thought to 
be taken up by clathrin-mediated endocytosis following GABA receptor binding (Fu et al., 
2013b).   
10 
 
Although receptor-dependent neuronal targeting proteins and peptides TTC, Tet1, 
and RDP were used in this thesis and introduced at length, other neuronal delivery vectors 
have been described in the literature.  KC2S, a 20 amino acid peptide derived from the loop 
2 segment of Ophiophagus hannah toxin b, has been shown to bind nAChR receptors with 
similar affinity as the Kumar et al. 29 amino acid RVG-derived peptide.  KC2S was shown 
to improve micelle-encapsulated drug delivery across the BBB (Zhan et al., 2010).  Also, 
in an analogous way TTC is used, the C-terminal 51 kDa binding domain of botulinum 
toxin can also be used as a neuronal delivery vector (Drachman et al., 2010).   
1.2. Photochemical Internalization (PCI) to Facilitate the Re-Distribution of 
Endocytosed Cargo Proteins 
The cell membrane is not the only barrier to intracellular biological activity of 
protein delivery vector-linked cargos.  As described at length in the previous section, after 
cell binding in a receptor-dependent or independent manner, most protein delivery vectors 
and their attached cargo are internalized via a variety of endocytotic mechanisms.  
Although CPPs do have the capability to escape endosomes following endocytosis, the vast 
majority of cargo proteins are sequestered in endosomal compartments and later trafficked 
to lysosomes for degradation.  Escape from endosomes is the rate-limiting step in the 
delivery of CPP-linked macromolecules (El Sayed et al., 2008).  Endosomal sequestering 
of proteins after endocytosis has been treated as both a barrier to be crossed, and a 
lysosomal delivery method in this thesis dissertation.  For transcription factors, the target 
organelle was the nucleus, so endosomal entrapment had the potential to prevent biological 
activity of the delivered factors.  The endosomal escape properties of Tat may not facilitate 
the nuclear delivery of a sufficient transcription factor concentration for intracellular 
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activity.  Conversely, in the delivery of lysosomal enzyme GCase, the endosomes are the 
target since they will deliver GCase to the lysosome where it can be activated by saposin 
C and degrade glycosphingolipid substrates.   
When the intracellular target for protein delivery vector-linked proteins is cytosolic 
or nuclear, methods to facilitate the endosomal escape of cargo become critical.  Numerous 
strategies have been successfully utilized to enhance endosomal escape including 
fusogenic lipids, membrane-disruptive peptides, membrane-disruptive polymers, 
lysosomotrophic agents, and photochemical internalization (El-Sayed et al., 2008).  
Photochemical internalization (PCI) is a particularly interesting technique to rupture 
endosomes.  Cells are treated with lipophilic photosensitizers that integrate in the cell 
membrane, and therefore, are localized in the endosomal membrane following endocytosis.  
The photosensitizers can be excited with specific wavelengths of light, causing a 
photochemical reaction that creates reactive oxygen species that damage endosomal 
membranes, releasing entrapped cargo (El-Sayed et al., 2008).  PCI can be used to mediate 
the delivery of a large variety of macromolecules and other endosomally entrapped cargo 
(Selbo et al., 2010).   
PCI was first described in 1999 using several different small molecule 
photosensitizers including AlPcS2a, TPPS2a, and TPPS4.  In this first paper, light was 
actually delivered with fluorescent tubes; AlPcS2a was excited with red light with 1.35 
mW/cm2 intensity and TPPS2a and TPPS4 were excited with blue light with 1.5 mW/cm
2 
intensity.  When TPPS2a and horseradish peroxidase (HRP) were delivered together and 
PCI was mediated, ~60% of HRP was released into the cytosol.  This publication also 
introduced a critical step in PCI: the incubation of cells in photosensitizer-free medium for 
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several hours before light treatment.  This incubation period allows photosensitizer to 
diffuse out of the extracellular membrane, preventing cell lysis upon light treatment (Berg 
et al., 1999).   
Despite the common practice of allowing excess photosensitizer to diffuse out of 
the cell membrane, some cytotoxicity is often observed in PCI.  In vitro, PCI has been 
shown to efficiently mediate cytosolic release with reasonable levels of cytotoxicity, 
although the light intensity must be carefully controlled as too much intensity can kill cells 
(Gramlich et al., 2013).  Some applications of PCI have taken advantage of the cytotoxic 
effects.  PCI technology has been utilized in the delivery of chemotherapeutic agents to 
cancer cells (Selbo et al., 2010).  Of particular recent interest, PCI has the potential for the 
treatment of drug-resistant cancers.  Specifically, PCI can circumvent drug resistance due 
to efflux pumps, a common mechanism of resistance (Weyergang et al., 2015).  PCI uses 
the same basic principle as the clinically-used photodynamic therapy.  In photodynamic 
therapy, photosensitizers are delivered to tumors and excited, leading to cytotoxicity.  The 
process can be well-controlled since singlet oxygen is around for only ~20 nanoseconds 
and has a very short range of action, ~10-20 nanometers.  Photodynamic therapy has been 
shown to kill cancer cells three ways: direct killing of the cell, indirectly by vascular 
shutdown, and by a photosensitized-induced immune response.  One of the limitations of 
photodynamic therapy is that light will penetrate a maximum of ~2 cm in low-pigmented 
tissue (Selbo et al., 2010).  Tissue penetration is not a concern for in vitro work as cells are 
grown in a thin layer. 
While the Berg group that invented and popularized PCI used a photosensitizer that 
was delivered at the same time, but not attached to the macromolecule of interest, 
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photosensitizers have been linked directly.  Direct linkage of the photosensitizer to the 
cargo has been most successful when the cargo contains a CPP.  When directly linked to 
CPPs, rhodamine has bene found to serve as a photosensitizer.  Although 5(6)-
carboxytetramethylrhodamine (TMR) was not found to serve as a photosensitizer alone or 
even attached to a K9 peptide, it was found to mediate endosomal release attached to CPPs 
Tat or R9 (Srinivasan et al., 2011).  This result was supported when another study compared 
the endosomal rupture following light treatment of cells that had internalized either 
rhodamine-labeled Tat-GFP or rhodamine-labeled TTC-GFP.  Endosmal rupture was only 
observed for the Tat-GFP containing cells (Gillmeister et al., 2013).    The mechanism by 
which CPPs such as Tat improve PCI efficiency of a conjugated photosensitizer is not fully 
understood.  It has been suggested that CPPs may increase singlet oxygen yield by a 
unknown mechanism (Srinivasan et al., 2011) while others feel that it is a function of the 
dual action of CPPs destabilizing the cell membrane and bringing the photosensitizer 
physically closer to the membrane (Meerovich et al., 2014).  There are advantages and 
disadvantages to using photosensitizers that are directly conjugated.   A strong argument 
for direct conjugation is that PCI will only be mediated in areas where the macromolecule 
of interest is sequestered (Gillmeister et al., 2013).  Conversely, when photosensitizers are 
physically close to the cargo, reactive oxygen species could damage the delivered 
macromolecule along with the endosomal membrane.  Overall, both conjugated (Endoh et 
al., 2008; Gillmeister et al., 2013; Matsushita et al., 2004) and unconjugated (Berg et al., 
1999; Fretz et al., 2007; Gianolio et al., 2010; Shiraishi et al., 2006; Shiraishi et al., 2011; 
Wang et al., 2011) methods have been used successfully.   
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Light delivery to mediate PCI can be performed at a variety of scales.  The original 
PCI experiments were performed using fluorescent tubes (Berg et al., 1999); a 
commercially available system called the Lumisource (PCI Biotech, Lysaker, Norway) 
uses this principle.  The Lumisource is optimized to deliver uniform light intensity over 
the 45cm x 17cm treatment area.  Uniform treatment is critical since high light intensity 
can lead to cytotoxicity.  For smaller scale PCI experimentation, a fluorescent microscope 
can be used to deliver fluorescent light of the appropriate wavelength (Endoh et al., 2008; 
Gillmeister et al., 2011; Gramlich et al., 2013; Matsushita et al., 2004;  Srinivasan et al., 
2011).   
1.3. Transcription Factor Delivery 
Parkinson’s disease (PD) has long been considered an ideal candidate for the 
development of cell-replacement therapy.  Since the disease is caused by the loss of 
dopaminergic substantia nigra neurons, the introduction of healthy replacement 
dopaminergic neurons could provide a successful PD treatment (Thomas, 2010).  Although 
complex genetic strategies exist to generate dopaminergic neurons, the genetic methods 
make these cells unfit for human transplantation due to safety concerns.  The 
overexpression of transcription factors, especially those delivered via viral infection, 
greatly increases the chances of tumor formation after cell transplantation.  We aimed to 
develop a method where the direct delivery of purified transcription factors could be used 
to generate neurons that would potentially be safe for human therapy.   
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1.3.1. The roles of transcription factors Mash1, Lmx1a, and Nurr1 genes in general 
neuronal and dopaminergic differentiation   
Caiazzo and colleagues directly converted human fibroblasts to functional 
dopaminergic neurons using the lentiviral delivery of proneural transcription factors 
Mash1, Lmx1a, and Nurr1 (Caiazzo et al., 2011).  Although the efficiency of the process 
was not high, this publication was particularly exciting since the source cells could be 
easily obtained without any regulatory concerns.  Additionally, source fibroblasts could 
come from the patient in need of the transdifferentiated replacement cells.  Although high 
risk, there was an enormous potential benefit of converting this transdifferentiation 
procedure from a lentiviral delivery to a protein delivery method.  Each of the three 
transcription factors utilized for transdifferentiation have important roles in neuronal 
differentiation.  If a method to produce and deliver biologically active transcription factor 
was developed, any one of the three transcription factors would be interesting to study 
independent of the other two.   
Mash1 is a member of the basic helix-loop-helix (bHLH) family of transcription 
factors that play a critical role in the maintenance and differentiation of neural stem cells.  
There are two types of bHLH genes, the repressor and activator classes.  The repressor 
bHLH genes include seven Hes genes that regulate both gliogenesis and neural stem cell 
maintenance.  The activator class of bHLH factors includes Mash1, Math, NeuroD, and 
Neurogenin.  These genes promote neurogenesis by binding to the E box.  All activator 
bHLH transcription factors, including Mash1, need to form a heterodimer with bHLH 
factor E47 to become biological active (Kageyama et al., 2005).  Mash1 is expressed in 
both the peripheral and central nervous systems by both neural stem cells and post-mitotic 
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immature neurons.  Significant insight regarding the role of Mash1 in neuronal 
differentiation was derived from Mash1-knockout mice.  Mash1-deficiency is fatal at birth, 
so the development of the peripheral and central nervous systems can’t be examined 
postnatal.  At birth, most issues are observed in the peripheral nervous system.  In the 
Mash1 deficient mice, neurons from the olfactory and autonomic systems were lost, 
although multipotent cells of each system still differentiated to neural precursors 
(Kageyama et al., 1997).  Mash1 is inhibited by Hes1 through two distinct mechanisms.  
First, Hes1 can bind directly to the Mash1 promotor to repress Mash1 expression.  Second, 
Hes1 forms a nonfunctional dimer with Mash1 activator E47 preventing Mash1-E47 dimer 
formation.  Hes1 expression is critical for the neural stem cell proliferation and 
maintenance.  Without Hes proteins, premature neuronal differentiation is observed 
causing severe developmental problems (Kageyama et al., 2005).  Although the overall 
roles of Mash1 and Hes1 in promoting neural stem cell proliferation and neuronal 
differentiation are understood, the mechanism by which this takes place is not fully 
characterized.  During neural stem cell proliferation, the expression of Mash1 and Hes1 
appears to oscillate until sustained Mash1 expression promotes differentiation 
(Vasconcelos et al., 2014) 
P19 embryonal carcinoma cells have been used as a model for bHLH transcription 
factor-mediated neuronal differentiation in vitro.  P19 cells are pluripotent and can be 
differentiated to neurons by transient transfection of numerous bHLH factors including 
Mash1 (Farah et al., 2000).  Mash1 has also been found to dramatically upregulate 
expression of cell cycle arrest factor Gadd45ɤ, a discovery that was utilized in the 
construction of the 281-EL2 Mash1 reporter construct (Huang et al., 2010).   
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 Lmx1a is a member of the large LIM-homeodomain (LIM-hd) family of 
transcription factors.  All LIM-hd family members have two N-terminal LIM motifs that 
bind proteins allowing LIM-hd factors to form tissue-specific heterodimers and a C-
terminal DNA-binding homeodomain.  There are six groups of LIM-hd factors that are 
categorized by sequence homology, one of which is the Lmx group containing two 
members.  Lmx1 group members Lmx1a and Lmx1b share the same homeodomain.  As 
with Mash1, the study of a mouse model where Lmx1a was mutated provided some of the 
first evidence that Lmx1a had a critical role in neuronal differentiation.  Dreher mice have 
one of eleven Lmx1a mutations which lead to abnormal pigmentation, deafness, and 
developmental issues in the cerebellum, hippocampus, and cortex (Koo et al., 2009).  The 
loss of Lmx1a has been found to affect the formation of the roof plate, the inner ear, the 
cerebellum, and the choroid plexus.  The number of dopaminergic neurons is also slightly 
reduced in Dreher mice (Griesel et al., 2011). 
Transcription factor Lmx1a is a critical factor in the early stages of dopaminergic 
differentiation.  Lmx1a induces the expression of msh homeobox 1 (Msx1), which itself 
induces the expression of neurogenesis-promoting Ngn2 (Cai et al., 2009).  In neural 
progenitor cells derived from embryonic stem cells, lentiviral expression of Lmx1a in 
combination with sonic hedgehog (Shh) and fibroblast growth factor 8 (FGF8) led to 
dopaminergic differentiation.  Lmx1a has been found to directly bind the tyrosine 
hydroxylase promoter (Hong et al., 2014).  Mesenchymal stem cells (MSCs) transduced 
with lentiviral vectors expressing Lmx1a and treated with Shh and FGF8 were also 
differentiated into dopaminergic neurons.  Expression of Lmx1a in the MSCs upregulated 
Sox2, Msx1, Ngn2, and hAsh1 (Barzilay et al., 2009).  Although Lmx1a is the first 
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dopaminergic determinant factor expressed, it also has a role in the maturation of midbrain 
dopaminergic neurons.  The discovery that Lmx1a regulates expression of the dopamine 
transporter gene was used to develop a Lmx1a reporter vector (Chung et al., 2012).   
Nurr1, also commonly known as NR4A2, is a member of the nuclear receptor family 
of transcription factors.  Nuclear receptor transcription factors are regulated by binding 
small lipophilic cofactors including steroid hormones, thyroid hormones, and retinoids.  
Even when the ligand is absent, nuclear receptors are found in the nucleus bound to co-
repressors.  Ligand-binding triggers a conformational change resulting in co-repressor 
dissociation and co-activator recruitment.  Nurr1 is one of over 20 orphan nuclear receptors 
that do not have an identified ligand, although Nurr1’s binding partner is known. For DNA 
binding, Nurr1 can bind as a monomer, homodimer, or heterodimer. Nurr1’s 
heterodimerization partner is the retinoid X receptor (RXR).  Since Nurr1’s ligand binding 
pocket is entirely filled with hydrophobic amino acid side chains, it is thought that Nurr1 
may act in a ligand-independent manner, a mechanism uncommon for nuclear receptor 
family members.  Nurr1 may be indirectly influenced by ligands through binding partner 
RXR (Perlmann et al., 2004).  Nurr1 binds DNA through a conserved domain consisting 
of two zinc fingers and has been shown to bind a NGFI-B response element (Rekha et al., 
2014).   
Nurr1 is critical for the normal development of ventral midbrain dopaminergic 
neurons.  In homozygous Nurr1 knockout mice, dopaminergic neurons were absent in the 
substantia nigra and animals died within 24 hours of birth (Jiang et al., 2005).  Although 
no dopaminergic markers were observed in the knockout mice, a number of other 
dopaminergic transcription factors were expressed, indicating that Nurr1 was not an early 
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activator of a dopaminergic phenotype.  Nurr1 also has roles outside dopaminergic 
development as the early death of knockout animals within 24 hours was not thought to be 
due to the lack of the dopaminergic neurons (Perlmann et al., 2004).  Mice that are 
heterozygous for Nurr1 knockout have reduced Nurr1 levels but can survive much longer, 
allowing more comprehensive study.  As they age, these mice provide an interesting PD 
model (Jiang et al., 2005; Zhang et al., 2012a).   
Overall, while Lmx1a is thought to be the first inducer of dopaminergic 
differentiation, Nurr1 is responsible for the maturation of the dopaminergic phenotype.  
Overexpression of Nurr1 and Pitx3, another dopaminergic factor, has been found to 
promote the midbrain dopaminergic phenotype in embryonic stem cells; a result neither 
factor can fully induce on its own (Martinat et al., 2006).  It has been discovered that Nurr1 
is also critical for the maintenance of mature dopaminergic neurons, and loss of Nurr1 can 
lead to neuronal degeneration (Kadkhodaei et al., 2009).  Nurr1 has a large variety of target 
genes that are affected on a Nurr1 concentration-dependent and gene-dependent manner 
(Johnson et al., 2011).     
Decreases in Nurr1 expression may contribute to PD pathogenesis, although it is 
not due directly to Nurr1 mutation.  Age-dependent decreases in Nurr1 levels are observed 
in dopaminergic neurons with PD pathology.  Nurr1 is one of numerous transcription 
factors whose function is affected by α-synuclein overexpression.  Interestingly, viral 
delivery of Nurr1 has been shown to protect dopaminergic neurons against α-synuclein 
toxicity.  Although the role of Nurr1 in PD is still under thorough investigation, it may be 
an interesting future PD therapeutic target (Decressac et al., 2013).   
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1.3.2. The delivery of transcription factors to mediate dopaminergic neuronal 
differentiation 
There is a substantial literature on dopaminergic differentiation from a variety of 
cell sources.  While a comprehensive review of the literature could be its own publication, 
the goal for this thesis is to briefly introduce the potential cell sources for dopaminergic 
neuron differentiation, methods for mediating the differentiation, and how transcription 
factor delivery has been used or can be used to enhance differentiation.   
The first issue in generating mature dopaminergic neurons for cell replacement 
therapy is selecting the appropriate source cells for the differentiation process.  This 
process is not as straightforward as choosing the ideal and/or most convenient source cell 
due to ethical, regulatory, and safety concerns.  It is noteworthy that although the 
generation of dopaminergic neurons is introduced here, analogous methods can be utilized 
for the generation of other neuronal cell types.  The first source of replacement 
dopaminergic neurons was fetal tissue.  Although some initial studies where PD patients 
received fetal tissue from 6-8 week old human embryos delivered promising results, there 
are obvious issues limiting fetal tissue transplantation to proof-of-concept work only.  
Dopaminergic neurons have been generated using human embryonic stem cells (Thomas 
et al., 2010).  The first method for differentiating hESCs to dopaminergic neurons was 
published in 2004, and used both co-culture with feeder cells, and the sequential addition 
of small molecules and growth factors (Perrier et al., 2004).  Transcription factor delivery 
can also be used to differentiate hESCs to dopaminergic neurons.  Retrovirus-mediated 
overexpression of each of dopaminergic transcription factors Lmx1a, Pitx3, and Nurr1 in 
hESC-derived neural progenitor cells led to the efficient generation of TH-position neurons 
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(Hong et al., 2014).  Although the pluripotent nature of hESCs presents a number of options 
for the generation of dopaminergic neurons, there are also issues with hESC acquisition 
limiting their potential for cell-replacement therapy.   
The discovery that induced pluripotent stem cells (iPSCs) could be generated 
through the viral-mediated overexpression of four transcription factors in fibroblasts 
presented an ethical way to obtain large quantities of pluripotent stem cells for neuronal 
differentiation (Takahashi et al., 2006).  Human iPSC lines have already been used to 
generate neurons expressing dopaminergic markers under defined conditions.  After iPSCs 
were differentiated to neural stem cells, about 30% of the iPSC-derived NSCs were 
tyrosine hydroxylase-positive (Swistowski et al., 2010).  While scientifically exciting, this 
discovery still presented limitations; the integration of lentiviral DNA and the introduction 
of powerful viral promoters dramatically increase the possibility of unwanted genetic 
consequences (Zhou et al., 2009).  These limitations were addressed using protein delivery.  
Direct delivery of the reprogramming factors as Tat-linked recombinant proteins has been 
used to generate iPSC lines without genetic modification (Kim et al., 2009; Nemes et al., 
2014; Zhou et al., 2009).   The creation of protein-induced PSCs not only generated a safe 
and ethical source of pluripotent cells but it also demonstrated the potential for protein 
delivery of transcription factors to mediate cellular reprogramming.  Although the direct 
protein delivery-mediated reprogramming was less efficient than the viral method (Kim et 
al., 2009), its success provided hope that recombinant transcription factors could be used 
in place of DNA overexpression for related applications.  Protein-induced PSCs could be 
a safe and ethical source of cells for dopaminergic differentiation, and progress towards 
this goal has been made.  From the piPSCs, 86.4% were differentiated into neural stem 
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cells.  Of these piPSC-induced NSCs, 60-70% were differentiated into TuJ1+ cells and 35-
45% of these TuJ1+ cells were TH+ (Rhee et al., 2011).  Overall, 26% of the NSCs were 
differentiated into TH+ cells, a value comparable with hESC differentiation procedures 
(Swistowski et al., 2010). It has been shown that dopaminergic differentiation efficiency is 
similar for mESCs and mouse piPSCs (Kwon et al., 2014).  Recombinant transcription 
factors could be a valuable asset in promoting dopaminergic differentiation and even 
enhancing current defined procedures involving sequential addition of small molecules and 
growth factors.   
In 2010, the idea of converting somatic cells to pluripotent stem cells made further 
progress when the Wernig group at Stanford published the conversion of fibroblasts to 
functional neurons, without an intermediate multipotent or pluripotent stem cell state.  
Lentiviral delivery of Mash1 alone was enough to induce immature neurons and the 
addition of Brn2 and Mytl1 improved efficiency close to 20% (Vierbuchen et al., 2010).  
This method has the potential to, in a straightforward manner, create patient-specific 
replacement cells.  Soon after, it was discovered that the addition of Lmx1a and FoxA2 led 
to the expression of dopaminergic markers with an overall transdifferentiation efficiency 
of ~10% (Pfisterer et al., 2011).  This process was further streamlined when lentiviral 
expression of Mash1, Nurr1, and Lmx1a were used to generate dopaminergic neurons from 
several fibroblasts sources.  The percentage of TH+ cells generated from mouse embryonic 
fibroblasts, human embryonic fibroblasts, and adult Parkinson’s patient fibroblasts was 
18%, 6%, and 3% respectively (Caiazzo et al., 2011).  Analogous high-profile papers were 
published around this time where Alzheimer’s disease (AD) skin fibroblasts were 
converted to neurons (Qiang et al., 2011), mouse and human fibroblasts were converted to 
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spinal motor neurons (Son et al., 2011), and differentiated hepatocytes were 
transdifferentiated to neurons (Marro et al., 2011).  Although efficiency was very low, two 
microRNAs alone were shown to transdifferentiate fibroblasts to neurons.  Efficiency of 
the process was improved with transcription factor delivery of NeuroD2 alone, but more 
so with Mash1 and Myt1l as well (Yoo et al., 2011).  Small molecules have been used to 
improve transdifferentiation efficiency with viral overexpression of Mash1 and Ngn2 
(Ladewig et al., 2012).   
  One of the major criticisms of the transdifferentiation process is that because the 
neurons generated do not proliferate and the efficiency is low, it is not a practical source 
of replacement neurons for transplantation.  Efforts have been made to transdifferentiate 
fibroblasts to midbrain dopaminergic progenitor cells capable of expansion.  This has been 
achieved through lentiviral expression of the Yamanaka reprogramming transcription 
factors Oct4, c-Myc, Klf4, and Sox2, followed by culturing in conditions to promote 
dopaminergic differentiation including the addition of Shh and FGF8.  The induced 
dopaminergic progenitors could be differentiated to dopaminergic neurons through 
removal of medium growth factors.  After 1-2 weeks of differentiation, ~27% of cells were 
TuJ1 and TH-positive (Kim et al., 2014).  Very recently, fibroblasts have been 
transdifferentiated to dopaminergic progenitors without genetic modification using the 
protein transduction of recombinant Tat-linked Sox2 and Lmx1a, and a cocktail of small 
molecules.  This publication represents the first time induced dopaminergic precursors 
were generated without genetic modification (Mirakhori et al., 2015).   
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1.4. Enzyme Replacement Therapy for Gaucher’s Disease 
Gaucher’s disease (GD) is a lysosomal storage disease caused by mutations in 
lysosomal enzyme glucocerebrosidase (GCase).  It is the most common lipid storage 
disease as well as the most common genetic disorder in the Ashkenazi Jewish population, 
although GD is observed in all ethnic groups (Hruska et al., 2008).  As a result of the 
enzyme mutation, glycosphingolipid substrates glucosylceramide (GlcCer) and 
glucosylsphingosine (GlcSph) accumulate, leading to heterogeneous phenotypes.  The 
effort to design RDP-IgAh-GCase required an understanding of the disease as well as 
numerous FDA-approved therapeutics that already exist for treatment of select disease 
subtypes.  While numerous neuronopathic GD therapies have been proposed, none have 
shown promising clinical results.  RDP-IgAh-GCase has the potential for fill a large void 
in the GD therapeutic toolkit.   
1.4.1. Gaucher’s disease 
GD is classified into three types, only two of which affect the nervous system.  Type 
1 GD is the most common form where the reticulo-endothelial system is primarily affected.  
The GCase substrates accumulate in lysosomes causing macrophages to become 
dramatically enlarged.  These engorged macrophages are historically known as “Gaucher 
cells.”  Types 2 and 3 GD both affect the central nervous system.  In acute neuronopathic 
type 2, rapid neurodegeneration leads to death in infancy.  Chronic neuronopathic type 3 
GD patients can have variable symptoms but typically have some of the reticulo-
endothelial issues of type 1 patients with some nervous system involvement.   The 
neurologic symptoms of type 3 GD are variable.  While symptoms can be severe, in less 
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severe cases, patients may only experience slowed horizontal saccadic eye movement 
(Sidransky, 2012).   
A large number GBA1, the gene for GCase, mutations have been described; the 
disease is diverse both in genotype and phenotype.  Of the nearly 300 GCase mutations 
identified, 203 are missense mutations, 18 are nonsense mutations, 36 are small insertions 
or deletions, 14 are splice junction mutations, and 13 are variants with 2 or more mutations.  
One of the reasons that phenotype is difficult to predict based on genotype is that most 
mutations are not found in the homozygous form and that some are found in a small sample 
size.  Although uncommon, there are some correlations.  GD patients with the N370S 
mutation typically do not have any neurological symptoms.  Interestingly, some individuals 
that are homozygous for the N370S mutation are asymptomatic.  Type 3 GD patients with 
visceral manifestations of the disease often carry the L444P and or the R463C mutations.  
Patients experiencing myoclonic epilepsy often carry the N188S or G377S mutations with 
a null or recombinant allele.  Overall, most reasonably accurate phenotype predictions 
come from homozygous individuals.  For example, homozygotes with the F213I or L444P 
often have Type 3 GD (Hruska et al., 2008).  Mutations in GBA1 can impact GCase 
multiple ways including one or a combination of activity, stability, trafficking to the 
lysosome, or interaction with GCase activators.   
 GCase is a 497 amino acid protein that has an unmodified polypeptide molecular 
weight of 56 kDa.  The actual molecular weight of the protein extracted from different 
tissue sources has been found to be between 59 and 67 kDa as a result of variable post 
translational modifications (Grace et al., 1994).  Specifically, GCase has 5 potential N-
glycosylation sites at Asn-19, Asn-59, Asn-146, Asn-270, and Asn-462.  The first four of 
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these sites are usually occupied in wild-type GCase.  The N19 glycosylation site is the only 
one that has been shown to be critical for enzyme activity.  Berg-Fussman and colleagues 
showed that enzymes with N19Q, N19E, or T21G mutations, where the glycosylation site 
was removed, had 3-60 fold decreases in enzyme activity.  Folding effects due to the 
mutation and/or the lack of N19 glycosylation clearly prevented the formation of a fully 
catalytically active enzyme (Berg-Fussman et al., 1993).  Two amino acids at the active 
site, E235 and E340, are critical to mediate the hydrolysis of glucosylceramide to glucose 
and ceramide (Dvir et al., 2003).  Surprisingly, there is no strong correlation between 
residual enzyme activity and accumulated substrate in GD patients (Sidransky, 2012).   
 GCase requires two activators, negatively charged lipids and saposin C (SapC) for 
function in vivo (Berg-Fussman et al., 1993; Dvir et al., 2003).  SapC is a small 80 amino 
acid, 9kDa glycoprotein that is derived from proteolysis of precursor protein prosaposin.  
If glycosylated at its N22 site, SapC can be 12kDa in size.  The exact mechanism by which 
saposin C activates GCase is not fully understood.  It is thought that SapC has two 
functions: binding GCase and helping it associate with the membrane, as well as extracting 
and solubilizing glycosphingolipid substrates to enable GCase-mediated hydrolysis.  
Negatively charged lipids in the cell membrane improve SapC membrane binding, further 
facilitating GCase activation (Tamargo et al., 2012).  Select GCase mutations have been 
shown to affect the ability of SapC to activate GCase.  For example, it was demonstrated 
that SapC was able to activate both wild-type and N370S GCase in the presence of high 
concentrations of anionic phospholipids.  However, if anionic phospholipid concentration 
was reduced to ~20%, only wild-type and not N370S GCase was activated (Salvioli et al., 
2005).   
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 Until recently, there were relatively few cell and animal models for the study of 
GD.  Although primary fibroblast cell lines with mutant GCase are available, there was not 
convenient source of Gaucher’s neurons for in vitro study.  This changed in 2012 when an 
induced pluripotent stem cell (iPSC) line was created from GD fibroblasts and it was 
demonstrated that these iPSCs could be differentiated into both Gaucher macrophages and 
Gaucher neurons (Panicker et al., 2012).  Another exciting advance in in vitro study was 
the creation of a SV40-immortalized GCase-knockout neuronal cell line (Wendy 
Westbroek, personal communication).  Although these cells have less true neuronal 
properties than the iPSC-derived Gaucher neurons, they can be expanded easily and 
cheaply for larger scale experimentation.   
 The first animal models for GD were chemically induced mouse models using 
conduritol-β-epoxide, a specific inhibitor of GCase activity.  A GCase-knockout mouse 
model was made in 1992, and although these mice had very low enzyme activity, their 
lifespan was very short due to a previously unknown induced defect in skin permeability, 
causing the mice to die of dehydration.  Recently, more complex genetic strategies have 
been utilized to generate knockout mice.  One example of a more complex strategy was 
used to generate the K14 line, the first neuronal GD model.  By breeding mice with a loxP-
Neo-loxP cassette in the GBA1 sequence with keratin-14-Cre transgenic mice, a line was 
made where GCase was knocked out except in skin where the K14 promoter drives 
excision of the Neo cassette (Farfel-Becker et al., 2011).   
 Although the study of GD is an important field itself, interest in the disease has 
grown considerably of late with the high profile discovery that GBA1 mutations are the 
greatest genetic risk factor for Parkinson’s disease.  The mechanism by which GCase and 
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alpha-synuclein interact is not known.  They seem to have a clear inverse relationship, 
although not a traditional enzyme-substrate connection (Siebert et al., 2014). 
1.4.2. Type 1 Gaucher’s disease therapy 
Type 1 GD is currently treated by enzyme replacement therapy (ERT) with 
recombinant GCase.  The original GCase for GD therapy was Ceredase (alglucerase, 
Genzyme), purified from human placental tissue.  Genzyme later replaced Ceredase with 
Cerezyme (imiglucerase), a recombinant form of the enzyme with a single amino acid 
substitution of histidine for arginine at position 495 (Pastores, 2010).  Cerezyme is 
produced in Chinese hamster ovary (CHO) suspension cells, a common cell line used for 
recombinant protein production.  Both of the GCase products produced by Genzyme were 
sequentially deglycosylated after production to expose terminal mannose residues.  This 
enzymatic modification takes advantage a mannose-binding lectin to target GCase to 
macrophages, the cell type most affected in Type 1 GD.  Originally, treatment of patients 
with native GCase was not effective because the enzyme was cleared too rapidly by cell 
types that were not intended targets.  The deglycoslyation procedure involved the 
sequential treatment of GCase with neuraminidase, β-galactosidase, and β-N-
acetylglucosaminidase to expose mannose by removing sialic acid, galactose, and N-
acetylglucosamine respectively (Furbish et al., 1981).   
Since the release of recombinant Cerezyme, two biosimilars have been FDA-
approved for GD ERT.  VPRIV (velaglucerase alfa, Shire) was the first of the two 
biosimilars released.  VPRIV is produced in a human fibroblast carcinoma cell line; 
mannose-terminal glycans are created due to the addition of mannosidase I inhibitor 
kifunesine to the extracellular medium during production.  Elelyso (taliglucerase alfa, 
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Protalix Biotherapeutics) is produced in a recombinant carrot cell line and takes advantage 
of targeting to a storage vacuole where glycans are remodeled to contain terminal mannose 
residues (Tekoah et al., 2013).  Aside from creating competition in the marketplace, the 
existence of multiple recombinant mannose-terminal GCase enzymes for ERT is 
important.  When Genzyme had a large-scale bioreactor viral contamination, their 
Cerezyme supply became limited, creating a global shortage of the therapeutic protein 
(Branco Novo et al., 2012).   
Although ERT is the preferred GD treatment method, two small molecule drugs 
also exist for GD treatment.  Zavesca (miglustat, Actelion Pharmaceuticals) is an N-
alkylated iminosugar that inhibits glycosylceramide synthase, an enzyme responsible for 
the production of glucosylceramide (GlcCer).  By decreasing the amount of GlcCer that 
accumulates in lysosomes, the residual enzyme activity often present in Type 1 GD patients 
prevents excessive substrate accumulation.  Zavesca was FDA-approved in 2002 for the 
treatment of type 1 GD patients that can’t tolerate the ERT infusions (Ficicioglu et al., 
2008; Pastores et al., 2010).  Although Zavesca is taken orally, providing a very convenient 
therapeutic option for patients, its use was limited by gastrointestinal and neurological side 
effects.  While neurological side effects were reversible when drug use was discontinued, 
30% of patients experienced tremors and 15-20% of patients had peripheral neuropathy 
during treatment (Ficicioglu et al., 2008).  When treated with Zavesca, patients displayed 
a wide tissue distribution including the CNS; this finding led to a clinical trial testing 
whether combinatorial treatments with Cerezyme and Zavesca could improve neurological 
symptoms of type 3 GD patients.  In 2007, a report was published indicating that a 31 year 
old patient who received 200mg Zavesca 3x per day and 60 IU/kg Cerezyme every two 
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weeks experienced an improvement in his neurological symptoms without side effects 
(Capablo et al., 2007).  While initially promising, the results of a 30 patient clinical trial 
released in 2008 indicated that this combinatorial treatment did not have a statistically 
significant neurological benefit compared to control patients that received Cerezyme only 
(Schiffmann et al., 2008).   
Cerdelga (eliglustat, Genzyme) is a second small molecule glucosylceramide 
analogue that serves as a glucosylceramide synthase inhibitor.  In 2014, it was FDA-
approved for type 1 GD treatment.  The development of Cerdelga is exciting, as it has been 
shown to have fewer unpleasant side effects than Zavesca, and clinical trials have shown 
similar efficacy to Cerezyme (Poole, 2014).  Moving forward, ERT is still likely to remain 
the primary treatment method for type 1 GD patients since the long-term outcomes with 
ERT are better characterized and the current cost of Cerdelga is similar to Cerezyme 
(Sinha, 2014).  Currently no clinical trials assessing Cerdelga in type 3 GD patients are in 
progress.   
1.4.3. Potential neuronopathic Gaucher’s disease treatments 
Although no FDA-approved type 2 or type 3 GD therapies exist, a number of 
potential options have been investigated over the past several years.  The strategies 
investigated for neuronopathic GD therapy can be generally organized in four categories: 
1) direct infusion of mannose-terminal GCase to the CNS, 2) the design of novel strategies 
to deliver GCase across the BBB or improve neuronal binding, 3) small molecules that can 
potentially cross the BBB, and 4) gene therapy.   
All FDA-approved recombinant GCase enzymes are engineered or modified to 
contain mannose-terminal N-glycans for macrophage targeting.  Although very useful for 
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the treatment of systemic Gaucher’s disease, they would not be predicted to preferentially 
bind neurons, possibly limiting the therapeutic potential of this strategy.  An in vitro study 
testing Ceredase binding and internalization used cholinergic LA-N-2 cells, dopaminergic 
SH-SY5Y cells, and NHA astrocytes.  Uptake of the Ceredase by the neuronal cell lines 
was found to be variable but uniformly inferior to the uptake by J774 macrophages.  The 
LA-N-2 cells had the best binding, but half-maximal uptake occurred at approximately 7x 
the concentration of Ceredase compared to the macrophage cell line.  The uptake by the 
LA-N-2 cells was found to be, at least in part, mannose-specific.  Uptake of the Ceredase 
by the SH-SY5Y cells was significantly less, and no uptake was observed for the astrocyte 
cell line (Scheuler et al., 2002).   
There has been a limited amount of in vivo CNS infusion of mannose-terminal 
GCase.  Cabrera-Salazar and colleagues at Genzyme were able to reduce substrate and 
extend the life of K14 neuronopathic GD model mice from 15 to 23 days with intra-
cerebroventricular infusion of reformulated Cerezyme three times, starting at postnatal day 
1 (Cabrera-Salazar et al., 2010).  Three young type 2 GD patients were given CSF infusions 
with Ceredase in the mid-1990s.  Although the lifespan of one patient was possibly 
extended, two of the others suffered continued neurological decline (Erikson et al., 1997).  
Convection-enhanced delivery (CED) showed potential for improving GCase distribution 
after infusion since the slower diffusion of the large molecule was not limiting.  In test rats, 
53% of the infused GCase activity was detected immediately after infusion and 10% was 
detected after 18 hours (Zirzow et al., 1999).  Further work showed effective and safe 
distribution of GCase activity in monkeys using CED (Lonser et al., 2005).  CED has been 
used to deliver Cerezyme to the CNS of human patients.  A young type 2 GD patient 
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received infusions at 10.5 and 13 months of age.  The CED Cerezyme infusion was found 
to be safe and at 19 months the patient had a stable neurological baseline although 
neurologic symptoms were not necessarily improved (Lonser et al., 2007).   
Since mannose-terminal GCase does not preferentially bind neurons or cross the 
BBB, some strategies have focused on engineering recombinant GCase enzymes for these 
purposes.  Tat has the potential to improve GCase delivery and mediate crossing of the 
BBB (Schwarze et al., 1999).  GCase-Tat was bound and internalized approximately 4 and 
10 fold better than control GCase or Cerezyme in type 1 and type 2 Gaucher fibroblasts, 
respectively (Lee et al., 2005).  Although promising, GCase-Tat was not delivered to any 
neuronal cell type nor was any reduction in substrate accumulation demonstrated.  Another 
lysosomal enzyme, galactocerebrosidase (GALC), was delivered to primary mouse 
neurons using Tat as the protein delivery vector.  The results of this study were less 
encouraging; less GALC-Tat was delivered compared to the control GALC protein, 
although the GALC-Tat delivery was less inhibited by the addition of mannose-6-
phosphate.  This indicated that Tat was mediating neuron binding (Zhang et al., 2008).  
Aside from Tat, the other strategy to delivery GCase across the BBB used the 38 amino 
acid low-density lipoprotein receptor binding domain of apolipoprotein B (Spencer et al., 
2007).  A portion of apolipoprotein E has also been shown to mediate BBB crossing 
(Böckenhoff et al., 2014).   
While a clinical trial for Zavesca indicated that patients’ neurological symptoms 
did not improve (Schiffmann et al., 2008), another glucosylceramide synthase small 
molecular inhibitor has recently showed promise in the K14 neuronopathic GD mouse 
model.  Genzyme identified GZ 161, a propriety inhibitor, and found that it was able to 
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extend the life of K14 mice from 14 to 18 days and reduced substrate levels over 60% by 
the end of life.  Although substrate levels were reduced, they were not normalized.  The 
GZ 161 molecule was injected intraperitoneal (IP) and was found to cross the BBB 
(Cabrera-Salazar et al., 2012).  Another small molecular therapeutic strategy involves 
chaperones that competitively inhibit glucocerebrosidase.  They bind in the endoplasmic 
reticulum where GCase is less stable and improve lysosomal trafficking and enzyme 
activity (Sun et al., 2011).  One chaperone, isofagomine, has been found to improve the 
activity of several mutant GCase variants including the L444P mutant common in 
neuronopathic GD (Khanna et al., 2010).  The in vivo effects of isofagomine were evaluated 
in the 4L;C* neuronopathic mouse model that has homozygous V394L GCase mutations 
and no saposin C.  Interestingly, while no decrease in substrate levels was observed (Sun 
et al., 2012) lifespan of the mice was extended ~34% with a 600 mg/kg/day isofagomine 
treatment given in their drinking water (Sun et al., 2011).  Ambroxol, another chaperone, 
has been tested in a very small clinical trial for type 1 GD and proposed for neuronopathic 
GD treatment but not tested for that purpose (Zimran et al., 2013).   
 The final category of potential neuronopathic GD treatments is gene therapy.  Gene 
therapy has long been an attractive idea for GD therapy since it has the potential to 
permanently cure the disease without need for repeat enzyme infusions over the patient’s 
lifespan.  The feasibility of gene therapy for type 1 GD was first demonstrated using CBE-
induced mouse model (Marshall et al., 2002).  Genzyme research has shown that intra-
cerebroventricular delivery of adenoviral vectors expressing GCase increased the K14 
mouse lifespan to 28.5 days compared to 15 days for the controls or 23 days for the mice 
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receiving three ICV infusions of enzyme beginning at postnatal day 1 (Cabrera-Salazar et 
al., 2010).   
1.5. Thesis Chapter Overview 
 This doctoral thesis is composed of three main chapters with a common theme: the 
design of therapeutic proteins and their delivery to the appropriate cellular compartments 
for biological activity.  Chapter 2 discusses the design and development of Tat-TTC, a 
neuronal cell type-specific protein delivery vector that can target cargo proteins to either 
endosomal and lysosomal compartments or the cytosol utilizing photochemical 
internalization.  In chapter 3, Tat-linked transcription factors were expressed with the 
intention of mediating neuronal differentiation.  In principle, the generated neurons could 
be used to treat Parkinson’s disease where this cell type is lost.  The factors were delivered 
using the Tat CPP.  Since transcription factors need to reach the nucleus to be biologically 
active, photochemical internalization was used to promote nuclear translocation.  The 
delivery of GCase to neurons presented a number of protein delivery challenges that are 
discussed in chapter 4.  Intracellularly, the targeted organelle for GCase is the lysosome so 
endosomal entrapment following uptake is preferred to cytosolic release.  However, 
commercially available recombinant GCase enzymes that can bind neurons poorly already 
exist.  The goal in chapter 4 was to develop a neuron-targeted and biologically active 
GCase, a therapeutic protein that has never been developed but for which there is a strong 
need.  To accomplish this goal, seventeen different variants were assessed.  The ability of 
Tat, TTC, and Tat-TTC protein delivery vectors to target GCase to neuronal cells was 
tested.  A new peptide, RDP, was found to be most appropriate for a number of reasons to 
be discussed at length.    
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Chapter 2: Tat-Tetanus Toxin Fragment C: A Novel Protein Delivery 
Vector and its Use with Photochemical Internalization 
2.1. Abstract 
Protein delivery vectors can be grouped into two classes, those with specific 
membrane receptors undergoing conventional endocytosis, and cell penetrating peptides 
(CPPs) that have the capacity to cross cell or endosomal membranes. For both forms of 
vectors, translocation across a membrane is usually an inefficient process.  In the current 
study, a novel vector combining the widely used CPP, Tat and the non-toxic neuronal 
binding domain of tetanus toxin (fragment C or TTC) was assessed for its capacity to 
deliver GFP as a test cargo protein to human neural progenitor cells (NPCs).  These two 
functional membrane interacting domains dramatically enhanced internalization of the 
conjugated cargo protein. Tat-TTC-GFP was found to be bound or internalized at least 83-
fold more than Tat-GFP and 33-fold more than TTC-GFP in NPCs by direct fluorimetry, 
and showed enhanced internalization by quantitative microscopy of 18 and 14 fold 
respectively.  This preferential internalization was observed to be specific to neuronal cell 
types.  Photochemical internalization (PCI) was utilized to facilitate escape of the 
endosome-sequestered proteins.  The combined use of the Tat-TTC delivery vector with 
PCI led to both enhancement of neural cell type specific delivery to an endosomal target, 
followed by the option of efficient release to the cytosol. 
*The majority of chapter 2 is derived from, with permission (p.183), Gramlich et al., 






Vectors for delivery of proteins to living cells can be grouped into two classes.  One 
group attempts to adapt the strategy of natural protein based toxins, such as plant derived  
ricin and bacterial toxins including botulinum toxin, tetanus toxin and diphtheria toxin. 
These toxins have a similar molecular design which includes: 1) a binding domain that 
recognizes a cell surface receptor, 2) a translocation domain that mediates passage through 
the plasma or endosomal membrane to deliver the toxin, and 3) a catalytic domain which 
mediates a toxic enzyme activity (Fishman, 2009; Sandvig et al., 2009). We have 
previously created delivery vectors based on the non-toxic binding domain of tetanus toxin, 
referred to currently as HCC (C terminus of heavy chain), and also known as tetanus toxin 
fragment C or TTC (Francis et al., 2000; Francis et al., 2004; Li et al., 2009).  The 
proteolytic activity of tetanus toxin comes from the toxin’s light chain.  Toxin with a 
mutation of amino acid Glu234 in the light chain, in combination with a wild-type heavy 
chain, was shown to be non-toxic (Li et al., 1994; Wang et al., 2012).  The advantages of 
TTC as a vector are its neural specificity, moderate binding avidity with high capacity, and 
properties of retrograde axonal and trans-synaptic transport (Figueiredo et al., 1997; 
Fishman and Savitt, 1989; Francis et al., 1995).  Neuronal binding properties of TTC stem 
from the binding of protein receptors and complex gangliosides.  Binding pockets for 
complex gangliosides GD1b and GT1b are within the C-terminal 34 amino acids of TTC.  
The membrane association of TTC is dependent on pH and ganglioside content.  
Endocytosis of TTC is also depended on receptor proteins P15 and SV2A/B binding (Calvo 
et al., 2012; Miana-Mena et al., 2002; Yeh et al., 2010).  TTC lacks the translocation 
domain of tetanus toxin and internalized proteins do not enter the free cytosolic 
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compartment (Figuererdo et al., 2000).  Hybrid bacterial toxins incorporating a 
translocation domain identify the membrane translocation process as the limiting aspect of 
protein delivery to non-endosomal cytosolic targets (Barati et al., 2002; Box et al., 2003; 
Kern et al., 2011).  An alternative to bacterial toxin domains as vectors to translocate cargo 
proteins across cell and endosomal membranes are small cationic peptides referred to as 
cell penetrating peptides (CPPs) (Reviews: Chauhan et al., 2007; Deshayes et al., 2005; 
Heitz et al., 2009; Zorko and Langel, 2005). The most widely used of these arginine rich 
peptides was originally derived from the trans-activator of transcription (Tat) protein of 
HIV (Frankel and Pabo, 1988).  Tat has been used to deliver functional protein in vitro and 
in vivo (Fawell et al., 1994; Schwarze et al., 1999).  Although over 20 Tat sequences have 
been used to mediate cell membrane translocation, the minimum sequence necessary is 
residues 49-57 of the Tat protein (Wender et al., 2000).   Although the mechanism of the 
Tat peptide translocation remains controversial and may vary with cell type and cargo 
protein, the consensus is that Tat, like many other CPPs, is internalized through endocytosis 
(Chauhan et al., 2007).  While lipid raft-dependent macropinocytosis is often mentioned as 
the mechanism by which Tat internalization occurs (Jones et al., 2005; Kaplan et al., 2005; 
Nakase et al., 2007; Wadia et al., 2004) clathrin-mediated endocytosis has also been 
suggested (Nakase et al., 2004; Rinne et al., 2007). Unlike bacterial toxins, CPP based 
protein delivery is usually non-specific for cell type or receptor, less avid, and less 
saturable.  
There is a strong rationale to investigate molecules that would include domains 
from both types of vectors, potentially combining the properties of both.  Such dual-domain 
molecules could potentially have enhanced uptake through the synergy of combined 
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binding domains as well as preserved cell-type specificity. There is also the potential of 
such vectors to impact both endosomal and cytosolic targets.  Although CPPs are well 
documented to deliver functional proteins to cytosolic targets, their cytosolic entry is also 
frequently limited by endosomal trapping (Kaplan et al., 2005).  Many estimates have 
>90% of Tat-linked cargoes trapped in endosomes (Wang et al., 2010).    While Tat can 
mediate minimal cytosolic release of delivered protein, more efficient methods are 
frequently needed to significantly enhance intracellular availability.  Methods described in 
the literature include: fusogenic lipids (Felgner et al., 1987), membrane-disruptive peptides 
(Wadia et al., 2004), membrane-disruptive polymers (Boussif et al., 1995), lysomotropic 
agents (Ciftci et al., 2001), and photochemical internalization (PCI) (Berg et al., 1999).     
Photochemical internalization (PCI) is a powerful technique to improve the 
efficiency of macromolecule delivery when cytosolic release is desired.  In PCI, a 
photosensitizer, usually with a porphyrin structure, preferentially locates to the cell 
membrane upon endocytosis (Fretz et al., 2007).  Upon exposure to a specific frequency of 
light, photosensitizers induce the formation of reactive oxygen species, damaging the 
endosomal membrane and releasing endosome contents.  Singlet oxygen’s 10-20 nm range 
of action limits the oxidative damage to the endosomal membrane (Berg et al., 1999).  The 
frequency of light applied is directly dependent on the photosensitizer used.  PCI has been 
demonstrated in over 80 cell types (Selbo et al., 2010) using the following two strategies: 
chemically conjugating the photosensitizer to the macromolecule of interest or delivering 
unlinked photosensitizer in combination with the macromolecule.  Both the conjugated 
(Endoh et al., 2008; Gillmeister et al., 2011; Matsushita et al., 2004) and unconjugated 
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(Berg et al., 1999; Fretz et al., 2007; Gianolio et al., 2011; Shiraishi et al., 2006; Shiraishi 
et al., 2011) approaches have been used successfully.    
The current study aimed to develop an efficient strategy to deliver proteins to 
human neural progenitor cells (NPCs).  Enhanced green fluorescent protein (GFP) was 
selected as a model protein for evaluating delivery.  We wanted to examine whether a 
vector including both Tat and TTC might be bound and internalized by neural cells to a 
greater extent than mediated by either domain alone.  TTC contains multiple neuronal-
specific binding domains including two complex ganglioside binding sites and protein 
receptors (Chen et al., 2009; Miana-Mena et al., 2002; Yeh et al., 2010) while Tat binds in 
a receptor-independent manner.  To test this hypothesis, three recombinant proteins were 
created and assessed: Tat-GFP, TTC-GFP, and Tat-TTC-GFP.  To determine if the TTC 
containing recombinant proteins retained neuronal cell type-specific binding and 
internalization properties of TTC, N18-RE-105 neuroblastoma cells and 3T3 fibroblasts 
were also transduced with the three proteins of interest.   
PCI was then utilized to mediate cytosolic release of the internalized recombinant 
proteins using incubation with unconjugated meso-tetraphenylporphine disulphonic acid 
dihydrochloride (TPPS2a). Since the method involves the oxidative damage of membranes, 
PCI has the capability to cause high cytotoxicity.  Often, PCI is utilized to enhance 
intracellular delivery of toxic drugs such as saporin or bleomycin in the setting of 
enhancing cancer cell death (Fretz et al., 2007; Wang et al., 2012).  However, because the 
goal of the current study was to delivery high quantities of protein to viable cells, 
characterizing and limiting cytotoxicity was a point of emphasis.  It has been suggested 
that ~50% of endosomally-entrapped protein can be released with subtoxic light treatment 
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(Selbo et al., 2010).  With high toxicity, essentially total endosomal rupture can be achieved 
with our PCI method.  However, with optimization of light treatment time and power, 
obvious cytosolic release was observed with acceptable levels of cytotoxicity.     
2.3. Methods and Materials 
2.3.1. Plasmid construction 
The Tat-GFP construct was created by separately cloning sequences for Tat and 
Enhanced Green Fluorescent Protein (EGFP) into pGEX6P-3 (GE Healthcare).  
Oligonucleotides for the 11 amino acid Tat sequence were made by the University of 
Maryland at Baltimore Biopolymer Laboratory.  This sequence represents residues 47-57 
of the HIV-1 protein Tat.  Tat was cloned into the BamHI-EcoRI sites of pGEX6P-3.  
EGFP was amplified from Clontech vector pEGFP-1 and cloned into the EcoRI-SalI sites 
of the Tat-containing pGEX6P-3.  This created plasmid pGEX6P3_Tat_GFP.   
To create the TTC-GFP construct, TTC and EGFP were cloned into the pGEX4T-
3 bacterial expression vector.  TTC was amplified from cDNA generously provided by Dr. 
Neil Fairweather of Imperial College (Makoff et al., 1989).  Similar to construction of 
pGEX6P3_Tat_GFP, EGFP was amplified from pEGFP-1.  TTC was cloned into 
pGEX4T-3 with BamHI and BglII-NotI sites that were designed in the primers.  
Subsequently, EGFP was cloned into pGEX4T-3 with BglII and NotI sites.  The final 
vector was named pGEX4T3_TTC_GFP. 
The pGEX4T3_Tat_TTC_GFP construct was created by inserting the Tat sequence 
into pGEX4T3_TTC_GFP using the same strategy employed in the creation of 
pGEX6P3_Tat_GFP.  All expression vectors were sequenced to confirm all cloned 
fragments were in-frame and not mutated.   
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2.3.2. Expression and purification of recombinant proteins 
  Bacteria transformed with the expression vectors for Tat-GFP, TTC-GFP, and Tat-
TTC-GFP were cultured to an OD600 of 0.6 at 37°C.  At this point, cultures were induced 
with 0.1mM IPTG (isopropyl-β-D-thiogalactopyranoside, Invitrogen) and grown overnight 
at 25°C.  After ~21 hours of growth, cultures were harvested by centrifugation.  After 
discarding the supernatant, cell pellets were frozen at -80°C until purification.  Cell pellets 
were thawed and lysed with 1mg/mL lysozyme (Sigma), 1% Triton X-100 and brief 
sonication.  After cell lysis, the lysate was centrifuged at 14,000 RPM for 30 minutes and 
pelleted insoluble cell debris was discarded.  The GST-linked proteins in the soluble 
fraction were purified using Glutathione Sepharose 4B resin according to the 
manufacturer’s protocol (GE Healthcare).  Following purification, the GST was cleaved 
off Tat-GFP using PreScission Protease (GE Healthcare) and dialyzed against 1X PBS.  
The GST was cleaved off TTC-GFP and Tat-TTC-GFP using Thrombin (GE Healthcare).  
Protein quality was confirmed by SDS-PAGE (Figure 2.1) and protein concentrations were 










Figure 2.1: SimplyBlue Safestain of 6.5 µg purified proteins of interest.  The expected 
molecular weights of Tat-GFP, TTC-GFP, and Tat-TTC-GFP are 28.6 kDa, 80.7 kDa, and 
82.3 kDa respectively.  Tat-GFP ran between the 25 kDa and 37 kDa standard bands while 
both TTC-GFP and Tat-TTC-GFP ran above the 75 kDa standard band of the Precision 
Plus All Blue Protein Standard (Roche).  These proteins have been run on 4-12% Bis Tris 
SDS-PAGE gels (Life Technologies) many times with highly consistent results.  The image 
of the gel was cropped to remove additional (identical) elutions. 
 
2.3.3. Cell culture and protein transduction  
 Human neural progenitor cells (hNPCs, Lonza) were cultured in hNPC starting 
medium (Ebert et al., 2008).  Shortly after vial thaw (2-5 days), passage 4 neurospheres 
were dissociated with Accutase (Sigma) and expanded as single cells.   For protein 
treatment, NPCs were re-plated in poly-L-lysine-coated 8-well chambered coverglasses 
(Nunc) and allowed to expand 4-7 days until cells reached a density of ~25,000 cells/cm2.  
The NPCs were plated in 50% hNPC starting medium and 50% MEM (Gibco) 
supplemented with 5% horse serum. 
 N18-RE-105 cells were grown in DMEM (Gibco Catalog #11965) supplemented 
with 10% Fetal Bovine Serum (FBS, Gibco), 1X HAT Supplement (Sigma), and 1:100 
Penn/Strep (Gibco).  The cell line was subcultured twice per week to avoid culture 
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overgrowth.  The 3T3 fibroblasts were cultured in DMEM (Gibco Catalog #11995) 
supplemented with 10% FBS (Gibco) and 1:100 Penn/Strep (Gibco).  Due to the faster 
growth rate of 3T3 cells, they were subcultured three times per week.  Both N18-RE-105 
and 3T3 cells were plated in poly-L-lysine-coated 8-well Lab Tek Chambered 
Coverglasses and allowed to expand for two days until they reached ~25,000 cells/cm2.  
All cell culture growth was performed in a humidified incubator at 37°C and 5% CO2. 
 Cells were treated with Tat-GFP, TTC-GFP, and Tat-TTC-GFP for 18 hours in 
either fresh 4% serum media (N18-RE-105 and 3T3 cells) or hNPC starting medium 
(NPCs) and incubated at 37°C and 5% CO2.  Serum concentration was reduced for N18-
RE-105 and 3T3 cells to limit interference with CPP internalization (Eiríksdóttir et al., 
2010).  Cells were treated with 20µg/mL protein for all work except the dose-response 
experiment.  After the overnight incubation, cells were washed three times and imaged 
live.  The NPCs were washed with 70% DMEM (Gibco Catalog #11965), 30% F12 (Gibco 
Catalog #11765), 1:50 B27 (Gibco), and 1:100 Penn/Strep (Gibco).  This is the hNPC 
starting medium without growth factors or heparan sulfate.  N18-RE-105 and 3T3 cells 
were washed using reduced 4% serum media with otherwise identical supplements to the 
10% serum media in the appropriate DMEM formulation.   
2.3.4. Assaying cell-associated protein 
 To determine how much of each protein was bound or internalized by NPCs, cells 
were treated with 7 different concentrations of each protein: 0, 0.512, 1.28, 3.2, 8, 20, and 
50 µg/mL in a total 2mL working volume in poly-L-lysine-coated 6-well plates (Corning).  
NPCs for this experiment were plated in standard hNPC Starting Medium.  Duplicate wells 
were treated for all protein concentrations.  After the overnight incubation, cells were 
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washed quickly and thoroughly with 1X PBS, detached with Accutase (Sigma), and lysed 
with 60μL M-PER Mammalian Protein Extraction Reagent containing Halt Protease 
Inhibitor (Thermo Scientific).  Duplicate wells were lysed using the same 60μL volume of 
M-PER reagent to concentrate the lysate.  This was done because pilot experiments 
indicated that fluorescence was not above background when low numbers of cells were 
lysed.  As a result, this experimental procedure aimed to concentrate samples as much as 
reasonably possible.  Samples were diluted 1:7 in 1X PBS to get enough volume to load 
100μL/well in triplicate in black 96-well plates (Microfluor 2, Thermo Scientific) and read 
on the Victor 3 Multilabel Counter (Perkin Elmer).  GFP was excited at 485nm and 
emission was read at 535nm.  Cell-associated fluorescence (which includes both 
internalized protein and protein that remained bound to the cell surface ) was quantitated 
by comparing fluorescence with a standard curve created with the appropriate protein 
diluted in 1X PBS containing the identical concentration of M-PER in the lysed samples.  
Each standard curve contained blank buffer and 12 protein concentrations ranging from 
5.24E-4 to 12.5 µg/mL.  Total protein concentration was determined by Bradford Assay 
using Coomassie Protein Assay Reagent (Thermo Scientific).    
2.3.5. Fluorescent microscopy and image quantitation 
 All fluorescent microscopy was performed using an Axio Observer Z1 Motorized 
fluorescent microscope (Carl Zeiss, Inc.) and HBO 100 Mercury Arc Lamp.  Zeiss Filter 
#10 was used for GFP excitation and emission (excitation: 450-490nm BP, emission: 515-
565nm BP).  Fluorescent images were taken with a Zeiss AxioCam MRm monochrome 




 Image quantitation was performed using Zeiss Axiovision Software Version 4.6.3.  
Each of NPCs, N18-RE-105 cells, and 3T3 cells were treated with Tat-GFP, TTC-GFP, 
and Tat-TTC-GFP as described above.  Image quantitation was utilized to quantitatively 
determine cell type specificity because sensitivity was not an issue and fluorescent signal 
is readily evident for all combinations of protein and cell type.   
For accurate fluorescent quantitation, images should be acquired under identical 
conditions unless there is a compelling reason for not doing so (Cromey, 2010).  For the 
current study, all images were taken under identical microscope and software conditions 
with the exception of camera exposure time.  For NPCs and N18-RE-105 cells, the 
fluorescent signal intensity following Tat-GFP/TTC-GFP treatment and Tat-TTC-GFP 
treatment was very different.  For the appropriate Tat-TTC-GFP exposure time, signal was 
not present for the other two proteins.  Conversely, at the appropriate Tat-GFP/TTC-GFP 
exposure time, Tat-TTC-GFP signal was totally saturated.  Therefore, for each cell 
line/protein combination 11-14 images were taken with an appropriate exposure time 
where signal was clear but not saturated.   
 For each cell line/protein combination, 45-58 cells were selected for quantitation.  
To avoid bias in cell selection, all cells were chosen for quantitation from the phase contrast 
image.  Cells were only selected for quantitation if they were sufficiently separated from 
other cells to insure all fluorescent intensity originated from the cell of interest.  To 
determine signal intensity, the entire cell was outlined using the “outline splice” feature of 
Axiovision.  Phase contrast images were taken for all images for which fluorescent 
quantitation was performed.  Furthermore, cells were outlined for densitometry using the 
phase contrast. To accurately account for background, local background was determined 
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next to each cell (Waters, 2009).  All cell fluorescent intensities were normalized to their 
local background.  Since the fluorescent signal saturation was minimized, normalized 
signal intensities were approximated as directly proportional to time (Schönhuber et al., 
1997).  This approximation provided an effective basis upon which to compare cell type 
specificity of the Tat-TTC-GFP protein.  This method was appropriate due to scaling; it 
was used to compare protein internalization on the order-of-magnitude scale to determine 
cell type specificity.  Furthermore, this linear approximation was not required for the 3T3 
cells since imaging with the same camera exposure time was possible for all proteins.   
2.3.6. Photochemical internalization 
 Photochemical internalization (PCI) was mediated in NPCs following protein 
transduction using photosensitizer TPPS2a and fluorescent light delivered by the Zeiss Axio 
Observer Z1 through the Zeiss Fluar 2.5x/0.12 objective and Zeiss Filter #47 (excitation: 
426-446 BP).  Light intensity was attenuated using the manual attenuator wheel of the Zeiss 
Axio Observer Z1 fluorescent microscope.  The wheel has six neutral density settings 
which from settings 1-6 represent 100%, 70%, 50%, 40%, 20%, and 2% maximum light 
intensity.  To mediate PCI, fluorescent light was delivered with neutral density filter setting 
4 or 5   (ND4, ND5) in place representing 40% and 20% maximum light intensity 
respectively.  The peak excitation wavelength of photosensitizer TPPS2a is 420nm.  To 
prepare a 2mg/mL TPPS2a solution, 10mg TPPS2a was dissolved in 1mL 0.1N NaOH.  
Once in solution, the TPPS2a was diluted to 2mg/mL with 1X PBS pH=7.3.  Aliquots of 
the TPPS2a solution were frozen at -20°C and thawed immediately before use
 (Berg et al., 
2010).  The protein transduction procedure preceding PCI was performed as described 
above, except TPPS2a was added at the same time as the protein at a final concentration of 
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0.2µg/mL.  Once photosensitizer was added, all procedure steps were performed in 
subdued light.  After the 18 hour incubation, cells were washed three times as described 
with hNPC starting medium without growth factors or heparan sulfate.  The NPC cultures 
were then incubated four additional hours in hNPC starting medium to facilitate the 
diffusion of excess photosensitizer from the cell membrane.  Cultures were then washed 
one additional time, given fresh hNPC starting medium, and treated with fluorescent light 
to mediate PCI.   To image cells before and after PCI, three representative fields were 
selected before and after light treatment using the C-Apochromat 40x/1.2 W Korr 
objective.   
2.3.7. Cytotoxicity of photochemical internalization 
 The cytotoxicity of PCI was determined using an LDH assay, the Cytotoxicity 
Detection Kit (Roche).  Protein transduction and PCI were performed for each protein of 
interest in NPCs.  Although cells for the cytotoxicity experiments were plated in hNPC 
Starting Medium, beginning with the protein treatment, hNPC Starting Medium without 
F12 was used because sodium pyruvate in the F12 medium would have interfered with the 
LDH assay.  The 30% F12 was replaced with the appropriate sodium pyruvate-free DMEM 
formulation.  The cytotoxicity of PCI for NPCs was determined by LDH assay 24 and 48 
hours after light treatment in two experiments.  First, NPCs were treated with 
photosensitizer and 20 µg/mL Tat-GFP.  PCI was mediated for 10, 30, and 60 seconds with 
ND4 and ND5.  Subsequently, NPCs treated with TTC-GFP and Tat-TTC-GFP were 
subjected to 3 light conditions: 10, 30, and 60 second light treatments with only ND4.  All 
experimental conditions included duplicate wells although a few conditions had only one 
well due to cell loss in the extensive washing required preceding PCI.  After photochemical 
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internalization, media samples were collected after 24 and 48 hours of incubation at 37°C 
and 5% CO2.  Percent cytotoxicity was calculated according to manufacturer’s 
recommendations: Percent cytotoxicity = ((Test condition – Low Control)/(High Control)) 
*100, where the low control is an identical sample that did not receive a light treatment and 
the high control received a 1% Triton X-100 treatment.   
2.4. Results 
2.4.1. Qualitative description of protein internalization in NPCs 
 When NPCs were treated with equal protein concentrations by weight, it was 
observed that Tat-TTC-GFP was internalized considerably more than either Tat-GFP or 
TTC-GFP.  NPCs treated with the proteins of interest could not be photographed using the 
same camera exposure time without saturating Tat-TTC-GFP signal (Figure 2.2).  When a 
750 ms exposure time was used to image treated NPCs, Tat-TTC-GFP signal was saturated 
in most cells (Figure 2.2C).  Instead, a 100 ms exposure was needed to observe the 
punctuate Tat-TTC-GFP distribution (Figure 2.2D) in NPCs.  At this exposure time, Tat-
GFP and TTC-GFP fluorescence was not visible.  The punctuate protein fluorescence in 
NPCs is consistent with the common observation of endosomal entrapment (Gillmeister et 
al., 2011).  With the imaging conditions used, cytosolic fluorescence was not observed for 






Figure 2.2: A qualitative comparison of GFP internalization in NPCs. (A) Tat-GFP, 
750 ms exposure (B) TTC-GFP, 750 ms exposure (C) Tat-TTC-GFP, 750 ms exposure (D) 
Tat-TTC-GFP, 100 ms exposure. 400X fluorescent images were taken with a Zeiss 
AxioCam MRm monochrome camera (1.3 megapixel, 12 bits/pixel) using the C-
Apochromat 40x/1.2 W Korr objective. 
 
2.4.2. Quantitation of cell-associated protein in NPCs 
The concentration of Tat-GFP, TTC-GFP, and Tat-TTC-GFP present in protein-
treated NPC lysate was determined by quantitative fluorimetry.  For each of the three 
recombinant proteins, normalized lysate fluorescence was compared to a standard curve of 
the treated protein.  Fluorescence of background samples for the protein standards and 
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negative control protein lysates were subtracted from the protein standards and lysates to 
obtain normalized fluorescence values.  For each sample, 58-89 µg total lysate protein was 
collected.  Although comparable quantities of total protein were collected for all treatment 
conditions, when lysates were read on the fluorimeter, no incubation concentrations of Tat-
GFP or TTC-GFP gave clear fluorescence signal in the cell lysates over background.  Since 
the quantity of cell associated Tat-GFP and TTC-GFP could not be directly quantitated, 
the lowest concentration at which cell associated Tat-GFP or TTC-GFP would have been 
detected was estimated using the sensitivity of the standard curve for each of the proteins 
(Figure 2.3A).  This analysis determined the minimum concentrations of Tat-GFP or TTC-
GFP that would have been readily detected in the lysates.   To conservatively determine a 
maximum possible Tat-GFP or TTC-GFP concentration, the standards for which 
fluorescence was approximately twofold greater than the ~180 RFU background were 
determined.  For standard concentrations 0.0082, 0.0205, and 0.0512 µg/mL Tat-GFP and 
TTC-GFP, fluorescence was 252.00, 362.00, and 619.33 and 229.67, 292.67, and 382.67 
in RFUs, respectively.  Conservatively, the maximum Tat-GFP concentration in the lysate 
for any treatment condition was found to be 0.0205 µg/mL.  With a similar conservative 
estimate, the maximum TTC-GFP concentration present in any culture supernatant must 
be at most 0.0512 µg/mL.  In contrast, cell lysate from all six Tat-TTC-GFP treatment 
concentrations had normalized average fluorescence values well above the background.  In 
order to determine the concentration of Tat-TTC-GFP in the cell lysate, the concentration 
of Tat-TTC-GFP was plotted against the independent variable, normalized average 
fluorescence, to generate a standard curve.  For a more accurate concentration 




Figure 2.3: Standard curves for quantitation of GFP fluorescence. (A) Plots of the 
fluorescence versus protein standard concentration for each of the test proteins.  (B) 
Second-order polynomial fit of the Tat-TTC-GFP standard curve with normalized average 
fluorescence as the dependent variable.  Tat-TTC-GFP concentration in cell lysate was 
determined from the equation y = 7.79E-4(x)-9.63E-04(x2).  All standard curves were 
generated by plotting the average of triplicate protein samples.  The triplicate samples 
exhibited very minimal variability.   
 
The quantities of Tat-TTC-GFP detected in NPC cell lysate were divided by the 
total concentration of protein collected for each sample.  From this data, a dose-response 
curve was generated plotting cell associated Tat-TTC-GFP per total lysate protein (ng/µg) 
versus the concentration of Tat-TTC-GFP provided in the media (µg/mL) (Figure 2.4).  
When cells were incubated with 20µg/mL, 9.71ng of cell associated Tat-TTC-GFP was 
detected per microgram total lysate protein representing 0.89% of total incubated 
fluorescent protein. 
 For the 20 µg/mL Tat-TTC-GFP treatment condition, 1.70 µg/mL Tat-TTC-GFP 
was detected in the cell lysate.  Using this data, the increase in protein bound and 
internalized by the cells can be approximated based upon the estimates of maximum cell 
associated Tat-GFP and TTC-GFP (0.0205 µg/mL and 0.0512 µg/mL respectively).  When 
NPCs were treated with 20 µg/mL of purified protein, Tat-TTC-GFP was bound or 
internalized at least 83-fold greater than Tat-GFP and 33-fold more than TTC-GFP.  The 
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dose-response curve for Tat-TTC-GFP indicates the approximately linear cellular 
association does not continue beyond 20 µg/mL treated Tat-TTC-GFP (Figure 2.4). 
 
Figure 2.4: Dose-response curve for Tat-TTC-GFP.  Each data point represents the 
lysate from pooled duplicate wells of six-well plates containing NPCs treated with varied 
concentrations of Tat-TTC-GFP.  All fluorimetry was performed on triplicate samples 
which exhibited very low variability.    
 
2.4.3. Enhanced Tat-TTC-GFP internalization is specific to neural cell types that 
bind TTC 
 In order to examine the cell type specificity of Tat-TTC-GFP binding, NPCs, N18-
RE-105 neuroblastoma cells, and non-neuronal 3T3 fibroblasts were incubated with Tat-
GFP, TTC-GFP and Tat-TTC-GFP.  Qualitatively, Tat-TTC-GFP-treated N18-RE-105 
cells exhibited much brighter fluorescence than either Tat-GFP or TTC-GFP-treated N18-
RE-105 cells.  Conversely, Tat-TTC-GFP did not seem to be preferentially internalized in 
3T3 cells.  As in our earlier experiments, marked differences in fluorescence intensity 
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necessitated different exposure times to image Tat-TTC-GFP internalization in NPCs and 
N18-RE-105 cells (Figure 2.5).   
 
Figure 2.5: Representative fields used for quantitation of fluorescence of internalized 
proteins in NPC, N18-RE-105, and 3T3 cells.  Camera exposure times are shown, and 
were chosen to limit signal saturation.  All images are 400X magnification.   
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For NPCs and N18-RE-105 cells, Tat-TTC-GFP fluorescence was greater than an 
order of magnitude above either Tat-GFP or TTC-GFP fluorescent intensity.  No increase 
in Tat-TTC-GFP internalization was observed compared to Tat-GFP internalization in 3T3 
cells (Table 1).  This fluorescence quantitation indicated that enhanced internalization of 
Tat-TTC-GFP is specific to neuronal cell types that bind TTC. 
 












Tat-GFP 749.83 285.29 285.29 1.00 
TTC-GFP 749.83 358.23 358.23 1.26 
Tat-TTC-GFP 99.90 686.80 5155.12 18.07 
N18-RE-
105 
Tat-GFP 2499.84 106.51 106.51 1.00 
TTC-GFP 2499.84 61.94 61.94 0.58 
Tat-TTC-GFP 749.83 438.27 1461.13 13.72 
3T3  
Tat-GFP 749.83 371.08 371.08 1.00 
TTC-GFP 749.83 94.48 94.48 0.25 
Tat-TTC-GFP 749.83 224.68 224.68 0.61 
 
Table 2.1: Summary of fluorescence image quantitation data for NPC, N18-RE-105, 
and 3T3 cells treated with Tat-GFP, TTC-GFP, and Tat-TTC-GFP.   
 
2.4.4. Photochemical internalization meditates the endosomal release of entrapped 
proteins in NPCs  
 Photochemical internalization (PCI) was used to mediate the cytosolic release of 
Tat-GFP, TTC-GFP, and Tat-TTC-GFP in NPCs.  Pilot experiments were performed to 
optimize the light treatment conditions that promoted the best balance of endosomal release 
and cell viability.  Using the Zeiss Axio Observer Z1 microscope, light intensities from 2% 
to 100% and treatment times up to five minutes were investigated (data not shown).  These 
initial experiments indicated that treating cells with 20% and 40% maximum light intensity 
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for up to 60 seconds facilitated endosomal rupture while maintaining cell viability.  For the 
higher light intensities and 60 second light treatment, nearly total endosomal release 
(Figure 2.6) but extremely high cell toxicity were observed.  This observation made it clear 
that working with higher intensities and longer treatment times was not necessary and 
excessive.   
 
Figure 2.6: NPCs treated with 20µg/mL Tat-GFP before (A) and after (B) PCI with 
60 seconds of maximum-intensity light treatment.  Minimal endosomal entrapment was 
observed post-PCI.  All images were taken at 400X magnification with a 1.5 s camera 
exposure time.  The displayed images are representative fields, not the same cells pre- and 
post-PCI. 
 
 While treatment times up to 60 seconds with 20%-40% maximum intensity light 
did not mediate total endosomal rupture, redistribution of all three proteins, (Tat-GFP, 
TTC-GFP, and Tat-TTC-GFP) from a punctate to a more uniform distribution was clearly 
observed (Figure 2.7).  Visually, clear GFP redistribution was observed for the 30 second 
treatment with 40% intensity and the 60 second treatment with 20% and 40% intensity 




Figure 2.7: PCI facilitates the cytosolic redistribution of Tat-GFP, TTC-GFP, and 
Tat-TTC-GFP in NPCs.  Light treatment was performed for 60 seconds with neutral 
density setting #4 representing 40% maximum light intensity.  All images were taken at 
400X magnification with a 750 ms camera exposure time.  Images are representative fields 
and not the same cells pre- and post-PCI.   
 
Two key observations were made from experiments at different light intensities 
where NPCs were treated with Tat-GFP only.  First, 40% intensity treatment for 10-60 
seconds resulted in higher cytotoxicity than the corresponding 20% intensity treatment.  
Second, cell survival was very similar for the 24 and 48 hour samples regardless of light 
exposure paradigm (Figure 2.8A).    Based upon this experiment with Tat-GFP, NPCs were 
treated with either TTC-GFP or Tat-TTC-GFP confirming the initial observation that light 
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intensity and treatment time were the only important factors determining cytotoxicity.  
While lower cytotoxicity levels sixty seconds after light treatment were generally observed 
with TTC-containing vectors, no obvious difference in cytotoxicity was observed based 
upon which protein was used.  For all proteins over both experiments, treatment times 
between 10 and 60 seconds with 40% light intensity yielded percent cytotoxicities of 0.5-
6.3%, 23.2-35.4%, and 46.4-71.3% respectively.  Interestingly, the 24 and 48 hour 
cytotoxicity data sets were very similar (Figure 2.8B).  All cytotoxicity data is summarized 
below (Table 2.2). 
 
Figure 2.8: PCI cytotoxicity for NPCs was assayed 24 and 48 hours after light 
treatment. (A) NPCs were treated with Tat-GFP and subjected to light treatments with 
neutral density settings #4 (ND4) and #5 (ND5) representing 40% and 20% maximum light 
intensity respectively.   (B) PCI cytotoxicity for NPCs treated with Tat-GFP, TTC-GFP, or 
Tat-TTC-GFP.  PCI was mediated with 40% maximum light intensity only.  LDH assay 
for all cell lysates was performed in triplicate with minimal variability.     
 
Control cultures were evaluated to examine for any potential cytotoxic effect of the 
photosensitizer and/or light treatment.  LDH absorbance was nearly identical for cells that 
did not receive treatment of any kind and cells treated with photosensitizer and protein but 
not exposed to light.  An additional set of control cells were treated only with the maximum 
intensity light used in the study: 60 seconds with 40% intensity.  This control indicated that 
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cells receiving light exposure without protein or photosensitizer treatment experienced 















24 Tat GFP 10 0.72 
24 Tat GFP 30 6.77 
24 Tat GFP 60 28.15 
40% 
24 Tat GFP 10 2.46 
24 Tat GFP 30 23.15 
24 Tat GFP 60 60.51 
40% 
24 TTC GFP 10 0.48 
24 TTC GFP 30 27.27 
24 TTC GFP 60 51.59 
40% 
24 Tat-TTC-GFP 10 1.68 
24 Tat-TTC-GFP 30 26.75 
24 Tat-TTC-GFP 60 67.41 
20% 
48 Tat GFP 10 0.2 
48 Tat GFP 30 5.62 
48 Tat GFP 60 32.02 
40% 
48 Tat GFP 10 0.58 
48 Tat GFP 30 26.99 
48 Tat GFP 60 71.29 
40% 
48 TTC GFP 10 2.91 
48 TTC GFP 30 26.65 
48 TTC GFP 60 46.37 
40% 
48 Tat-TTC-GFP 10 6.28 
48 Tat-TTC-GFP 30 35.41 
48 Tat-TTC-GFP 60 48.74 
 
Table 2.2: Compilation of cytotoxicity data for NPCs 24-48 hours after 
binding/internalization of Tat-GFP, TTC-GFP, or Tat-TTC-GFP and light treatment 
to mediate photochemical internalization.  The ND4 and ND5 filters referenced in the 





Our observation that Tat considerably increases protein internalization in 
conjunction with TTC is reasonable when considering the mechanism of TTC binding 
itself.  TTC promotes high-capacity neuron-specific binding using multiple binding sites 
for a variety of neuronal receptors (Fishman, 2009).   Two carbohydrate binding pockets 
interact with complex gangliosides (Chen et al., 2009).    TTC can also interact with N-
glycosylated P15 and the recently determined SV2A/B protein binding site (Miana-Mena 
et al., 2002; Yeh et al., 2010).  TTC has been previously combined to a non-specific vector 
as a ternary complex with plasmid DNA and PEI to improve the transfection efficiency of 
neurons (Oliveira et al., 2010).  Although the exact mechanism of Tat is not fully 
understood, Tat is commonly thought to mediate cellular uptake in a receptor-independent 
manner (Jones et al., 2005; Kaplan et al., 2005; Nakase et al., 2007; Wadia et al., 2004).  
The addition of Tat to the TTC-GFP vector may provide an additional binding site to 
enhance the membrane association of TTC without interfering with the membrane binding 
properties of TTC. 
While the mechanisms for Tat and TTC uptake are different, upon cellular 
internalization both Tat and TTC-conjugated proteins are sequestered in endosomal 
vesicles.  Tat is able to promote limited endosomal escape, while TTC is unable to mediate 
endosomal membrane translocation (Gillmeister et al., 2011).  The minimal escape 
afforded by Tat is not sufficient for many potential applications of protein transduction.  In 
the current study, all test proteins were internalized in endosomal vesicles and cytosolic 
GFP fluorescence was not observed following treatment even with Tat conjugated proteins.  
This finding is consistent with our previous study of Tat-GFP and TTC-GFP where 
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conjugation of rhodamine to Tat-GFP was required to observe cytosolic fluorescence.  
Even with the rhodamine tag, quantitation of the distribution of Tat-GFP was not 
significantly different from that of TTC-GFP (Gillmeister et al., 2011).  Thus, facilitating 
the cytosolic release of entrapped proteins was an additional goal of the current study, 
because maximizing internalization is not very useful if the protein is not biologically 
available.  As mentioned in the introduction, the method of Tat-conjugated cargo protein 
internalization remains controversial.  While endocytosis is clearly involved, both lipid 
raft-dependent macropinocytosis and clathrin-mediated endocytosis have been implicated 
(Jones et al., 2005; Kaplan et al., 2005; Nakase et al., 2007; Rinne et al., 2007; Wadia et 
al., 2004).  While the mechanism of endocytosis was not determined for the recombinant 
proteins in the current study, the localization of Tat-GFP, TTC-GFP, and Tat-TTC-GFP 
was consistent with past observations of endosomal entrapment for both Tat and TTC-
conjugated cargo proteins.   
Multiple domains have also been previously used to improve CPP-linked delivery.  
Plasmid DNA delivery was increased through covalent linkage of a polyarginine CPP and 
a piggyBac transposase (Lee et al., 2011).  Branched CPPs exhibited higher biological 
activity for the delivery of PNAs (Saleh et al., 2010).  Tat conjugated to an integrin-binding 
motif increased DNA transfection efficiency with lipofectamine 5-fold over transfection 
with lipofectamine alone (Renigunta et al., 2006).    The delivery of siRNA was enhanced 
by the addition of a CPP and fatty acid to a protein nucleic acid (PNA). The CPP mediated 
internalization while the fatty acid facilitated endosomal escape (Shiraishi et al., 2011).  
Similarly, antisense oligonucleotide delivery was enhanced using stearylated CPPs 
(Hassane et al., 2011).  Dimerization of CPPs was found to facilitate direct transport over 
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endocytosis.  This effectively increased internalization of protein and eliminated the need 
for endosomal escape (Geisler et al., 2011).  A novel peptide CAYHRLRRC was identified 
for the delivery of therapeutic agents preferentially to leukemia and lymphoma cells.  This 
peptide contained a region for lymph node targeting and a sequence for cell penetration 
(Nishimura et al., 2008).   
While Tat promotes cellular uptake of protein in many cell types, TTC is a highly 
efficient delivery vector for only neuronal cell types with the appropriate receptors.  As a 
result, Tat-TTC-GFP appears to significantly increase GFP internalization in only cell 
types that bind TTC.  This hypothesis was confirmed by treating N18-RE-105 and 3T3 
fibroblast cells with all three proteins of interest and imaging the cells to compare 
internalization.  N18-RE-105 neuroblastoma cells express complex gangliosides including 
GT1b and have been previously used as a positive control for TTC-binding
 (Walton et al., 
1988).   The 3T3 cell line has also been previously used as a negative control for non-
specific TTC binding (Oliveira et al., 2010).  Both visual observations and fluorescent 
quantitation confirmed that Tat-TTC-GFP was preferentially internalized in NPCs and 
N18-RE-105 cells but not in 3T3 cells, where TTC linked proteins showed no superiority 
over Tat linkage alone (Table 1).   Direct fluorometic measurements of cell lysates were 
highly consistent with the quantitative microscopy data sets demonstrating enhanced 
protein internalization with the recombinant combination of Tat and TTC.  The approach 
utilizing fluorimetry although more direct, does not  measure  solely  recombinant protein 
that is internalized, but also  includes protein that remains on the cell surface after washing.  
Tat-TTC-GFP was internalized or bound at least 83-fold higher than Tat-GFP and at least 
33-fold higher than TTC-GFP.  These estimates are comparable to an order of magnitude 
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enhancement of internalization for Tat-TTC-GFP over Tat-GFP and TTC-GFP 
respectively by quantitative microscopy. 
This combined Tat-TTC delivery strategy represents a novel method to increase 
internalization of a full-length protein over a control CPP-protein conjugate for neuronal 
cell types.  Previous approaches have been considered to increase both CPP internalization 
as well as transduction into the cytosol.  Dimeric cationic amphiphilic CPP P11LRR was 
found to mediate cellular uptake ~30-fold over Tat.  At higher concentrations this CPP also 
exhibited direct transport to the cytosol over endocytosis (Geisler et al., 2011).  Another 
CPP modification strategy to improve uptake and cytosolic availability attached the 
GKPILFF sequence of Cathespin D to CPP R8.  This R8-CathD CPP was internalized 5-
fold over the R8 CPP itself.  The inverted R8-CathD CPP was internalized 18-fold over the 
R8 CPP.  Both of these modified CPPs were found to increase endosomal escape over the 
control (Takayama et al., 2009).  These studies did not investigate whether uptake was still 
enhanced with conjugation to a cargo protein (Manosroi et al., 2011).   
Successful strategies to enhance the delivery of full length proteins are less 
prevalent in the literature.  One study found that 10% DMSO pretreatment increased FITC-
Tat uptake 2 to 4-fold depending on the cell line used.  Tat-GFP uptake was also shown to 
increase significantly following the DMSO pretreatment although quantitative results were 
not provided (Wang et al., 2010).  Nanovesicular systems of liposomes and niosomes were 
used to deliver Tat-GFP to HT-29 colon carcinoma cells.  When loaded into elastic anionic 
niosomes, Tat-GFP was internalized 2.8-fold more than unloaded Tat-GFP (Manosroi et 
al., 2011).  Numerous gene delivery systems have utilized Tat in conjunction with other 
functional domains to increase membrane binding or nucleic acid delivery.  The use of 
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multiple binding domains was successful although the outputs, such as splice-correction, 
are difficult to compare to direct protein internalization (Hassane et al., 2011; Lee et al., 
2011; Renigunta et al., 2006).  Indeed, the Tat-TTC protein delivery vector provides a 
dramatic advancement in the efficiency of protein delivery to neuronal cell types.   
We recognize that the rationale for combining TTC and Tat may appear 
counterintuitive since the entire 100 kDa heavy chain of tetanus toxin, which contains both 
the membrane binding (TTC) and translocation domains of tetanus, could have been used 
to deliver the model cargo protein GFP.  There are a number of reasons why we chose to 
investigate the use of Tat as a membrane binding and translocation domain.  First and most 
importantly, our laboratory and others have found that the heavy chain of tetanus toxin 
does not efficiently mediate the membrane translocation when conjugated to a cargo 
protein.  Second, Tat provides a receptor-independent binding domain to act in conjunction 
with the receptor-dependent TTC.  Third, use of the heavy chain over Tat-TTC essentially 
doubles the size of the binding domain and would likely lead to increased difficulties in 
protein expression.   
Different strategies for promoting the endosomal escape of cargo macromolecules 
have been examined and evaluated in the literature with varying effectiveness (El-Sayed et 
al., 2009).  We chose to use PCI because of its potential to induce cytosolic release with 
very high efficiency, and its lack of a requirement for further modification of the protein 
to be delivered.  To mediate PCI in the NPCs, photosensitizer TPPS2a was delivered in 
combination but not linked to the proteins of interest.  PCI methods employing linked 
photosensitizers have also been used with success, but diminished fluorescence within the 
endosomes has been observed (Matsushita et al., 2004). 
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 Our method for mediating PCI using a fluorescent microscope proved very efficient 
at facilitating the release of protein from the endosomes.  When maximum intensity light 
was delivered for 60 seconds, virtually total endosomal rupture was observed.  While 
powerful, this method was highly cytotoxic and required further optimization for practical 
use.  Experimentation with a wide range of combinations of light intensity and treatment 
time allowed us to identify the range in which PCI was efficient with acceptable 
cytotoxicity.  No toxicity was observed for protein and photosensitizer treatment without 
PCI.  Treating NPCs with 20-40% maximum intensity light for 0-60 seconds yielded 
cytotoxicity from less than 1% to 70%.  Furthermore, the cytotoxicity profiles indicate 
further optimization of cytosolic release and cytotoxicity is possible.  This study 
demonstrates that effectively mediating PCI while maintaining 80% cell viability is clearly 
possible.  Toxicity in samples treated with light for 60 seconds, especially 48 hours after 
light treatment, appeared to be lowest when TTC-conjugated proteins were delivered, an 
observation that could be due to the described neuroprotective properties of TTC (Calvo et 
al., 2012).     
 The PCI toxicity observations reported here are consistent with the relatively 
limited available data from the literature.  Light doses leading to 30-50% toxicity are 
recommended for photochemical transfections (Berg et al., 2010).  Tat conjugated to 5(6)-
carboxytetramethylrhodamine (TMR) was found to be an efficient photosensitizer, 
mediating endosomal release within a few hundred milliseconds upon light treatment.  
However, extremely high toxicity was observed from this treatment (Srinivasan et al., 
2011).  Another application of PCI was using photosensitizer TPPS2a to promote the 
endosomal escape of saporin delivered in liposomes.  The method alone without saporin 
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found 45-120 second light treatments caused 20-50% cytotoxicity 48 hours after treatment.  
As we observed, longer light treatments yielded more cell death (Fretz et al., 2007).  PCI 
using a macromolecule-linked photosensitizer method has also been found to be toxic.  An 
Alexa Fluor 546 fluorophore was conjugated to a U1A RNA-binding domain for siRNA 
delivery.  PCI was mediated to enhance delivery and 22 hours after light treatment, ~40% 
cytotoxicity was observed (Endoh et al., 2008). 
2.6. Conclusions  
Cellular uptake and cytosolic release are two major challenges to protein 
transduction efficiency (El-Sayed et al., 2009).  In the current study, the use of multiple 
functional binding domains and photochemical internalization (PCI) effectively addressed 
both of these challenges to enhance protein delivery in neural progenitor cells (NPCs).  
Cellular association and internalization of GFP was dramatically enhanced by the addition 
of both Tat and TTC domains, while the specificity of neural cell delivery of TTC was 
preserved. The combination of a small CPP and a receptor specific vector yielding 
enhanced binding and internalization, and retention of cell-specific binding, could apply to 
a variety of receptor specific vectors and cell types.    
None of the vectors, including the hybrid vector in the current study, demonstrated 
detectable translocation to the cell cytosol. This limitation was successfully addressed with 
the application of PCI. The PCI procedure outlined here is probably not cell type specific, 
and could be useful to anyone interested in macromolecule delivery.  The combinatorial 
use of multiple binding domains and PCI could be an invaluable tool for direct protein 




Chapter 3: Production and Delivery of Recombinant Transcription 
Factors 
3.1. Abstract 
 The last decade has seen a dramatic improvement in genetic-modification based 
strategies for stem cell differentiation.  While exciting, any cell generated by a 
differentiation approach that involves genetic modification is unsuitable for human 
transplantation.  Genetic modification, especially with the introduction of powerful viral 
promoters, increases the risk of tumor formation.  This is an outcome that would outweigh 
any therapeutic effects provided by the delivered cells.  The current study proposed that 
neuronal differentiation could be mediated through the direct treatment of cells with cell-
penetrating peptide-linked recombinant transcription factors.  While a protein delivery 
approach faces a number of additional challenges, it would generate cells that are safe for 
human therapy. 
 In pursuit of mediating neuronal differentiation with a protein-based approach, Tat-
linked Mash1 and Lmx1a with and without GFP were expressed via transient transfection 
of HEK 293F cells and purified from the insoluble fraction of cell lysate.  The biological 
activity of transcription factors was evaluated by testing for nuclear delivery following 
protein transduction and photochemical internalization and evaluating the induction of 
reporter gene expression after transcription factors were delivered by either co-transfection 
with the reporter vector or directly as a purified protein.  The majority of designed 
transcription factors induced reporter expression following co-transfection.  However, 
these results could not be reproduced with direct protein delivery, calling the efficiency of 
protein delivery and/or the functionality of the transcription factors produced into question.  
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The first step towards overcoming these limitations has been successfully accomplished; a 
new mammalian cell in vitro translation kit was successfully used to produce high 
concentrations of soluble Tat-Mash1 and Tat-Mash1-GFP.  The use of an in vitro 
transcription factor production method has not been described in the literature.  This 
finding could be critical for future efforts to mediate neuronal differentiation with defined 
purified factors.   
3.2. Introduction 
 Cell-replacement therapy has long been considered an exciting option for 
neurodegenerative disease therapy.  In cell-replacement therapy, the neuronal cell type lost 
due to the disease would be delivered; as the new cells integrate with the rest of the nervous 
system the disease phenotype would become less severe and possibly even reversed.  
Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons from the 
substantia nigra, affecting 1% of individuals over the age of 60.  Currently, PD is viewed 
as an ideal candidate for cell replacement therapy (Thomas, 2010).   
 Despite the potential for cell-replacement therapy for PD, there are a number of 
limiting factors that include obtaining stem cells to differentiate and the safety of the 
differentiation process.  The discovery of induced pluripotent stem cells (iPSCs) as an 
alternative to human embryonic stem cells (hESCs) in recent years has made cell 
replacement therapy a more viable therapeutic option since a potentially limitless supply 
of stem cells for differentiation could be available without any ethical or regulatory 
concerns regarding the source of the cells.  In 2006, the Yamanaka lab discovered that the 
infection of fibroblasts with lentiviral vectors expressing transcription factors Oct4, Sox2, 
c-Myc, and Klf4 induced pluripotency (Takahashi et al., 2006).   
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 Although iPSCs potentially alleviate the concerns of sourcing large quantities of 
stem cells, they present safety issues.  The lentivirus-mediated genetic manipulation and 
overexpression of transcription factors dramatically enhances the tumor-forming potential 
of transplanted cells.  Even when the transcription factor gene sequence can be removed 
after differentiation, safety concerns are not fully alleviated.  In 2009, an iPSC line was 
generated by the direct delivery of the four purified transcription factors.  Critically, these 
protein-induced PSCs (piPSCs) were capable of indefinite expansion (Zhou et al., 2009).  
These transcription factors were expressed with an 11 amino acid polyarginine sequence 
to facilitate binding and internalization of the purified transcription factors.   
 In 2010, the idea of iPSC creation as a source of stem cells from which 
dopaminergic neurons could be generated was taken a step farther when the Wernig 
laboratory published the direct conversion of fibroblasts to neurons without an intermediate 
pluripotent state.  Originally, it was thought that this direct conversion would be 
impossible.  To test their hypothesis that such a direct conversion was possible, 19 different 
transcription factor lentiviral expression vectors were created.  From this pool, it was found 
that a combination of three was necessary to facilitate neuronal transdifferentiation: Mash1 
(AsclI), Brn2, and Mytl1 (Vierbuchen et al., 2010).  After this discovery was published, 
two methods describing the generation of dopaminergic neurons directly from fibroblasts 
were developed.  The first published method used the initial transdifferentiation cocktail 
plus dopaminergic factors FoxA2 and Lmx1a (Pfisterer et al., 2011).  The second published 
method generated dopaminergic neurons directly from fibroblasts directly via delivery of 
Mash1, Lmx1a, and Nurr1 (Caiazzo et al., 2011).   
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 The differentiation of stem cells or transdifferentiation of fibroblasts has 
traditionally been done in a method analogous to the creation of iPSCs.  Expression vectors 
for transcription factors of interest are transfected into cells or lentiviral vectors are used 
to force continuous high level transcription factor expression.  While genetic manipulation 
is a powerful strategy for modifying cellular phenotypes, genetically modified 
dopaminergic neurons are not a practical source of replacement cells for PD patients.  As 
a result, there is a need for a method to induce neuronal differentiation or 
transdifferentation without genetic modification.  To accomplish this goal, the lab aimed 
to express and purify a library of recombinant transcription factors.  In 2011, it was reported 
that microRNA (miRNA) alone was capable of mediating transdifferentiation of fibroblasts 
to neurons.  However, this process was inefficient without the expression of at least 
NeuroD2 with two miRNAs (Yoo et al., 2011).  Even in this miRNA-based system, 
purified transcription factors would be an asset to improve efficiency.  The use of protein 
treatment of transcription factors to induce transdifferentiation has only very recently been 
shown.  Dopaminergic precursor cells were induced from fibroblasts using a complex 
procedure involving small molecules and Tat-linked Sox2 and Lmx1a (Mirakhori et al., 
2015).  This work was published only a month before this thesis was completed and 
unfortunately was not a useful reference when the work was completed from 2011-2012. 
 The long-term goal of the project was to design, express, and purify a small library 
of cell-penetrating peptide-linked functional transcription factors for the differentiation or 
transdifferentiation of source cells to dopaminergic neurons.  Initially, Mash1, Lmx1a, and 
Nurr1 were chosen for study based on Caiazzo et al. published in 2011.  However, each of 
these transcription factors has an important role in neuronal development and would be 
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interesting even independently of the others.  Mash1 (AsclI) is a member of the bHLH 
family of transcription factors and controls various stages of the neurogenesis process 
including neuronal differentiation, migration, axon guidance, and synapse formation 
(Vasconcelos et al., 2014).  Lmx1a is a critical factor involved in dopaminergic 
differentiation.  It was the first dopaminergic determinant transcription factor expressed 
and it binds to the tyrosine hydroxylase promoter (Barzilay et al., 2009).  Nurr1 is a member 
of the nuclear receptor superfamily and regulates the differentiation, migration, and 
maturation of mesencephalic dopaminergic neurons (Li et al., 2011).   
 In pursuit of the goal of mediating neuronal differentiation using purified 
transcription factors, expression vectors for Tat-Mash1, Tat-Mash1-GFP, Tat-Lmx1a, Tat-
Lmx1a-GFP, Tat-Nurr1, and Tat-Nurr1-GFP were designed.  Recombinant Tat-linked 
variants for each factor were designed with and without GFP because GFP had the potential 
to improve protein expression and enabled the binding and internalization of the 
transcription factors to be assessed.  The downside of adding GFP was a potential negative 
impact on transcription factor activity.  Transcription factors were expressed via the 
transient transfection of HEK 293F suspension cells and purified from the insoluble 
fraction of the cell lysate.  The functionality of recombinant Mash1 and Lmx1a proteins 
was assessed.  While all transcription factors besides Tat-Mash1-GFP were functional 
when delivered by co-transfection, the purified proteins were not observed to have any 
significant activity.  For future work, alternate expression systems were assessed with the 
goal of producing high-levels of soluble transcription factors.  A commercially available 
HeLa cell lysate in vitro translation system was identified for its potential for soluble 
transcription factor production.  The results of this study show that before neuronal 
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differentiation can be mediated with defined purified transcription factors, the issues of 
production, solubility, and delivery efficiency must be addressed.   
3.3. Materials and Methods 
3.3.1. Creation of pSecTag2a-based transcription factor expression vectors 
 Expression vectors for six Tat-linked transcription factors were created: Tat-
Mash1, Tat-Mash1-GFP, Tat-Lmx1a, Tat-Lmx1a-GFP, Tat-Nurr1, and Tat-Nurr1-GFP.  
All were created using a modified pSecTag2a (Life Technologies) containing Tat in the 5’ 
end of the multiple cloning site.  The pSecTag2a expression vector possesses a number of 
features that lend it itself to the expression of recombinant transcription factors including 
an IgK signal peptide to facilitate secretion, a myc epitope tag to enable easy detection, and 
a 6x His tag for affinity purification.   
 The human Mash1 gene was recovered from a fibroblast cell line infected with a 
lentivirus generated by GeneCopoeia.  RNA was purified from fibroblast cells and cDNA 
was generated.  Mash1 was amplified using PCR and cloned into pSecTag2a containing 
the Tat sequence using HindIII and BamHI restriction sites.  Restriction sites were designed 
into the PCR primers for cloning.  This completed sequence was confirmed and given the 
name pTagTat_Mash1.  The completed pTagTat_Mash1 was used to create 
pTagTat_Mash1_GFP.  The sequence for EGFP was cloned into the backbone via BamHI 
and NotI restriction sites.   
 Each of the pTagTat_Lmx1a, pTagTat_Lmx1a_GFP, pTagTat_Nurr1 and 
pTagTat_Nurr1_GFP constructs were created using an analogous procedure with the same 
starting expression vector and added HindIII and BamHI restriction sites.  Human Lmx1a 
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cDNA was purchased from Origene for use as a PCR template.  Similarly, pTagTat_Nurr1 
and pTagTat_Nurr1_GFP were created 
3.3.2. Cell culture 
HEK 293F suspension cells grown in CD CHO medium (Life Technologies) were 
adapted into Freestyle 293 medium (Life Technologies) since CD CHO contains an anti-
clumping agent that inhibits transfection.  HEK 293F suspension cells were passaged in 
Freestyle 293F medium three times per week seeding at 2-4E5 cells/mL and passaging 
before the cells exceeded the cell density of 2E6 cells/mL.  Cultures were vortexed for 30 
seconds before each passage to break up cell clumps.   
Neural Progenitor Cells (NPCs) and select immortalized cell lines were used to 
evaluate the transcription factors binding/internalization and functionality.  NPCs and 3T3 
cells were cultured as described in Chapter 2, Section 2.3.3.  SK-N-BE(2)C neuroblastoma 
cells were grown in 50% EMEM medium (ATCC) and 50% F12 medium (Gibco) 
supplemented with 10% fetal bovine serum (Gibco).  The cells were subcultured twice per 
week. 
3.3.3. Transient expression of recombinant Tat-linked transcription factors in HEK 
293F suspension cells 
  Tat-linked transcription factors were produced by transient transfection of HEK 
293F cells using 293fectin reagent (Life Technologies).  One day before transfection, cells 
were seeded at 7E5 cells/mL in either 40mL in a 125mL vented non-baffled shake flask or 
160mL in a 500mL vented non-baffled shake flask.  Cultures were grown overnight until 
a cell density of 1.2E6-1.5E6 cells/mL was reached.  At this time, 3.0E7 cells were 
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transfected in a final volume of 30mL with 30µg of DNA complexed with 293fectin at a 
2:1 ratio of 293fectin reagent and plasmid DNA.   
 Transfected cultures were maintained at 37ºC and 5% CO2 for 2-3 days before 
being harvested.  Samples of medium and cells were taken daily during production for 
evaluation of protein secretion and yields before purification.  Cell-free medium was 
collected and stored at 4ºC pending evaluation of its transcription factor content.  The cell 
pellet was washed 1X with an equal volume of 1X PBS pH = 7.4 and frozen at -80ºC.   
 Small-scale samples were lysed with M-PER protein extraction reagent (Pierce) 
and centrifuged at 14,000xg for 15 minutes to collect the soluble fraction of the lysate.  The 
insoluble pellet was dissolved in SDS-containing sample loading buffer (Invitrogen) in 
preparation for SDS-PAGE analysis.  Samples of cell-free medium, soluble lysate, and 
insoluble lysate were evaluated for protein content by western blotting for the myc epitope 
tag.   
3.3.4. Purification of Tat-Mash1 and Tat-Lmx1a from the soluble and insoluble 
fractions of HEK 293F producer cells 
 Tat-Mash1, Tat-Mash1-GFP, and Tat-Lmx1a-GFP were purified from both the 
soluble and insoluble lysates where as Tat-Lmx1a was only purified from the insoluble 
lysate as no soluble material was detected.  Frozen cell pellets were lysed with 1mL M-
PER protein extraction reagent for every 100mg cell pellet.  Insoluble material was 
dissolved by adding 1mL 1X PBS pH = 7.4 containing 8M Urea for each 100mg of wet 
insoluble pellet, vortexing vigorously, and sonicating 30 seconds with 1 second pulses at 
50% power.  After centrifugation at 15,000xg for 10 minutes, any material not re-
solubilized was discarded. 
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 Proteins were purified using HisPur Ni-NTA Resin (Pierce) and purification buffers 
of 1X PBS pH = 7.4 (20mM sodium phosphate, 300mM NaCl) containing varied 
concentrations of imidazole.  Equilibration, wash, and elution buffers contained 10mM, 
25mM, and 250mM imidazole respectively.  All buffers used for purification of insoluble 
lysates contained 8M urea.   
 Protein was purified from soluble and insoluble lysates by adding an appropriate 
amount of equilibration buffer and binding 0.5mL Ni-NTA resin overnight at 4ºC.  
Following batch binding, the resin/lysate suspension was poured into a 2mL column and 
allowed to drain by gravity flow.  After the flow-through was applied over the resin one 
additional time, the resin bed was washed 3-4 times with two bed volumes of wash buffer 
until the A280 reading reached baseline followed by 3-4 elutions.  Later purifications used 
only 3 washes and elutions after that was determined to be more than sufficient.  Elutions 
of interest were dialyzed against 1X PBS pH = 7.4 using 10kDa MWCO Slide-A-Lyzer 
cassettes (Pierce) to remove 8M urea.  Final elutions were quantitated by Bradford assay.  
Densitometry was not performed on the specific bands because bands were not visible by 
coomassie staining.   
3.3.5. Protein transduction and nuclear delivery of recombinant factors using 
photochemical internalization (PCI) 
 Nuclear Tat-Mash1-GFP and Tat-Lmx1a-GFP delivery was attempted in NPCs by 
mediating photochemical internalization (PCI) following protein transduction.  NPCs were 
plated on poly-L-lysine-coated 8-well chambered coverglasses and allowed to expand 6 
days to ~2.5E4 cells/cm2.  After the six days, cells were treated with purified protein.  In 
the first experiment, cells were treated with either 1µg/mL Tat-GFP or 1µg/mL Tat-
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Lmx1a-GFP and 0.2µg/mL photosensitizer TPPS2a in NPC starting medium.  Since Tat-
Mash1-GFP purification yields were higher, in the second experiment, NPCs were treated 
with 1, 2.5, or 5µg/mL Tat-GFP or Tat-Mash1-GFP and 0.2µg/mL photosensitizer TPPS2a 
in NPC starting medium.   
Following an 18 hour overnight protein treatment, cells were washed three times in 
NPC starting medium without growth factors and incubated for 4 hours in NPC starting 
medium without photosensitizer at 37ºC and 5% CO2 in preparation for light treatment to 
mediate PCI.  Before PCI, three representative 400X images were taken for each treated 
well using the Zeiss Axio Observer Z1 fluorescent microscope.  PCI was mediated using 
the Fluar 2.5x/0.12 objective and Zeiss filter set #47 (excitation 426nm-446nm) by 
delivering 20-40% maximum intensity light for either 30 or 60 seconds.  Following PCI, 
cells were returned to the 37ºC incubator for four hours when 400X “post-PCI” images 
were taken to observe GFP signal after endosomal release.   
3.3.6. Promoter/reporter assays to test functionality of transcription factors 
delivered by cotransfection 
 Promoter/reporter assays were chosen as the most straightforward test for 
transcription factor functionality.  These promoter/reporter experiments were made 
possible by the generous gift of two reporter constructs for Mash1 and Lmx1a respectively.  
The 281-EL2 Mash1 reporter plasmid was provided by the Turner Lab and consists of a 
region of the Gadd45γ promoter upstream of luciferase (Huang et al., 2010).  The Lmx1a 
DAT-A reporter construct consists of a region of the dopamine transporter (DAT) gene 
repeated 14 times upstream of a luciferase (Chung et al., 2012).  This DAT-A reporter was 
a generous gift from Kwang-Soo Kim.   
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 In preparation for co-transfection of the reporter plasmids and transcription factor-
expressing plasmids, 10,000 cells/well of 3T3 or SK-N-BE(2)C cells were plated in 96-
well plates in antibiotic-free medium and allowed to double overnight.  At least 30 minutes 
before transfection, the culture medium was removed from all wells and 100µL Opti-MEM 
medium (Gibco) was added.  Each well was transfected with complexes of plasmid DNA 
and Lipofectamine 2000 in OptiMEM medium (Life Technologies).  Master mixes were 
prepared where single wells received 200ng total of plasmid, 100ng of each of a reporter 
plasmid and transcription factor-expressing plasmid, and 0.5µL Lipofectamine 2000.  To 
test background luciferase expression, reporter plasmids were co-transfected with pCMV-
MCS, an empty vector.  Six hours after transfection, complex-containing medium was 
discarded and fresh antibiotic-containing culture medium was added.  The Britelite Plus 
kit (Perkin Elmer) was used to assay luciferase activity 48-72 hours after transfection.   
3.3.7. Promoter/reporter assays to test functionality of transcription factors 
delivered via protein treatment 
 Two experiments were designed to test Tat-Mash1 and Tat-Mash1-GFP protein 
functionality using the 281-EL2 reporter vector.  Both experiments were initiated by 
transfecting 3T3 cells in 6-well plate format with the reporter vector.  Cells were 
transfected by creating complexes where each well received 4µg plasmid DNA and 10µL 
Lipofectamine 2000.  Complexes were added to 1.5mL OptiMEM medium in a volume of 
0.5mL OptiMEM.  All other steps of the reporter plasmid transfection were analogous to 
the procedure described in Section 3.3.6.  Transfected cells were incubated at 37ºC and 5% 
CO2 for 24 hours at which time protein treatment was performed.  For protein treatment 
and possible light treatment to mediate PCI, cells needed to be in 8-well chambered 
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coverglasses.  Cells transfected with 281-EL2 were dissociated using TrypLE Express and 
counted.  Master mixes containing protein with and without TPPS2a were created and used 
to resuspend transfected cells to plate 3.37E4 cells/well in poly-L-Lysine coated 
chambered coverglasses.  Cell density was calculated so the 8-well coverglasses were 
approximately 80% confluent.  PCI was mediated after an 18 hour protein treatment; the 
light treatment condition chosen was 20% maximum lamp power for 60 seconds.  The 
Britelite Plus kit was used to assay luciferase expression 24 hours after PCI.   
 Although the two experiments performed had a similar design, they varied in their 
protein treatment conditions.  For the first experiment, 3T3 cells were treated with 1µg/mL 
Tat-Mash1 or Tat-Mash1-GFP with or without 0.2µg/mL TPPS2a.  For each protein 
treatment condition and negative control, duplicate wells either did or did not undergo PCI.  
Mash1 protein was diluted in 3T3 base medium containing 4% FBS instead of the standard 
10% FBS for all protein transduction experiments.   
For the second experiment, cells were treated with cell lysate instead of purified 
protein.  Purified protein was only obtained in reasonable amounts from the insoluble 
fraction of cell lysates.  Due to concerns that protein derived from insoluble material might 
not be properly folded, cells were treated directly with lysate containing soluble protein.  
HEK 293F cell pellets from transient transfections were lysed by freeze/thaw to ensure the 
soluble protein was present in a buffer that would not be cytotoxic to the treated 3T3 cells.  
A pilot experiment was performed to determine what lysis method would harvest soluble 




Lane Description:  
  
1.       Precision Plus Standard 8.       Tat-Mash1-GFP, Sonication 
2.     Tat-Mash1, M-PER 9.       Tat-Mash1-GFP, Freeze/Thaw + Sonication 
3.     Tat-Mash1, Freeze/Thaw 10.   Negative, M-PER 
4.       Tat-Mash1, Sonication 11.   Negative, Freeze/Thaw 
5.       Tat-Mash1, Freeze/Thaw + Sonication 12.   Negative, Sonication 
6.       Tat-Mash1-GFP, M-PER 13.   Negative, Freeze/Thaw + Sonication 
7.       Tat-Mash1-GFP, Freeze/Thaw  
 
Figure 3.1: Comparison of soluble protein yields from selected lysis techniques.  HEK 
293F pellets transiently transfected with pTagTat_Mash1, pTagTat_Mash1_GFP, or the 
untransfected negative control were thawed and lysed.  Cell pellets were lysed by either 
M-PER lysis buffer treatment, freeze-thaw, sonication, or a combination of freeze-thaw 
and sonication.  Equal volumes of soluble lysate were run on a 4-12% Bis Tris SDS-PAGE 
gel and analyzed by anti-myc western blotting (5 minute exposure).  Expected sizes were 
Tat-Mash1= 33.6 kDa and Tat-Mash1-GFP= 60.5 kDa. 
 
 
Tat-Mash1, Tat-Mash1-GFP, and negative control transiently transfected cell 
pellets contained between 25-33 million cells.  Frozen cell pellets were thawed and 
resuspended in 133µL 1X PBS pH = 7.4 for each 1E6 cells and subjected to four 
freeze/thaw cycles in a dry ice/isopropanol bath.  Whole cell lysate was centrifuged at 
14,000xg for 15 minutes to remove any insoluble material.  Each well containing 3.37E4 
cells/well was treated with 75µL soluble lysate in 300µL total medium.  As with the first 
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experiment, TPPS2a was added to the master mix for duplicate wells for one set of each 
protein treatment condition so that PCI could be mediated.  Besides the protein treatment, 
the second experiment was identical to the first experiment.      
3.3.8. Production of soluble Tat-Mash1 using in vitro translation 
 Two in vitro translation systems were selected to attempt to improve the production 
of soluble Tat-Mash1 and Tat-Mash1-GFP.  The first system, the One-Step High Yield 
IVT Kit (Pierce), used HeLa cell lysate. The second was the Expressway Cell-Free 
Expression System (Life Technologies) using E. coli cell lysate.  Both systems were 
coupled in vitro transcription and translation kits requiring the input of only plasmid DNA.  
Furthermore, both IVT systems could be tested at the small scale but scaled-up to produce 
quantities of protein potentially enabling significant experimentation.   
 The expression vector chosen for the HeLa IVT kit was pT7CFE1 (Pierce) 
containing a C-terminal 6x His sequence for purification.  The Tat-Mash1-myc or Tat-
Mash1-GFP-myc sequences were amplified out of pTagTat_Mash1 or 
pTagTat_Mash1_GFP via PCR.  Restriction sites NdeI and SalI were engineered into the 
PCR primers for cloning into pT7CFE1.   
For the E. coli IVT system, Tat-Mash1 and Tat-Mash1-GFP were cloned into 
pEXP5-CT/TOPO using the pEXP5-CT/TOPO TA Expression Kit (Life Technologies).  
The final pEXP5_TatMash1 construct was confirmed to be the correct sequence.  It was 
found that the final pEXP5_TatMash1GFP construct contained an isoleucine to valine 
point mutation at amino acid #390 within the GFP sequence.  While this construct would 
not have been suitable for experimentation, it was used for an initial evaluation of the IVT 
system.   
80 
 
The Pierce IVT reactions were setup according to manufacturer’s 
recommendations.  All reactions were performed in the recommended tube setup where the 
outer tube contained 1X dialysis buffer prepared in nuclease-free water.  For the HeLa IVT 
kit, each 100µL reaction consisted of 50µL HeLa lysate, 10µL accessory proteins, 20µL 
reaction mix, 8µL 0.5µg/µL plasmid DNA, and 12µL nuclease-free water.  The HeLa IVT 
kit was also tried with half of the plasmid DNA in the mix above being replaced by the 
281-EL2 reporter vector to see if the promoter-reporter system could be activated in the 
IVT reaction.  All reactions were incubated at 30ºC for 24 hours without mixing.   
Expressway E. coli IVT reactions were also performed according to manufacturer’s 
recommended parameters.  Each 50uL reaction contained 20µL E. coli slyD extract, 25µL 
2X reaction buffer, 1.25µL 50mM amino acids without methionine, 1µL 75mM 
methionine, 1µL T7 enzyme mix, 1µL of 1µg/µL plasmid DNA, and 0.75µL nuclease-free 
water.  Reactions were incubated at 30ºC and 300RPM for 30 minutes at which time 50µL 
of 1X feed buffer were added.  The feed buffer master mix contained 100µL IVPS Feed 
Buffer, 6µL 50mM amino acids, 4µL75mM methionine, and 90µL nuclease-free water.  
Reactions were incubated at 30ºC and 300RPM 5.5 additional hours at which time they 
were stored at 4ºC awaiting SDS-PAGE.  
 Production yields from all IVT reactions were assessed using anti-Myc western 
blotting following SDS-PAGE.  HeLa IVT reactions were centrifuged for 5 minutes at 
10,000 RCF; insoluble pellets were discarded and the soluble supernatant was transferred 
to a fresh tube for analysis.  Expressway reactions were sampled for a “whole lysate” 




3.4.1. Transient expression of Mash1, Lmx1a, and Nurr1  
 Recombinant transcription factors were expressed by the transient transfection of 
HEK 293F suspension cells.  While the pSecTag2a base expression vector contained an 
IgK signal peptide to facilitate recombinant protein secretion, it was critical to determine 
if the produced transcription factors were secreted into the extracellular medium.  Past 
Fishman Laboratory experience expressing Tat-NeuroD2 and Tat-NeuroD2-GFP with the 
pSecTag2a vector indicated that expressed NeuroD2 was translocated to the nucleus and 
not secreted despite the presence of the secretion signal (Gillmeister, 2009).  This 
phenomenon was observed for all expressed transcription factors; a representative image 
for Tat-Mash1-GFP is provided below along with a representative image of a comparator 
secreted protein (Figure 3.2).   
 
Figure 3.2:  Transcription factors expressed in HEK 293F cells are translocated to the 
nucleus and not secreted.  Tat-Mash1-GFP fluorescence is found almost exclusively in 
the nucleus of producer cells.  Tat-GCase-GFP is a recombinant enzyme expressed and 
secreted in HEK 293F producer cells using the pSecTag2a vector (P. Gramlich Thesis 
Chapter 4).  Images were taken using the Zeiss Axiovert 40 CFL microscope and 20X 
objective.    Exposure times for the images were 372ms and 2000ms respectively for Tat-




 Equal volumes of cell-free medium, soluble lysate, and insoluble lysate were run 
on 4-12% SDS-PAGE gels to determine the fraction containing the majority of the final 
product.  The soluble and insoluble lysates were ~4x more concentrated than the cell-free 
medium.  Overall, the vast majority of produced protein was found in the insoluble lysate.  
Detectable signal in the cell-free medium was not observed for Tat-Lmx1a, Tat-Lmx1a-
GFP, or Tat-Mash1.  At higher western blot exposure times, some Tat-Mash1-GFP was 
found in the cell-free medium although it was insignificant compared to even the quantity 
found in the soluble lysate (data not shown).  Small quantities of each transcription factor 
were observed in the soluble lysate, with the maximum amount observed at day 2.  While 
observable, the amount of soluble protein was far less than the insoluble protein.  Total 
production was much higher for Mash1 compared to Lmx1a; the Lmx1a western blot is a 












Lane Description:  
  
1.       Precision Plus Standard 8.      GFP, Insoluble Lysate Day 2 
2.       Soluble Lysate, Day 2 9.      GFP, Cell-Free Medium, Day 3 
3.       Insoluble Lysate, Day 2 10.    GFP, Soluble Lysate, Day 3 
4.       Cell-Free Medium, Day 3 11.    GFP, Insoluble Lysate, Day 3 
5.       Soluble Lysate, Day 3 12.    Negative Cell-Free Medium, Day 3 
6.       Insoluble Lysate, Day 3 13.    Negative Soluble Lysate, Day 3 
7.       GFP, Soluble Lysate Day 2 14.    Negative Insoluble Lysate, Day 3 
 
Figure 3.3:  The majority of transiently expressed Mash1 and Lmx1a transcription 
factors was found in the insoluble fraction of the cell lysate.  HEK 293F cells transiently 
transfected with pTagTat_Lmx1a, pTagTat_Lmx1a_GFP, pTagTat_Mash1, and 
pTagTat_Mash1_GFP were lysed with M-PER protein extraction reagent to harvest 
soluble lysate.  Insoluble material was dissolved in the concentrated sample loading buffer.  
Cell-free medium, soluble lysate, and insoluble lysate samples were run on 4-12% Bis-Tris 
gels and analyzed by anti-Myc epitope tag western blotting.  The westerns above are not 
the same exposure time; Lmx1a exposure time was 30 seconds while Mash1 exposure time 
was 1 second.  Samples labeled “GFP” refer to the Tat-Lmx1a/Mash1-GFP variant.  
Expected sizes are: Tat-Mash1= 33.6 kDa, Tat-Mash1-GFP= 60.5 kDa, Tat-Lmx1a= 50.9 
kDa, and Tat-Lmx1a-GFP= 77.8 kDa.   
 
 Tat-Nurr1 and Tat-Nurr1-GFP expressed at too low a level to support any 
experimentation.  Even with a 10 minute western blot exposure time, only relatively light 
bands were observed in the insoluble fraction of Tat-Nurr1 and Tat-Nurr1-GFP.  HEK 
293F cells expressing Nurr1 were harvested after 2 days in an attempt to maximize any 
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soluble protein although none was observed.  The limited quantity of protein expressed 
was all found in the insoluble lysate (Figure 3.4).   
 
Lane Description:  
  
1.       Precision Plus Standard 8.       Tat-Nurr1-GFP Insoluble Day 1 
2.       Tat-Nurr1 Soluble, Day 1 9.       Tat-Nurr1-GFP Medium, Day 2 
3.       Tat-Nurr1 Insoluble, Day 1 10.    Tat-Nurr1-GFP Soluble, Day 2 
4.       Tat-Nurr1 Medium, Day 2 11.    Tat-Nurr1-GFP Insoluble, Day 2 
5.       Tat-Nurr1 Soluble, Day 2 12.    Negative Control Medium, Day 2 
6.       Tat-Nurr1 Insoluble, Day 2 13.    Negative Control Soluble, Day 2 
7.       Tat-Nurr1-GFP Soluble Day 1 14.    Negative Control Insoluble, Day 2 
 
Figure 3.4: Tat-Nurr1 and Tat-Nurr1-GFP expressed poorly and were found only in 
the insoluble lysate.  HEK 293F cells were transiently transfected with pTagTat_Nurr1 
and pTagTat_Nurr1_GFP.  Equal volumes of cell-free medium, soluble lysate, and 
insoluble lysate were loaded on 4-12% Bis Tris SDS-PAGE gels and analyzed for 
production using anti-myc western blotting.  The film exposure time for the western blot 
was 10 minutes; the long exposure time was necessary to observe any signal at all.  
Expected sizes were Tat-Nurr1= 74.7 kDa and Tat-Nurr1-GFP= 101.7 kDa. 
 
3.4.2. Transcription factor purification 
 The insoluble fractions of the cell lysate for Tat-Lmx1a and Tat-Lmx1a-GFP were 
solubilized in 1mL 1X PBS containing 8M Urea per 0.1g wet insoluble pellet.  The 
purification input is shown for the two proteins respectively in lanes 3 and 12 (Figure 3.5).  
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Almost all of the purified protein was found in Elution #1 with very little observed loss in 
the flow-through or washes.  Purification efficiency appeared to be higher for Tat-Lmx1a-
GFP compared to Tat-Lmx1a.  Purification samples were also run on 4-12% Bis Tris gels 
and subjected to Simply Blue Safestain but the method was not sensitive enough to detect 
bands for the proteins of interest.   
 
Lane Description:  
  
1.       Precision Plus Standard 10.       Tat-Lmx1a Elution 3 
2.       Tat-Lmx1a Soluble Lysate 11.       Tat-Lmx1a Elution 4 
3.       Tat-Lmx1a Insoluble Lysate 12.       Tat-Lmx1a-GFP Insoluble Lysate 
4.       Tat-Lmx1a Flow-Through 13.       Tat-Lmx1a-GFP Flow-Through 
5.       Tat-Lmx1a Wash 1 14.       Tat-Lmx1a-GFP Wash 1 
6.       Tat-Lmx1a Wash 2 15.       Tat-Lmx1a-GFP Elution 1 
7.       Tat-Lmx1a Wash 4 16       Tat-Lmx1a-GFP Elution 2 
8.       Tat-Lmx1a Elution 1 17.       Tat-Lmx1a-GFP Elution 3 
9.       Tat-Lmx1a Elution 2 18.       Tat-Lmx1a-GFP Elution 4 
 
Figure 3.5: Purification of Tat-Lmx1a and Tat-Lmx1a from the insoluble fraction of 
the cell lysate.  Frozen cell pellets from HEK 293F cells transiently transfected with 
pTagTat_Lmx1a and pTagTag_Lmx1a_GFP and harvested at day 3 were thawed, lysed 
with MPER protein extraction reagent, and the insoluble material was dissolved in 1X 
PBS pH = 7.4 containing 8M Urea.  Equal volumes of selected purification samples were 
run on 4-12% Bis Tris SDS-PAGE gels and assayed with anti-myc western blotting.  The 
blots shown above are 30 second exposures. 
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 The insoluble lysates containing Tat-Mash1 and Tat-Mash1-GFP were purified 
using the HisPur Ni-NTA resin and purification samples were analyzed.  The anti-myc 
westerns indicated that while all elutions contained some Tat-Mash1 or Tat-Mash1-GFP, 
significant protein was lost in both the flow-through and the first wash.  The amount of 
protein lost relative to the amount of protein in the final elutions was greater for Tat-Mash1 
compared to Tat-Mash1-GFP.  Initial input samples were very bright and not included in 
Figure 3.6 (Figure 3.3).  Due to signal intensity, experimentation was performed with Tat-
Mash1 elutions 1 and 3 and Tat-Mash1-GFP elutions 1-3.   
 
Lane Description:  
  
1.       Precision Plus Standard 9.       Tat-Mash1-GFP Flow-Through 
2.       Tat-Mash1 Flow-Through 10.    Tat-Mash1-GFP Wash 1 
3.       Tat-Mash1 Wash 1 11.    Tat-Mash1-GFP Wash 3 
4.       Tat-Mash1 Wash 3 12.    Tat-Mash1-GFP Elution 1 
5.       Tat-Mash1 Elution 1 13.    Tat-Mash1-GFP Elution 2 
6.       Tat-Mash1 Elution 2 14.    Tat-Mash1-GFP Elution 3 
7.       Tat-Mash1 Elution 3 15.    Tat-Mash1-GFP Elution 4 
8.       Tat-Mash1 Elution 4  
 
Figure 3.6: Purification of Tat-Mash1 and Tat-Mash1-GFP from the insoluble 
fraction of the cell lysate.  HEK 293F cells transfected with pTagTat_Mash1 and 
pTagTat_Mash1_GFP were harvested after 3 days and frozen until cell lysis.  Equal 
volumes of purification fractions were run on 4-12% Bis Tris SDS-PAGE gels and 
analyzed by anti-myc western blotting.  The exposure time for the blots shown above was 
very short, approximately one second.   
87 
 
3.4.3. Tat-Lmx1a-GFP is delivered to the nucleus following protein transduction and 
photochemical internalization 
 After production, transcription factor functionality was assessed.  Unlike enzymes 
where protein functionality is assessed using relatively straightforward enzyme assays, 
transcription factor function cannot be assaying using a simple well-controlled cell-free in 
vitro system.  During production, it was clear that the majority of Tat-Lmx1a-GFP or Tat-
Mash1-GFP was translocated to the nucleus.  As a result, the first question we aimed to 
answer is whether purified Tat-Lmx1a-GFP and Tat-Mash1-GFP were transported to the 
nucleus following protein transduction and photochemical internalization (PCI). 
 For both Tat-Lmx1a-GFP and Tat-Mash1-GFP, NPCs were treated with 1µg/mL 
purified protein for 18 hours.  Tat-GFP was included in both experiments as a control for 
cytosolic localization following PCI.  The first experiment using Tat-Lmx1a-GFP and Tat-
GFP gave the clearest result.  Before PCI, GFP signal was punctate for both proteins while 
four hours after PCI, Tat-GFP signal was distributed throughout the cell while Tat-Lmx1a 
signal was localized to the nuclear compartment (Figure 3.7).  This same experiment was 
performed for Tat-Mash1-GFP but results were far less clear.  While after PCI, Tat-GFP 
was located throughout the cytosol, Tat-Mash1-GFP distribution was heterogeneous.  
Furthermore, protein precipitation at higher concentrations made effective qualitative 




Figure 3.7: Qualitative comparison of Tat-Lmx1a-GFP and Tat-GFP intracellular 
distribution before and after photochemical internalization.  Following 18 hours of 
protein treatment with 1µg/mL purified Tat-Lmx1a-GFP or Tat-GFP, cells were washed, 
incubated for four hours in photosensitizer-free medium, and treated with light at 20% 
maximum intensity for 60 seconds to mediate PCI.  Several representative images were 
taken before and after PCI to determine the distribution of GFP signal.  400X fluorescent 
images were taken with a Zeiss AxioCam MRm monochrome camera (1.3 megapixel, 12 
bits/pixel) using the C-Apochromat 40x/1.2 W Korr objective. 
 
3.4.4. Promoter/Reporter assays to test functionality of transcription factors 
delivered by co-transfection 
 Promoter/reporter vectors provided the most straightforward test of recombinant 
transcription factor functionality.  Using the 281-EL2 Mash1 reporter vector and the DAT-
A Lmx1a reporter vector, transcription factor functionality was assessed in 3T3 fibroblasts 
and SK-N-BE(2)C neuroblastoma cells.  Before any recombinant protein was delivered, 
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transcription factor was delivered by co-transfection with the reporter vector.  Initially, 3T3 
fibroblasts were transfected with vectors for Tat-Mash1, Tat-Mash1-GFP, Tat-Lmx1a, and 
Tat-Lmx1a-GFP and the appropriate reporter vector and luciferase expression was assayed 
48-72 hours later.  Tat-Mash1 was found to clearly induce luciferase expression, with 
average increases over the background of 2.39-2.79 fold after 48-72 hours.  Conversely, 
Tat-Mash1-GFP did not convincingly induce luciferase expression.  With co-transfection 
of Tat-Mash1-GFP and 281-EL2, luciferase production increased 0.76-1.39 fold after 48-
72 hours.  Neither Tat-Lmx1a nor Tat-Lmx1a-GFP induced luciferase expression over the 
background value in 3T3 cells.  In fact, the transfection of Lmx1a inhibited luciferase 
expression in 3T3 cells.  After 72 hours, Tat-Lmx1a and Tat-Lmx1a-GFP transfected 3T3 
cells expressed luciferase 0.41X and 0.17X background levels respectively (Figure 3.8). 
   
 
Figure 3.8: Induction of luciferase expression from Mash1 reporter vector 281-EL2 
when 3T3 fibroblasts were co-transfected with pTagTat_Mash1 or 
pTagTat_Mash1_GFP.  Following transfection, 3T3 cells were maintained at 37ºC and 
5% CO2 for 48-72 hours at which time luciferase expression was analyzed.  The data in 
the chart above represents triplicate data points repeated twice for the day 2 values and 
three times for the day 3 values.  Error bars (standard error) show that while trends were 





















































 To test whether Tat-Lmx1a and Tat-Lmx1a-GFP were not functional or whether 
the DAT-A promoter/reporter vector functioned in a cell type-specific manner, all four 
transcription factor expression vectors were co-transfected with the appropriate reporter 
vectors in SK-N-BE(2)C neuroblastoma cells.  This was the cell line used in the paper 
where the DAT-A vector was described (Chung et al., 2012).  In the SK-N-BE(2)C cells, 
Tat-Mash1 and Tat-Mash1-GFP induced reporter expression 1.88X and 1.65X over the 
background value.  Tat-Lmx1a and Tat-Lmx1a-GFP also induced luciferase expression 
4.91X and 3.34X respectively.  This experiment clearly showed that the DAT-A reporter 
vector must be used with the SK-N-BE(2)C cell line while 281-EL2 is likely less cell-type 
specific (Figure 3.9).   
 
Figure 3.9: Induction of luciferase expression 48 hours after the co-transfection of 
SK-N-BE(2)C cells with transcription factor expression vectors and 
promoter/reporter vectors.  Following transfection, cells were maintained at 37ºC and 
5% CO2 for 48 hours at which time luciferase expression was analyzed using the Perkin-
Elmer Britelite Plus kit.  All data points in the above chart represent the average of triplicate 
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3.4.5. Direct protein treatment of 281-EL2 reporter vector-transfected 3T3 cells to 
test Tat-Mash1 and Tat-Mash1-GFP functionality 
 Co-transfection of 3T3 cells with 281-EL2 and with pTagTat_Mash1 or 
pTagTat_Mash1_GFP indicated that while Tat-Mash1 was able to induce reporter 
expression, Tat-Mash1-GFP was not.  As a result, the functionality of Tat-Mash1 was 
confirmed while the functionality of Tat-Mash1-GFP was called into question.  The next 
set of experiments aimed to determine whether, when delivered directly, protein Tat-Mash1 
could induce luciferase expression in 281-EL2 transfected 3T3 cells.   
 Both experiments were conducted using identical procedures with the exception of 
the protein treatment step.  In the first experiment, 1 µg/mL Tat-Mash1 or Tat-Mash1-GFP 
purified from the insoluble lysate were added to 281-EL2 transfected 3T3 cells.  The 
protein treatment conditions were not found to increase luciferase expression; in fact 
luciferase expression was observed to be slightly lower than the baseline with protein 









Figure 3.10: Reporter gene expression following the treatment of 281-EL2 transfected 
3T3 cells with purified Tat-Mash1 or Tat-Mash1-GFP.  3T3 fibroblasts were 
transfected with reporter vector 281-EL2 and 24 hours later treated with 1 µg/mL Tat-
Mash1 or Tat-Mash1-GFP.  Following the 18 hour protein treatment, cells were washed 
for 4 hours and light treatment was performed (for half of the samples).  Luciferase 
expression was assayed 24 hours after PCI.  All data points above represent the average of 
duplicate samples with data normalized to the untreated control.  PCI decreased baseline 
luciferase expression across the board; the PCI-treated untreated control had 38.1% the 
luciferase activity of the untreated control without PCI.   
 
 
 The results of the first experiment raised major questions regarding whether the 
proteins purified from the insoluble fraction of the lysate were functional.  As a result, the 
experiment was repeated with soluble lysates harvested by freeze-thawing producer cells 
in 1X PBS pH = 7.4 so the soluble lysate could be directly added to 3T3 fibroblast medium.  
Unlike in the first experiment, Tat-Mash1 and Tat-Mash1-GFP treated wells had slightly 
higher luciferase expression than the negative controls.  Without PCI, results were variable, 
but with PCI, Tat-Mash1 and Tat-Mash1-GFP both gave 16-19% higher luciferase 
expression.  While this value is somewhat consistent with co-transfection data for Tat-
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Overall, while the soluble protein may have led to a small increase in reporter expression 
with PCI, increases were not of the same magnitude seen when transcription factors were 
delivered by co-transfection.   
 
 
Figure 3.11: Reporter gene expression following the treatment of 281-EL2 transfected 
3T3 fibroblasts with soluble lysate of HEK 293F producer cells containing either Tat-
Mash1 or Tat-Mash1-GFP.  3T3 cells were treated with 25% soluble lysate and 75% 3T3 
medium containing only 4% FBS.  All data is reported as the average of duplicate 
conditions, normalized to the appropriate untreated control.  PCI decreased baseline 
luciferase expression in the negative controls; the untreated control subjected to PCI had 
34.4% of the baseline luciferase expression of the control on which PCI was not performed.   
 
3.4.6. Production of soluble Tat-Mash1 and Tat-Mash1-GFP using in vitro 
translation 
 Commercially available in vitro translation (IVT) systems were pursued for the 
production of Tat-Mash1 and Tat-Mash1-GFP in an attempt to improve protein solubility 
during production to yield a much higher concentration of soluble product.  Two 
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using HeLa cell lysate and the Expressway Cell-Free Expression System (Invitrogen) using 
E. coli cell lysate.   
 The mammalian lysate system yielded excellent soluble expression of both Tat-
Mash1 and Tat-Mash1-GFP at the expected sizes.  The majority of the produced protein 
was soluble (Figure 3.12).  Furthermore, far more soluble protein was produced than 
through the transient transfection of HEK 293F cells (Figures 3.3, 3.12).  In an additional 
experiment, the 281-EL2 reporter vector was added to the IVT reaction as well to determine 
if soluble protein could induce luciferase expression.  No luciferase induction was 
observed; this could very well be due to the absence of coactivators (data not shown).   
 
Lane Description:  
  
1.       Precision Plus Standard 4.       Tat-Mash1-GFP, Total IVT Reaction 
2.     Tat-Mash1, Total IVT Reaction 5.       Tat-Mash1-GFP, Soluble IVT Fraction 
3.     Tat-Mash1, Soluble IVT Fraction 6.     Tat-GCase-GFP Western Control 
 
Figure 3.12: Expression of soluble Tat-Mash1 and Tat-Mash1-GFP using a HeLa cell 
lysate in vitro translation system.  At the conclusion of the IVT reactions, a sample of the 
whole reaction was taken (total IVT), and the remaining reaction was centrifuged.  The 
supernatant was removed to yield the soluble fraction.  Equal volumes of both the total 
reaction and soluble fraction were loaded onto 4-12% Bis Tris SDS-PAGE gels for each 
of Tat-Mash1 and Tat-Mash1-GFP.  The anti-myc western blot shown above was a 3 
second exposure to film.   
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 The E. coli IVT system had significantly less overall and soluble protein 
production.  While most of the protein was soluble in the HeLa IVT system (Figure 3.12), 
the majority of Tat-Mash1 and Tat-Mash1-GFP produced in the Expressway system was 
removed with centrifugation after the IVT reaction was concluded.  Tat-Mash1-GFP 
appeared to express in a full-length form but there were numerous truncated products 
observed on the anti-myc western blot (Figure 3.13).   
 
Lane Description:  
  
1.       Precision Plus Standard 5.       Tat-Mash1-GFP, Soluble IVT Fraction 
2.     Tat-Mash1, Total IVT Reaction 6.     Negative, Total IVT Reaction 
3.     Tat-Mash1, Soluble IVT Fraction 7.     Negative, Soluble IVT Reaction 
4.       Tat-Mash1-GFP, Total IVT Reaction 8.     Tat-GCase-GFP Western Control 
 
Figure 3.13: Expression of Tat-Mash1 and Tat-Mash1-GFP using the Expressway E. 
coli in vitro translation system.  Equal volumes of the total IVT reaction and the soluble 
fraction of the IVT reaction were run on a 4-12% Bis Tris SDS-PAGE gel and analyzed by 




 The goal of the research presented in this chapter, to design, express, and purify 
transcription factors to mediate neuronal differentiation through direct protein treatment, 
96 
 
was not accomplished.  Although numerous factors contributed to this goal not being met, 
the low expression of soluble and/or functional protein, and the efficiency of protein 
delivery, were the most glaring.  Neuronal differentiation via genetic approaches is an 
already inefficient process made even more difficult by low protein delivery and quality.  
The results presented in sections 3.4.1 to 3.4.6 clearly point out the flaws in the 
transcription factor production methods employed.  A method to produce high levels of 
soluble Tat-Mash1 and Tat-Mash1-GFP was identified: the HeLa cell lysate IVT system.  
Despite the failure to demonstrate purified transcription factor functionality, this chapter 
provides a framework that could be used in the future development of a protein-based 
neuronal differentiation procedure and contains significant results. 
Mammalian expression vectors for Tat-Mash1, Tat-Mash1-GFP, Tat-Lmx1a, Tat-
Lmx1a-GFP, Tat-Nurr1, and Tat-Nurr1-GFP were designed using pSecTag2a.  Proteins 
were expressed via the transient transfection of HEK 293F suspension cells.  Bacterial 
expression was not explored for Mash1, Lmx1a, or Nurr1 as a result of past issues 
expressing transcription factors in bacteria in the Fishman laboratory.  Tat-NeuroD2 was 
not expressed in a full length form (Gillmeister et al., 2009) and Tat-Lmx1a was totally 
insoluble once 8M urea was removed (Fishman Lab, unpublished data).  During the 
expression work, Tat-Mash1-GFP and Tat-Lmx1a-GFP were observed only in the nucleus 
of producer cells, despite the presence of the signal peptide (Figure 3.2).  This same 
phenomenon was observed during the expression of Tat-NeuroD2-GFP (Gillmeister et al., 
2009).  The vast majority of expressed Tat-Mash1, Tat-Mash1-GFP, Tat-Lmx1a, and Tat-
Lmx1-GFP was found in the insoluble fraction of the HEK 293F producer cell lysate 
(Figure 3.3).  Tat-Nurr1 and Tat-Nurr1-GFP expressed at very low levels insufficient for 
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any experimentation (Figure 3.4).  Mash1 soluble protein production was better than 
Lmx1a but the insoluble protein fraction still contained the majority of the final product.  
Insoluble proteins were solubilized using 8M urea-containing buffers and purified by Ni-
NTA affinity chromatography.  Purified Tat-Lmx1a and Tat-Lmx1a-GFP were 
concentrated in single elutions (Figure 3.5).  Tat-Mash1 and Tat-Mash1-GFP purification 
yields were much higher compared to Lmx1a, with purified protein distributed over several 
elutions (Figure 3.6).   
We hypothesized that the transcription factor insolubility was directly related to the 
translocation of the factors to the producer cell nucleus.  In the nucleus, the transcription 
factor could bind DNA and interact with other factors creating complexes that could fall 
out of solution upon cell lysis.  One potential approach to improve solubility could be to 
inhibit nuclear importation pathways during protein production.  Importazole (2,4-
diaminoquinazoline) is a small molecular inhibitor of the importin-β nuclear importation 
pathway (Soderholm et al., 2011).  Preliminary data showed that importazole addition did 
not improve soluble protein production.  Additionally, overall protein production was 
inhibited with increased importazole concentrations (Fishman Lab, unpublished results).  
However, with further development, inhibition of nuclear importation could be a strategy 
to improve transcription factor solubility. 
 Initially, the ability of Tat-Mash1-GFP and Tat-Lmx1a-GFP to translocate to the 
cell nucleus following protein transduction and photochemical internalization was 
assessed.  Nuclear transport of transcription factor after release from endosomes would not 
have been a confirmation of protein functionality, but it would have been a promising 
observation.  Nuclear importation has been used to test transcription factor functionality in 
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published literature (Tachikawa et al., 2004).  While Tat-Lmx1a-GFP was found in the 
nucleus 4 hours after PCI, Tat-Mash1-GFP was not.  Promoter/reporter assays were chosen 
as a relatively straightforward approach to quantitatively test transcription factor function, 
and had been used previously by other labs (Koya et al., 2008; Lan et al., 2014).  When 
3T3 cells were co-transfected with the appropriate reporter construct, only Tat-Mash1 was 
reproducibly able to induce reporter gene expression.  Tat-Mash1-GFP was not able to 
induce luciferase expression in 3T3 cells (Figure 3.8).  However, it was able to induce 
reporter expression in SK-N-BE(2)C cells (Figure 3.9).  As a result, while GFP appears to 
reduce the activity of Tat-Mash1, it does not totally eliminate it.  Tat-Lmx1a and Tat-
Lmx1a-GFP were only able to induce luciferase expression from the DAT-A reporter 
vector using the SK-N-BE(2)C cells, indicating that promoter/reporter system activation 
was cell-type specific (Figure 3.9).   
Purified transcription factor function was tested using Tat-Mash1 due to the much 
higher expression level compared to Tat-Lmx1a or Tat-Lmx1a-GFP.  Two protein delivery 
approaches were attempted with Tat-Mash1 to reproduce co-transfection results, but 
neither was able to do so effectively (Figures 3.10, 3.11).  Comparing the two experiments, 
the treatment of 3T3 cells with soluble lysate delivered more promising results, where it 
appeared protein treatment may have increased reporter expression.  While the increases 
observed were small, this result further brought doubt to the functionality of transcription 
factors purified from the insoluble fraction of the cell lysate. 
It became clear that to successfully generate neurons using a protein-delivery based 
approach, we would need large quantities of soluble transcription factors.  Our hypothesis 
was that protein insolubility was due, at least in part, to the nuclear importation of the 
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protein following production.  Since pilot work with small molecule inhibition of nuclear 
importation was not promising, we next aimed to remove the nucleus from the production 
system altogether using in vitro translation systems.  While in vitro translation systems are 
much more expensive methods to produce protein and not nearly as scalable as transient 
transfection, they were the most direct way to test the hypothesis.  Furthermore, two new 
commercially available in vitro translation systems looked especially promising, 
advertising the potential to produce milligram quantities of protein.  The Expressway Cell-
Free IVT system (Invitrogen) used an E. coli cell lysate.  While the Fishman Lab previously 
had poor luck with bacterial expression of transcription factors, a cell-free system had 
never been attempted.  Furthermore, this E. coli lysate system was reasonably affordable 
advertised as capable of producing ~1mg protein for ~400 dollars.  The One-Step Human 
High-Yield IVT Kit (Pierce) also reported the potential to make milligram quantities of 
protein.  Although the projected cost was higher, at ~1mg for ~1100 dollars, mammalian 
cell lysate had a better chance of producing full-length, soluble transcription factors.   
 Appropriate Tat-Mash1 and Tat-Mash1-GFP expression vectors were created for 
each of the IVT systems using the pEXP5 and pT7CFE1 plasmids for the E. coli and HeLa 
lysate systems, respectively.  IVT reactions were performed for each system and the HeLa 
cell lysate produced a much higher concentration of full length soluble protein (Figure 
3.12).  While the E. coli lysate did produce some full-length Tat-Mash1 and Tat-Mash1-
GFP, overall yield was much lower and a portion of the expressed protein was insoluble.  
Furthermore, there were a number of myc-positive bands observed in the Tat-Mash1-GFP 
reaction, indicating expression of some truncated final products.  The large-scale One-Step 
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Human High Yield IVT kit showed potential for the production of transcription factors for 
neuronal differentiation.   
 The available published literature describing the production of recombinant 
transcription factors is small, likely reflecting the considerable protein expression 
challenges described at length in this chapter.  Published recombinant transcription factor 
delivery papers fall into one of two categories: the creation of protein induced pluripotent 
stem cells (piPSCs) and all other papers where gene expression or cell differentiation is 
modified for a variety of applications.  The creation of piPSCs is the largest specific 
application of the technology and has been a valuable resource for better understanding the 
potential and limitations of transcription factor delivery.   
 Reprogramming CPP-linked transcription factors Oct4, Klf4, Sox2, and c-Myc 
have been expressed both in E. coli (Nemes et al., 2014; Pan et al., 2010; Zhou et al., 2009) 
and mammalian HEK 293 cells (Kim et al., 2009).    Reports regarding solubility of the 
reprogramming factors were variable.  The first report of piPSC generation used factors 
solubilized from the insoluble lysate and refolded them before purification (Zhou et al., 
2009).  Conversely, a recent paper did not mention any inclusion body production or 
denaturing purification conditions implying that E. coli expressed soluble protein (Nemes 
et al., 2014).  The biological activity of transcription factors purified from the insoluble 
lysate has been disputed; Pan et al. found that recombinant reprogramming transcription 
factors they purified from inclusion bodies had minimal biological activity (Pan et al., 
2010).  There is no published work comparing the activity of transcription factors purified 
from both the soluble and insoluble fractions of the lysate.  While there is some published 
work indicating that denatured Tat-linked proteins are refolded and active after cellular 
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uptake, this work did not directly involve transcription factors (Jin et al., 2001). One 
publication used soluble transcription factors produced in HEK 293 cells.  Interestingly, 
they did not purify the factors, but only lysed the cells in a buffer appropriate for cell 
treatment.  As a result, the transcription factor dose was not clear.  While Kim et al. did not 
state the reasons for not purifying the transcription factor from the lysate, it very well could 
have been due to the insolubility of protein and low purification yields following traditional 
lysis methods (Kim et al., 2009).  The approach used by Kim and colleagues is fairly similar 
to one of our approaches to deliver soluble Tat-Mash1 and Tat-Mash1-GFP (Figure 3.11).   
The concentration of delivered protein was a major pitfall of our work; it is possible 
that for our Tat-Mash1 and Tat-Mash1-GFP delivery work, we needed a much higher 
treatment dose.  The two successful publications describing piPSC generation with 
bacteria-expressed proteins used 8 μg/mL purified protein, 8x more that we were able to 
use (Zhou et al., 2009; Nemes et al., 2014).  Pan et al. reported minimal biological activity 
for their purified factors; they treated with 40nM.  For reference, 1 μg/mL Tat-Mash1 or 
Tat-Mash1-GFP would equal ~30nM or ~15nM respectively.  It cannot be ruled out that 
poor activity observed in our work, and the work of Pan and colleagues, could have been 
due to low treatment doses.  Despite the success by multiple laboratories in creating 
piPSCs, all report that protein-based methods are less efficient than viral methods, with 
one report giving iPSC generation efficiency at 0.001% of input cells for protein-based 
methods compared to 0.01% for genetic methods (Kim et al., 2009).   
 Aside from piPSC generation, most other transcription factor delivery work is 
spread over a number of fields.  The first published report of direct protein delivery of a 
transcription factor involved the production of a soluble artificial transcription factor (ATF) 
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linked to a cell-penetrating peptide.  The CPP-ATF was produced in E. coli and was 
extracted and purified in its soluble form.  Following delivery of a high CPP-ATF dose of 
500nM, VEGF-A expression was increased, indicating the factor was biologically active 
(Tachikawa et al., 2004).  In 2008, soluble pancreatic homeobox-1 transcription factor 
Pdx1 was expressed in E. coli.  No additional CPP was included as Pdx1 already contained 
a protein transduction domain.  Using a promoter/reporter system, Koya et al. demonstrated 
that 1 μM Pdx1 was able to induce reporter expression similarly to lentiviral infection.  In 
vivo, Koya and colleagues found that delivered Pdx1 could promote β-cell regeneration 
and differentiation of liver cells to insulin-producing cells (Koya et al., 2008).   
 Aside from the work of Tachikawa et al. and Koya et al., no additional transcription 
factor delivery papers were published until 2014, when several appeared.  Estrogen-related 
receptor β (ESRRB) containing a R7 CPP was expressed as a soluble protein in E. coli and 
delivered to human mesenchymal stem cells at a 50 μg/mL dose.  RT-PCR was used to 
confirm the increase in expression of several pluripotency markers with addition of the 
ESRRB protein (Jo et al., 2014).  Tat-conjugated Nanog was expressed in E. coli and 
purified from the soluble lysate.  While the protein was soluble at production, the treatment 
scheme implies there were solubility issues.  The protein transduction procedure was 
atypical; protein-containing medium was incubated at 37C for two hours, centrifuged, and 
the precipitate free medium was filtered before protein transduction.  Final Nanog-Tat 
concentration was 100nM but initial concentrations could have been much higher.  Protein 
functionality was demonstrated two ways: the ability to bind a consensus DNA sequence 
and showing that treatment with Nanog-Tat was able to support ESC self-renewal 
independent of critical factor LIF (Peitz et al., 2014).  In another example of recombinant 
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transcription factor delivery, TAZ was expressed in E. coli conjugated to an arginine-rich 
CPP.  The recombinant TAZ was purified from the insoluble lysate and desalted; it was 
used to treat cells at a 100nM concentration without any specific refolding procedure.  
Activity of the CPP-TAZ was demonstrated in vitro through osteogenic differentiation of 
human mesenchymal stem cells and in vivo using a rabbit bone formation assay (Suh et al., 
2014).   
 Two papers where protein delivery was used to promote transdifferentiation have 
been published.  In the first, pancreatic acinar cells were transdifferentiated into insulin-
positive cells.  Tat-linked islet transcription factors Ngn3, Pdx1, and NeuroD/β2 were 
expressed in E. coli and purified from the insoluble lysate.  After purification, proteins 
were dialyzed in a step-wise fashion to facilitate protein renaturation.  Protein treatment 
with 1µM Tat-Pdx1 or Tat-NeuroD/β2 induced luciferase reporter gene expression 2X over 
a control.  Also, and more importantly, rat acinar cell line AR42 was converted to insulin-
positive cells after 3 days of treatment with all 3 factors (Lan et al., 2014).  
 In March 2015, the first paper employing transcription factors for neuronal 
transdifferentation was published.  Recombinant Tat-Sox2 and Tat-Lmx1a, with a cocktail 
of small molecules, were used to transdifferentiate human foreskin fibroblasts to induced 
dopaminergic progenitor cells.  The recombinant proteins were expressed in E. coli and 
purified from the insoluble lysate.  Fibroblasts were transdifferentiated in a complex 
procedure involving seven 48 hour protein and small molecule-treatment cycles.  In each 
treatment, cells were given 10 µg/mL of both Tat-Sox2 and Tat-Lmx1a.  Although 
efficiency was not discussed in the manuscript, indicating that it may have been quite low, 




Although there has long been interest in protein-based neuronal differentiation, 
evidence that this is technically feasible has only been recently presented (Mirakhori et al., 
2015), and even then, was aided by a cocktail of small molecules.  Another substantial 
accomplishment in the direct delivery of transcription factors has been the creation of 
multiple piPSC lines.  Despite the success, there were multiple drawbacks of the approach, 
particularly that piPSC generation is even less efficient than iPSC generation via genetic 
approaches.  Beginning in 2014, successful transcription factor protein delivery has been 
accomplished in fields besides piPSC generation.  However, these studies typically used 
very high protein concentrations and had relatively low efficiency.  Most transcription 
factor expression literature indicates that protein solubility upon lysis is relatively poor and 
that purifying active transcription factor is a significant biotechnology challenge.     
Many of the methods employed in this chapter have been used in the literature.  
Transcription factors have been purified from the insoluble lysate or added to cells in a 
crude soluble lysate.  Both nuclear importation and promoter/reporter systems are tests for 
transcription factor functionality.  Despite these approaches, the overall goal of this study 
was not achieved for two main reasons: biological activity of the proteins and the treatment 
dose.  Both of these pitfalls can be potentially addressed by the described in vitro translation 
method used to successfully generate high concentrations of soluble protein.  Although not 
particularly cost effective, in vitro translation likely represents the best method currently 
available for transcription factor production.  IVT for transcription factor production has 
not been described or employed anywhere else in the literature.  With efficient soluble 
production, this project could be revisited using many of the same methods attempted.  
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With more biologically active protein, the dose could be increased to 100 nM - 1 µM, the 
treatment concentrations where successful functional outcomes were typically observed.  
Creative approaches in protein expression and purification will be critical to achieving 
protein-based neuronal differentiation and potentially making these procedures as efficient 

















Chapter 4: A Peptide Linked Recombinant Glucocerebrosidase for 
Targeted Neuronal Delivery: Design, Production, and Assessment  
4.1. Abstract 
Although recombinant glucocerebrosidase (GCase) is the standard therapy for 
Gaucher’s disease, the commonest inherited lysosomal storage disease, enzyme 
replacement is not effective when the central nervous system is affected.  Linkage to a 
membrane binding peptide is a strategy to enhance neuronal uptake of proteins such as 
GCase, where the native protein is not well internalized by neurons.  We created a series 
of recombinant genes/proteins where GCase was linked to different membrane binding 
peptides including the Tat peptide, the rabies glycoprotein derived peptide (RDP), the 
binding domain from tetanus toxin (TTC), and a tetanus-like peptide (Tet1).  The majority 
of these proteins showed adequate expression in a mammalian producer cell line (HEK 
293F), and most were secreted in soluble form into the media as predicted by the inclusion 
of a secretary domain.   Purified recombinant Tat-GCase and RDP-GCase showed similar 
GCase protein delivery to neuronal cells in culture and superior delivery to native GCase.  
This initial result was unexpected based on observations of superior protein delivery to 
neurons with RDP as a vector.  A recombinant protein where a fragment of the flexible 
hinge region from IgA (IgAh) was introduced between RDP and GCase showed 
substantially enhanced GCase neuronal delivery (2.5 times over Tat-GCase), suggesting 
that the original construct resulted in interference with RDP’s capacity to bind neuronal 
membranes.  Incubation with both RDP-IgAh-GCase and Tat-GCase proteins for 18 hours 
resulted in a significant increase in GCase activity in a mutant neuronal cell line with little 
untreated GCase activity. This cell line also accumulates large amounts of the pathologic 
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Gaucher’s disease lipid substrate glucosylsphingosine. Extended treatment of these mutant 
neuronal cells with either Tat-GCase or RDP-IgAh-GCase resulted in a >90% reduction in 
glucosylsphingosine content, approaching normal levels. RDP-IgAh-GCase, as well as 
Tat-GCase, merit study in vivo to assess their potential as treatment for neuronopathic 
forms of GD.  Both peptide vectors are reported to also be capable of carrying a protein 
across the blood brain barrier, suggesting the possibility of avoiding invasive direct brain 
delivery.   
*Chapter 4 is reproduced, in part, from a paper submitted for peer review.  Permission 
information from the reviewing journal can be found on page 184. 
 
4.2 Introduction 
 Nearly 35 years ago, the discovery that glycan engineering of glucocerebrosidase 
could target the enzyme efficiently to non-parenchymal liver cells facilitated the 
development of the first FDA-approved biologic for Gaucher’s disease therapy.  It was 
found that the exposure of terminal mannose residues on the N-glycans of 
glucocerebrosidase (GCase) dramatically increased enzyme targeting to macrophages 
(Busterbosch et al., 1996; Friedman et al., 1999; Furbish et al., 1981) due to their mannose-
binding lectin (Stahl et al., 1978).  This facilitated the practical application of enzyme 
replacement therapy for type 1 Gaucher’s disease (GD).  Gaucher’s disease is an inherited 
lysosomal storage disease where homozygous mutations in the gene for glucocerebrosidase 
result in accumulation of glycosphingolipid substrates glucosylceramide and 
glucosylsphingosine.  GD is classified by its three subtypes: non-neuronopathic type 1, 
acute neuronopathic type 2, and chronic neuronopathic type 3 (Branco Novo et al., 2012; 
Cabrera-Salazar et al., 2010; Lee et al., 2005).  
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 In 1991, Ceredase (alglucerase, Genzyme Corp) became the first FDA-approved 
sequentially deglycosylated GCase (Branco Novo et al., 2012).  Although Ceredase was 
purified from human placental tissue, three recombinant GCase enzymes have since been 
introduced for enzyme replacement therapy (ERT).  All expose mannose-terminal residues 
on N-glycans using a variety of strategies.  Cerezyme (imiglucerase, Genezyme) is 
produced in Chinese Hamster Ovary (CHO) cells and enzymatically deglycosylated to 
expose mannose residues like Ceredase.  VPRIV (velaglucerase alfa, Shire) is a 
recombinant GCase produced in human fibroblast carcinoma cells and treated with 
mannosidase I inhibitor kifunesine during production to produce mannose terminal 
glycans.  Finally, Elelyso (taliglucerase alfa, Protalix) is produced in carrot cells and 
targeted to storage vacuoles where mannose-terminal residues are exposed (Shaaltiel et al., 
2007; Tekoah et al., 2013).  The four N-glycosylation sites that are occupied in wild-type 
GCase are all occupied in the recombinant GCase enzymes (Brumshtein et al., 2010).  
Imiglucerase and taliglucerase alfa have an average glycan mass of 1160 daltons while 
velaglucerase alfa has an average glycan mass of 1790 daltons (Tekoah et al., 2013).  The 
effect of mannose-chain length has been somewhat controversial, being reported to both 
have no effect on macrophage binding (Van Patten et al., 2007) and improve macrophage 
binding (Brumshtein et al., 2010).   
Along with the recombinant enzyme therapies, two small molecule 
glucosylceramide synthase inhibitors have been approved for type 1 GD therapy.  Zavesca 
(miglustat, Actelion Pharmaceuticals), was approved in 2002 for type 1 therapy when ERT 
is not an option (Ficicioglu et al., 2008; Pastores, 2010).  Cerdelga (eliglustat, Genzyme) 
was FDA-approved in 2014 and has been shown to have similar efficacy to Cerezyme and 
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notably, does not have the unpleasant gastrointestinal and neurological side effects of 
Zavesca (Poole et al., 2014).   Initially, there was hope that Zavesca could be useful for 
neuronopathic GD therapy.  However, it was not shown to improve the neurologic 
symptoms of type 3 GD patients in a clinical trial (Schiffmann et al., 2008).  Currently, no 
type 3 GD clinical trials are in progress for Cerdelga.  Research has also focused on 
chaperones that can competitively bind glucocerebrosidase in the endoplasmic reticulum 
and improve lysosomal trafficking and enzyme activity.  Isofagomine has shown 
neuronopathic GD therapeutic potential in a type 2 GD mouse model (Sun et al., 2011; Sun 
et al., 2012).  While it has never been tested for neuronopathic GD, chaperone ambroxol 
could also have potential (Zimran et al., 2013).  Genzyme has published data on a propriety 
small molecule GZ 161 that extended the life of type 2 GD mice (Cabrera-Salazar et al., 
2012).  Although ERT is the standard of care for GD therapy, small molecule therapeutics 
are valuable treatment options with potential for future growth.   
 Although three recombinant GCase enzymes and the two glucosylceramide 
synthase inhibitors are commercially available, all treat only the non-neuronopathic type 1 
GD.  None of these GCase enzymes will cross the blood brain barrier due to their size and 
the lack of mannose receptors on brain endothelia (Grubb et al., 2010), nor do they have 
any predicted preferential neuronal-targeting properties.  Efficiency of uptake in neuronal 
cell lines is significantly less than in macrophages and has been shown to be variable based 
on the cell line used (Schueler et al., 2002).  Currently, there is no available therapy for 
neuronopathic types 2 or 3 GD.  As a result, there is a distinct need for an engineered 
recombinant GCase enzyme for neuronal delivery enabling the possibility of enzyme 
replacement therapy for types 2/3 GD, analogous to how glycan modification facilitated 
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the development of an enzyme for type 1 therapy.  A neuron-targeted GCase would need 
to preferentially bind neurons and ideally, would cross the blood-brain barrier (BBB) 
increasing the options for therapeutic delivery. 
 There are a wide variety of peptide delivery vectors capable of facilitating the 
endocytosis of GCase in neurons.  These peptides can be generally separated into two 
classes: receptor-independent peptides that lack cell type specificity and receptor-
dependent peptides that have retained cell-type specificity.  These delivery vectors also 
vary with additional parameters including their ability to cross the BBB and feasibility for 
use in vivo.   The first category of receptor-independent peptides includes cell-penetrating 
peptides (CPPs) that have the ability to deliver proteins to any cell type (Reviews: Chauhan 
et al., 2007; Deshayes et al., 2005; Heitz et al., 2009; Zorko et al., 2005).  While originally 
controversial, it is now widely accepted that these peptides are taken into cells through 
endocytosis.  CPPs have been shown to deliver cargo proteins across the BBB (Schwarze 
et al., 1999) although this has been reported to be very low efficiency (Xia et al., 2001).  
While a large number of different CPPs exist, Tat, an 11 amino acid peptide originally 
derived from the transactivator protein of HIV (Tat), was the first to be described (Frankel 
et al., 1988) and remains one of the more widely used varieties.  Tat is taken up by receptor-
independent macropinocytosis and following uptake, most of the Tat-linked cargo protein 
is sequestered in endosomes (Chauhan et al., 2007; Gillmeister et al., 2011).   
 Tat has been used, in a limited capacity, to enhance the delivery of lysosomal 
enzymes in vitro.  Types 1 and 2 Gaucher fibroblasts were treated with GCase-Tat resulting 
in approximately 4 and 10 fold more intracellular enzyme activity compared to control 
GCase, for types 1 and 2 fibroblasts respectively (Lee et al., 2005).  Tat has also been 
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linked to another lysosomal enzyme, galactocerebrosidase (GALC), for delivery to a wider 
variety of cell types with variable results.  Tat improved delivery to COS-7 cells ~1.5x 
compared to the control proteins.  No improvement in GALC delivery was observed with 
primary fibroblasts and Tat decreased delivery of GALC to primary mouse cortical neurons 
(Zhang et al., 2008).   
 Another class of receptor-dependent cell type-specific peptides derived from 
neuron binding virus and toxins may prove to be more promising candidates for neuronal 
delivery of GCase.  Tetanus toxin fragment C (TTC), the non-toxin ~50kDa neuronal 
binding domain of tetanus toxin, is one of the most well characterized binding domains 
from this class.  TTC has been used extensively to deliver cargo proteins (Francis et al., 
2000; Francis et al., 2004; Li et al., 2009) and has a strong affinity for neurons through its 
binding of complex gangliosides and protein receptors P15 and SV2A/B (Calvo et al., 
2012; Miana-Mena et al. 2002; Yeh et al., 2010).  While it could dramatically enhance the 
binding of GCase to neurons, TTC does not cross the blood brain barrier and could raise 
concerns regarding an in vivo immune response.  As a result, the potential of TTC as an in 
vivo delivery domain is likely also limited.  Smaller toxin or virus-derived peptides with 
less immunogenic potential would be preferable to TTC.  Tet1, a 12 amino acid peptide 
identified for ganglioside properties similar to TTC, is a small peptide option (Federici et 
al., 2007).  Until recently, the ability of Tet1 to deliver cargo protein was never directly 
compared to TTC or a CPP such as Tat (Mello et al., in preparation).  As a result, the ability 
of Tet1 to facilitate neuronal binding of GCase is uncertain.  Furthermore, Tet1 will not 
mediate translocation across the BBB.  
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 For the delivery of GCase to the brain, rabies-derived peptide (RDP) may have the 
most potential.  Several varieties of RDP have been derived from either of the two regions 
of the rabies virus glycoprotein (RVG) responsible for nerve binding (Fu and Zhang et al., 
2013).  Both varieties have been reported to cross the BBB and bind neurons.  A 29 amino 
acid portion derived from RVG amino acid sequence 175-203 has been used for delivery 
with a nonarginine attached by a sequence of three glycines (Gong et al., 2012; Kumar et 
al., 2007; Xiang et al., 2011) and by itself (Gao et al., 2014; Liu et al., 2009).  Both DNA 
and protein have been delivered with a 39 amino acid peptide where a 27 amino acid 
portion derived from RVG sequence 330-356 is connected to a nonarginine by a sequence 
of 3 glycines (Fu et al., 2012; Fu et al., 2013a; Fu et al., 2013b).  RDP has been shown to 
deliver model protein GFP to neural progenitor cells (NPCs) better than Tat, Tet1, or TTC 
(Mello et al., in preparation).  A number of proteins have been successfully delivered across 
the BBB using RDP including luciferase, β-galactosidase, BDNF, GDNF, and GFP (Fu et 
al., 2012; Fu et al., 2013b). 
 With the goal of producing a neuronal cell type targeted recombinant GCase 
enzyme, 17 variants were designed, expressed, and if expressed successfully, purified and 
assessed for enzyme activity and neuronal binding and internalization.  For recombinant 
GCase, binding domains including Tat, RDP, Tet1, and TTC were assessed and compared 
to each other and FDA-approved Cerezyme (Genzyme Corp).  Combinations of Tat and 
the receptor-dependent peptides were also investigated as the combination of Tat and TTC 
has been shown to work better than either Tat or TTC alone (Gramlich et al., 2013).  Design 
of the candidate genes and enzymes reflected goals of high level expression, enzyme 
activity, and neuronal binding.  GFP was also included in some of the constructs to allow 
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for histologic assessment of binding and internalization.  Following initial screening, 
enzyme internalization of promising GCase variants was assayed quantitatively by lysing 
cells after protein treatment and quantitating the concentrations of active enzyme in the cell 
lysate.  Substrate reduction capabilities for Tat-linked GCase and the most promising 
neuron-targeted recombinant GCase were also quantitatively tested. 
4.3. Methods and Materials 
4.3.1. Construction of glucocerebrosidase expression vectors 
 All glucocerebrosidase expression vectors were creating using the base plasmid 
pSecTag2a (Life Technologies) containing an IgK leader sequence to promote secretion 
upstream of the multiple cloning site, and both a myc epitope tag and 6x His purification 
tag downstream of the multiple cloning site.  The wild-type glucocerebrosidase gene 
(GBA1) sequence was amplified from a lentiviral expression vector generously provided 
by Dr. Ricardo Feldman, University of Maryland Baltimore (Panicker et al., 2012).  GBA1 
was cloned into the pSecTag2a backbone using EcoRI and EcoRV restriction sites creating 
pTag_GBA.  For cloning of additional domains, AgeI and BsiWI restriction sites were 
introduced in frame at the 5’ and 3’ ends respectively of GBA1.  Enhanced green 
fluorescent protein (EGFP) sequence was amplified by PCR and cloned into the 
pTag_GBA sequence 3’ of the GBA1 gene using BsiWI and XhoI restriction sites.  This 
plasmid, named, pTag_GBA_GFP was used for the construction of all GFP-containing 
GBA1 expression vectors.  The EGFP sequence was derived from Clontech plasmid 
pEGFP-1.   
 All cell-penetrating peptides or neuronal-targeting domains were cloned into either 
pTag_GBA or pTag_GBA_GFP via AscI and AgeI restriction sites.  Unless a linker region 
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was specifically designed into the expression vector, only the AgeI restriction site separated 
the 5’ domain and GBA1.  The TTC and Tat-TTC sequences were amplified from the 
pGEX4T3_Tat_TTC_GFP vector (Gramlich et al., 2013) using PCR.  Each of the Tat, 
Tet1, and Tat-Tet1 sequences were made as duplex oligos by Integrated DNA Technologies 
(IDT) and cloned into either pTag_GBA or pTag_GBA_GFP.  Tet1 was cloned 3’ of GFP 
in one expression vector using the XhoI restriction site.  All other sequences were created 
using the IDT gblock synthetic gene construction service.  Sequences constructed as 
gblocks included Tat_5xTet1, 5xTet1, RDP, RDP_GFP, RDP_Tat, RDP_Flex, RDP_IgAh, 
and RDP_Rigid.  All gblocks were first cloned into the PCR Blunt (Life Technologies) 
vector for sequence confirmation before introduction into either pTag_GBA or 
pTag_GBA_GFP via the AscI and AgeI restriction sites.    
4.3.2. Cell culture 
 HEK 293F suspension cells were maintained at a 40mL working volume in 125mL 
vented non-baffled shake flasks (Corning) and passaged three times per week.  For standard 
passaging, cultures were seeded at 2E5-4E5 cells/mL and not allowed to exceed 2E6 
cells/mL to avoid excessive cell aggregation.  All suspension cultures were grown at 37ºC 
and 8% CO2 with shaking at 125 RPM on an innova 2000 shaker (New Brunswick 
Scientific). 
Human neural progenitor cells (hNPCs, Lonza) were grown in hNPC starting 
medium (3).  Passage 4 vials of neurospheres were thawed into hNPC starting medium and 
allowed to attach over 2-4 days at which time the plated neurospheres were dissociated 
with Accutase (Sigma) and replated in 50% hNPC starting medium and 50% MEM 
medium containing 5% horse serum.  Re-plated hNPCs were maintained until dense 
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enough for experimental use and fed 5mL medium once per week.  For protein transduction 
and imaging, hNPCs were plated in poly-L-lysine coated 8-well chambered coverglasses 
(Nunc) and expanded for 4 days until cells reached the density of ~25,000 cells/cm2. 
 Glucocerebrosidase-knockout (GCKO) and wild-type (WT) SV40-immortalized 
mouse neuronal cell lines were generously provided by Dr. Wendy Westbroek and Dr. 
Ellen Sidransky (National Institutes of Health).  These cells were maintained in Neurobasal 
medium supplemented with 1X B27, 1mM L-glutamine, and 1X Penicillin/Streptomycin 
(Life Technologies).  Cultures were passaged once per week and medium was changed the 
day after passaging and every three days afterwards.  All culture vessels were coated with 
poly-L-lysine (Sigma P9155) to facilitate cell attachment.  For protein transduction, cells 
were plated in poly-L-lysine coated 6-well plates and allowed to expanded 4-6 days until 
80-90% confluent.  The iPSC-derived Gaucher and WT neurons were generously provided 
by the lab of Ricardo Feldman and were differentiated and cultured as previously described 
(Panicker et al., 2012; Panicker et al., 2014).   
4.3.3. Expression of recombinant glucocerebrosidase 
 All recombinant GCase enzymes were expressed using transient transfection of 
HEK 293F suspension cells (Life Technologies).  Four expression and harvesting schemes 
were utilized varying length of protein expression and culture scale.  HEK 293F cells were 
transfected at 1E6 cells/mL with 30mL in 125mL vented non-baffled shake flasks 
(Corning) and 120mL in 500mL vented non-baffled shake flasks (Corning).  Large scale 
plasmid preps were performed using the Endotoxin-Free Megaprep Kit (Qiagen).  Cultures 
were transfected with 1µg plasmid DNA for each 1E6 cells in culture.  Plasmid DNA was 
complexed with 2µL 293fectin reagent (Life Technologies) per µg DNA for 30 minutes at 
116 
 
room temperature before addition to the culture.  Complexes were prepared using 
OptiMEM serum-free medium containing GlutaMax (Life Technologies).  All HEK 293F 
culture work was performed using Freestyle 293 medium (Life Technologies).     
 Transiently transfected batch cultures were maintained at 37ºC and 8% CO2 for 48 
hours or 96 hours.  Samples of culture medium and cells were taken during batch culture 
expression to determine ideal harvest time and whether the extracellular medium, soluble 
lysate, or insoluble lysate contained the most GCase.  Batch cultures were harvested by 
centrifuging at 3500 RPM for 10 minutes at which time cell-free culture medium was 
removed and stored at 4ºC until purification.  The cell pellet was washed with 1X PBS pH 
= 7.4, centrifuged again, and frozen at -80C until ready for cell lysis and protein 
purification.  All 30mL expression batch cultures were purified directly.  Unless otherwise 
stated, medium from the 120mL cultures was first concentrated ~5-10x using Amicon Ultra 
50,000 dalton molecular weight cutoff centrifugal filters.  This medium concentration was 
done to facilitate resin binding with a reasonable volume for the resin bed volume.  Medium 
was not concentrated before the scaled-up purification performed to assess substrate 
accumulation and reduction.   
4.3.4. Purification of recombinant glucocerebrosidase 
 Following protein expression, culture medium or concentrated culture medium 
containing the expressed GCase was stored at 4ºC until ready for purification.  For select 
GCase enzymes that were not secreted, cell pellets were lysed with 1mL MPER non-
denaturing lysis buffer (Pierce) for each 100mg cell pellet according the manufacturer’s 
recommended protocol.  Proteins were purified using Ni-NTA Resin (Pierce) and three 
buffers, all with the same 1X PBS pH=7.4 base (20mM sodium phosphate, 300mM sodium 
117 
 
chloride).  Equilibration buffer, Wash Buffer, and Elution Buffer were each pH = 7.4 and 
contained 10mM, 25mM, and 250mM imidazole respectively.   
 The protein purification method used was a combination of standard batch and 
column purification methods.  An equal volume of cold Equilibration Buffer was added to 
medium or soluble lysate, up to a 44mL final volume, and the solution was added to a 
washed 0.5mL bed volume of Ni-NTA resin and bound overnight at 4ºC for ~20-21 hours.  
Following overnight binding in batch mode, the resin suspension was equilibrated to room 
temperature, at which time the resin suspension was slowly poured into a 5mL column to 
pack the resin bed.  The flow-through solution was poured over the resin bed two additional 
times and allowed to empty by gravity flow at a rate of approximately 1mL/min.  Each 
resin bed was washed three times with 1mL, two resin bed volumes, of Wash Buffer.  The 
GCase was eluted off the column with three separate 1mL volumes of Elution Buffer.  
Before flowing off the column by gravity flow, each column was capped and the Elution 
Buffer was allowed to sit on the resin bed for five minutes.  All purification samples were 
run on 4-12% SDS-PAGE gels and stained with SimplyBlue Safestain (Life Technologies).  
Total protein in GCase-containing elutions was quantitated by Bradford Assay (Thermo 
Scientific).  The specific GCase concentration was determined by densitometry using the 
ImageLab 3.0 (Biorad) software.  All elutions containing reasonable amounts of purified 
GCase were supplemented with 1mg/mL BSA and stored at 4ºC until use.   
4.3.5. Glucocerebrosidase activity assay 
 GCase enzyme activity was determined using a 0.1M acetate assay buffer pH = 5.0 
containing 3mM 4-MUG (4-Methylumbelliferyl β-D-glucopyranoside), 0.15% (v/v) Triton 
X-100, and 0.15% (w/v) taurodeoxycholic acid sodium salt (Calbiochem).  Purified GCase 
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or cell lysate was added to the activity assay buffer and incubated at 37ºC for one hour.  
The reaction was stopped with the addition of a 2X volume of 0.2M glycine buffer pH = 
10.8.  Product 4-methylumbelliferone was detected using the Victor 3 fluorimeter (filter 
set excitation = 355nm, emission = 460nm).  Black 96-well plates were typically used 
although initial work was performed with white 96-well plates.  The 4-
methylumbelliferone detection is highly linear between 10nM-10µM in the black 96-well 
plate and between 10nm-5µM in the white 96-well plate.  Enzyme activity units are defined 
as nmol 4-methylumbelliferone released per hour.         
4.3.6. Assessing glucocerebrosidase binding and internalization 
 Due to the large number of recombinant GCase vectors constructed, initial 
screening of GFP-containing recombinant GCase binding and internalization was 
accomplished with protein transduction of GCase following by live-cell imaging of the 
GFP fluorescence.  NPCs were treated with 1µg/mL enzyme in NPC starting medium for 
18 hours.  After the overnight incubation, cells were washed 3X in NPC starting medium 
without growth factors or heparin and immediately imaged using the Axio Observer Z1 
Motorized fluorescent microscope (Carl Zeiss Inc., Oberkochen, Germany).  An analogous 
procedure was performed for the iPSC-derived Gaucher neurons with the exception that all 
washing was performed with complete medium.   
 Quantitative assessment of GCase binding and internalization was performed using 
GCase-knockout mouse neurons (Sidransky Lab) for recombinant GCase enzymes that 
showed promise in initial screening.  All experiments included the appropriate wild-type 
controls for each of the two cell types.  GCKO and WT mouse neurons were plated in poly-
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L-lysine coated 6-well plates and cells were allowed to expand 4-6 days until 80-90% 
confluent.  Duplicate wells were used for each treatment condition.   
Cells were treated with 12µg/mL recombinant enzyme overnight for 18 hours at 
which time the cells were extensively washed with 1X PBS to remove excess protein.  Cells 
were harvested from well plates using TrypLE Express (Life Technologies) and lysed using 
MPER non-denaturing cell lysis buffer (Pierce).  Lysate protein concentrations were 
determined by Bradford Assay (Thermo Scientific).  Enzyme activity in the cell lysates 
was determined by adding lysate to the 0.1M acetate assay buffer and incubating at 37ºC 
for one hour.  Experiments used different amounts of lysate depending on lysate 
concentration.  Final concentrations ranged from 10-20µg/100µL with a total volume of 
200-300µL per reaction.  Standard curves for each recombinant enzyme were generated to 
quantitate the concentration of enzyme detected in the lysate.  Units of enzyme activity in 
the lysate were calculated using a 4-methylumbelliferone standard curve.   
4.3.7. Assessment of glucosylsphingosine reduction using LC-MS/MS 
 To assess glucosylsphingosine accumulation and potential reduction with protein 
treatment, immortalized GCKO and WT mouse neuronal cultures were plated in poly-L-
lysine coated 6-well plates and allowed to expand four days until ~80% confluent.  To 
perform the complete experiment, 18 wells of GCKO cells and 6 wells WT cells were 
plated.  Four treatment conditions were planned: Tat-GCase treatment of GCKO cells, 
RDP-IgAh-GCase treatment of GCKO cells, an untreated GCKO control, and an untreated 
WT control.  Each treatment condition was performed in duplicate with each of the 
duplicates consisting of three pooled wells to ensure there was enough material collected 
to detect glucosylsphingosine accumulation.    
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 Tat-GCase and RDP-IgAh-GCase were expressed and purified using a scaled-up 
version of the procedure performed for assessing recombinant enzyme 
binding/internalization (previous section).  The transiently transfected flask was scaled up 
4X; 120mL culture was transfected in a 500mL non-baffled shake flask.  Purification scale 
up was performed to keep protein concentration similar to the small scale procedure 
throughout the purification process.  This was done since concentration of protein had been 
found to reduce enzyme activity (Figure 4.3).  BioRad Econo-Pac polypropylene 
chromatography columns with a 15mm internal diameter were chosen so a 2mL resin bed 
would have the same bed height compared to when the 5mL columns were used in the 
smaller scale procedure.   
 Aside from the 4x scale-up of production and purification processes, one additional 
step was performed for the protein purification to investigate substrate accumulation and 
reduction; final 4mL elutions were desalted using Zeba 7kDa MWCO desalting columns 
with a 10mL resin bed (Pierce).  Buffer exchange was performed into 1X PBS pH = 7.4 
(Life Technologies).  Pilot experiments showed that while treatment of the GCKO mouse 
neuronal cultures with protein elution buffer for <24 hours was acceptable, cell loss was 
high with longer protein treatments.  The cell loss with extended treatment was found to 
result from the components of the elution buffer, likely the 250mM imidazole.  In a mock 
treatment experiment, dilution of medium with 1X PBS alone did not lead to any 
appreciable cell detachment and/or death.   
 After four days of cell growth, duplicate sets of wells were treated with either 10 
µg/mL protein diluted in fresh medium or fresh medium alone for untreated controls.  
Duplicate treatment conditions were performed for each of Tat-GCase and RDP-IgAh-
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GCase.  Every 24 hours, for 72 hours total, medium was exchanged, adding fresh protein 
or fresh medium only.  Following 72 hours of treatment, cells were washed 2X with 1X 
PBS pH = 7.4 and harvested by scraping.  PBS was removed by centrifugation and cell 
pellets were frozen at -80C.  Frozen cell pellets were shipped on dry ice to Cincinnati 
Children’s Hospital for glycosphingolipid analysis.  Lipid extraction and LC-MS/MS 
analysis of glucosylceramide and glucosylsphingosine accumulation was performed as 
previously described (Sun et al., 2012; Sun et al., 2013).  All quantitative glycosphingolipid 
data was normalized to total protein detected in the cell lysate.   
4.4. Results 
4.4.1. Protein expression and purification 
 A total of seventeen GCase expression vectors were created evaluating a number 
of different parameters including: the presence of a cell-penetrating peptide or neuronal 
delivery vector, the presence of GFP, the order of protein domains, and the linker regions 
between domains.  Besides varying design in one of the aforementioned categories, all 
expression vectors used pSecTag2a as the base and contained an IgK leader sequence at 
the 5’ end and a myc epitope tag and 6xHis tag at the 3’ end.  Of the 17 recombinant GCase 
enzymes expressed, only 3 failed to express correctly (Table 4.1).  Tat-TTC-GCase-GFP 
and RDP-GFP-GCase were expressed as smaller truncated forms at a high level.  A low 
level of full-length Tat-TTC-GCase-GFP was observed via western blot while no full-
length RDP-GFP-GCase was observed.  Tat-GCase-GFP-5xTet1 was the only enzyme to 
not be expressed at all.  GFP fluorescence was not even observed in the producer cells and 
no myc-containing bands were found in the supernatant or soluble lysate of the producer 
cells.   
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The IgK signal peptide facilitated the secretion of all enzymes (Figure 4.1) except 
for the TTC-containing TTC-GCase-GFP and Tat-TTC-GCase-GFP.  Interestingly, the 
~100 kDa truncated Tat-TTC-GCase-GFP fragment was secreted while the full length Tat-
TTC-GCase-GFP was found only in the soluble lysate.  TTC-GCase-GFP was expressed 
at a high level but found only in the soluble lysate of the producer HEK 293F cells.  
Secreted GCase was several kilodaltons larger than non-secreted GCase (Figure 4.1), a size 
difference consistent with differences in glycosylation (Berg-Fussman et al., 1993; Grace 
et al., 1994).  A size difference between secreted and intracellular GCase has been observed 
(Branco Novo et al., 2012).  GCase has five N-glycosylation sites, four of which are 
typically occupied in wild-type GCase (Shaaltiel et al., 2007; Tekoah et al., 2013).  Proper 










Figure 4.1: The IgK signal peptide facilitated efficient GCase secretion for most 
engineered enzymes.  Predicted molecular weights (polypeptide only): Tat-GCase: 66.1 
kDa, RDP-Tat-GCase: 70.7 kDa, RDP-Flex-GCase: 69.7 kDa, RDP-IgAh-GCase: 71.1 
kDa, and RDP-Rigid-GCase: 71.2 kDa.  Following transient transfection, cell-free medium 
and HEK 293F soluble lysate were run on 4-12% NuPage Bis-Tris gels and a western blot 
was performed for the myc epitope tag.  For each condition, samples collected both two 
and four days after transfection were run.  Three-fold more cell-free supernatant was run 
on the gels compared to soluble lysate to account for the at least 3x more concentrated 
soluble lysate.  The results shown for the five enzymes were typical for all the secreted 
glucocerebrosidases.  Extending batch duration increases the quantity of secreted protein 
in the extracellular medium but does not increase the quantity of protein in the soluble 
lysate.  
 
 All proteins were purified using HisPur Ni-NTA resin (Pierce).  While all proteins 
co-purified with a number of other proteins, the band of interest was dramatically 
concentrated (Figure 4.2A).  Recombinant GCase is not visible in the supernatant via SDS-
PAGE and Simply Blue Safestain (Life Technologies) before purification.  Along with the 
assessment of enzyme activity, product quality for all purified proteins was confirmed via 
SDS-PAGE and Simply Blue Safestain (Figure 4.2A) and anti-myc western blot (Figure 
4.2B).  Final yield of purified GCase was calculated by first performing a Bradford assay 
to determine total protein and then densitometry to account for the impurities in the final 




Figure 4.2: Purification of Tat-GCase and RDP-IgAh-GCase.  The main elutions for 
Tat-GCase (1) and RDP-IgAh-GCase (2) were run on 4-12% NuPage Bis-Tris SDS-PAGE 
gels.  SimplyBlue Safestain was used to examine total protein in the elution (A) and an 
anti-myc western blot (B) was utilized to confirm the location of the purified GCase on the 
gels.  Both Tat-GCase and RDP-IgAh-GCase were found ~75 kDa, a size consistent with 
their predicted molecular weight and glycosylation.  Comparable SDS-PAGE gels exist for 
all purified proteins referenced in Table 4.1.   
 
For practical reasons, all parameters were not varied with all delivery domains and 
linker regions utilized in the construction of the recombinant enzymes.  However, since 
there is quite a bit of overlap among the design of the recombinant GCase enzymes (Table 
1), a number of inferences regarding the effect of enzyme design on expression level and 
activity can be made.  First, commercial product Cerezyme (Genzyme Corp.) had a specific 
enzyme activity that was ~3.5X higher than the most active novel enzyme described here.  
The higher activity of Cerezyme is due, at least in part, to its increased purity (Van Patten 
et al., 2007).  Second, the presence of CPP Tat or the CPP-containing neuronal delivery 
domain RDP at the N-terminal end of an expressed glucocerebrosidase appeared to 
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improve the level of expression consistent with previously described attempts at 
recombinant GCase expression (Lee et al., 2005; Vaags et al., 2005).  CPP VP22 has also 
been shown to enhance GCase expression (Jin et al., 2012).  Third, the only full-length 
GCase to not be secreted, TTC-GCase-GFP, was the least active enzyme by far.  Fourth, 
while most enzymes were expressed fairly well, a select few were expressed at lower levels 
with final elutions containing <10 µg/mL purified protein.  Fifth, there does not seem to be 
any correlation between protein expression level and enzyme specific activity.  Finally, the 
presence of GFP decreased both production yields and specific activity.  Specific activity 
was decreased by a greater degree than what would be expected due to the difference in 
molecular weight alone.  Due to the decrease in activity and yield, after the design of the 















Summary of Recombinant GCase Activity and Expression Level 
GCase Specific Activity (U/mg) Expression Level 
Cerezyme 1.28E+05 N/A 
RDP-GCase 3.67E+04 Acceptable 
Tat-GCase-GFP-Tet1 3.26E+04 Low 
Tat-GCase 3.24E+04 Acceptable 
Tat-5xTet1-GCase-GFP 2.79E+04 Low 
RDP-Rigid-GCase 2.53E+04 Acceptable 
RDP-Flex-GCase 2.46E+04 Acceptable 
RDP-Tat-GCase 2.24E+04 Acceptable 
GCase (Fishman Lab) 2.04E+04 Low 
Tat-GCase-GFP 1.99E+04 Acceptable 
Tat-Tet1-GCase-GFP 1.81E+04 Acceptable 
RDP-IgAh-GCase 1.78E+04 Acceptable 
RDP-GCase-GFP 1.53E+04 Acceptable 
Tet1-GCase-GFP 1.23E+04 Low 
TTC-GCase-GFP 5.95E+03 Acceptable 
Tat-TTC-GCase-GFP N/A Expressed in Truncated Form 
RDP-GFP-GCase N/A Expressed in Truncated Form 
Tat-GCase-GFP-5xTet1 N/A Not Expressed 
 
Table 4.1: Summary of GCase enzyme activity and protein expression efficiency data.  
Seventeen recombinant GCase enzymes plus commercially available Cerezyme (Genzyme 
Corp) are listed in the table.  Enzymes are listed in order of specific activity given as units 
enzyme per mg recombinant protein.  One U is defined as the amount of enzyme to release 
1 nmol 4-methylumbelliferone per hour.  Except for the three enzymes that were not 
appropriately expressed, expression levels were found to be approximately bimodal where 
a select group of enzymes were expressed at a low level with final yields of 10 µg/mL or 
less.  Other recombinant GCase enzymes were typically purified at yields several fold 
higher.  Specific activity values represent the average of all preparations of each listed 
enzyme.   
 
4.4.2. Production scheme impacted enzyme yield and activity 
 Four different production schemes utilizing transient transfection of HEK 293F 
suspension cells were used to express the recombinant GCase enzymes.  For practical 
reasons, all production schemes were not tested for all enzymes.  Figure 4.3 illustrates how 
production scheme affected the yield and activity of Tat-GCase.  Production schemes 
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included: 1) Two days of batch growth for a 30mL culture, 2) Two days of batch growth 
for a 120mL culture, 3) Four days of batch growth for a 30mL culture, and 4) Four days of 
batch growth for a 120mL culture.  The larger scale cultures were concentrated 5-11x by 
centrifugal filtration before binding the Ni-NTA resin.  At harvest, culture viabilities were 
consistently ~90% for the 48 hour batches and ~60-70% for the 96 hour batches.   
 
Figure 4.3: The effect of production scheme on Tat-GCase production yields and 
specific activity.  Production schemes included: 1) Two days for a 30mL culture, 2) Two 
days for a 120mL culture, 3) Four days for a 30mL culture, and 4) Four days for a 120mL 
culture.  Before purification, the medium from 120mL batch cultures was concentrated 5-
11x by centrifugal filtration.   
 
 For small scale experiments, production scheme #3 was found to be preferable.  
While the final product was less active than scheme #1 or #2, far less transfection reagent 
was used and more than enough enzyme was obtained to screen enzyme activity and cell 
binding/internalization.  However, the highest quality and most active final product was 
achieved with the shorter production time.  Longer production time with the medium 
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concentration led to a much less active final product; as a result, production scheme #4 was 
deemed unacceptable for use despite delivering the highest yields by far.     
4.4.3. Assessment of recombinant GCase binding/internalization using fluorescent 
microscopy 
 Since initial purification yields were low and the number of recombinant GCase 
candidates was numerous, initial screening of neuronal binding and internalization was 
performed by treating NPCs with 1 µg/mL purified protein and using fluorescent 
microscopy to compare GFP fluorescence (Figure 4.4).  Qualitatively, NPCs bound similar 
amounts of Tat-GCase-GFP and TTC-GCase-GFP.  For NPC binding, Tet1 alone was 
insufficient, nor did Tet1 provide any enhancement in combination with Tat.  In fact, 
combinations of Tat and Tet1 were bound/internalized by NPCs less than Tat-GCase-GFP 
itself.   
 Protein transduction and imaging of GFP fluorescence was repeated in iPSC-
derived Gaucher neurons generously provided by Dr. Ricardo Feldman, University of 
Maryland Baltimore.  While imaging individual neurons was challenging due to the cell 
clustering, a qualitative comparison was possible.  Proportionally to Tat-GCase-GFP, Tet1-
GCase-GFP was bound by neurons better than it had been by NPCs.  However, Tet1 alone 
was not better than Tat, nor was any combination of Tat and Tet1.  GFP fluorescence in 
the TTC-GCase-GFP treated Gaucher neurons was qualitatively the brightest.  However, 
TTC-GCase-GFP was not secreted and had much lower enzyme activity than the other 
enzymes produced (Table 4.1).  Additionally, TTC would be highly immunogenic in vivo; 




Figure 4.4: Qualitative comparison of recombinant glucocerebrosidase binding and 
internalization in both Neural Progenitor Cells (NPCs) and iPSC-derived Gaucher 
neurons.  Cells were treated for 18 hours with 1 µg/mL purified protein, thoroughly 
washed, and imaged live using the Zeiss Axio Observer Z1 fluorescent microscope.  400X 
fluorescent images were taken with a Zeiss AxioCam MRm monochrome camera (1.3 
megapixel, 12 bits/pixel) using the C-Apochromat 40x/1.2 W Korr objective.  The 




 A Tet1-containing construct, Tat-5xTet1-GCase-GFP, tested the hypothesis that 
multiple repeats of the 12 amino acid Tet1 peptide might lead to enhanced neuronal cell 
binding.  NPCs were treated with Tat-Tet1-GCase-GFP and Tat-5xTet1-GCase-GFP in 
parallel and GFP fluorescence was qualitatively compared.  In combination with Tat, 
additional Tet1 repeats did not appear to offer any binding advantage (data not shown).  
Furthermore, additional Tet1 repeats led to several-fold lower levels of protein expression.   
4.4.4. Quantitative assessment of RDP-containing GCase binding and 
internalization in a GCase-knockout mouse neuronal cell line 
 While initial screening using the qualitative comparison of GFP fluorescence 
following the protein transduction of GFP-containing GCase enzymes successfully ruled 
out Tet1 as a GCase delivery vector, it was clear that a more quantitative method was 
required for future work.  The advantage of the imaging studies was the low concentration 
of protein needed; 1 µg/mL treatment concentrations led to visible GFP fluorescence after 
18 hours.  To quantitate intracellular GCase activity, both higher purified protein yields 
and a cell line with low wild-type GCase activity were required. 
 Quantitatively, recombinant GCase enzymes without GFP and with either Tat or 
RDP at the N-terminus were evaluated as these attributes tended to give high protein 
expression, enabling treatment of cells with at least 12 µg/mL purified protein.  Initial pilot 
studies tested whether NPCs were a suitable cell line for quantitative work and they were 
not due to high background wild-type GCase activity.  While iPSC-derived Gaucher 
neurons had very low wild-type activity and were an interesting scientific model, the 
number of cells required made this cell option expensive and less ideal.   The ideal cell 
type for this work proved to be a SV40-transformed glucocerebrosidase-knockout mouse 
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neuronal cell line generously provided by Wendy Westbroek and Ellen Sidransky (NIH, 
Bethesda, MD).  Pilot studies indicated that this cell line had very low wild-type GCase 
activity and preferentially bound RDP and TTC-linked recombinant GFP proteins. 
 For the first RDP-GCase enzyme created, the 39 amino acid RDP peptide was 
inserted in place of Tat in the Tat-GCase construct.  RDP and GCase were separated by 
only two amino acids, Thr-Gly, due to the presence of the AgeI restriction site used in 
subcloning.  The first quantitative experiment performed with the GCKO mouse neurons 
compared the uptake of Tat-GCase, RDP-GCase, and Cerezyme following an 18 hour 
treatment with 12 µg/mL purified protein.  Enzyme uptake was compared two ways: the 
concentration of active GCase harvested in cell lysate and the activity of GCase found in 
the cell lysate.  The concentration of enzyme internalized was determined using standard 
curves of each purified GCase.  While standard curves were approximately linear between 
50-400 ng/mL purified enzyme, a second or third order polynomial best fit the curve.  
Specifically a second order polynomial fit was used for this initial experiment while, with 
more data points, a third-order polynomial fit was used for all subsequent experiments.  
Due to the higher activity of Cerezyme, comparing concentration of active internalized 
enzyme is the fairest comparison of enzyme delivery.   
 Unexpectedly, RDP-GCase was not delivered preferentially compared to Tat-
GCase, and by concentration, both RDP-GCase and Tat-GCase were internalized only 
marginally better than Cerezyme in the GCKO mouse neuronal line (Table 4.2).  Both were 
able to deliver 3% of wild-type SV40-converted mouse neuron GCase activity.  This result 
was inconsistent with our observation that, in neuronal cell types, RDP improves 
recombinant protein delivery considerably compared to Tat (Mello et al., in preparation), 
132 
 
leading to the hypothesis that, in this  first generation RDP-GCase recombinant enzyme, 
RDP folding or binding was sterically hindered.   
 




Normalized to  
Tat-GCase 
Percent WT Activity 
Delivered 
Tat-GCase 135.74 1.00 3.07 
RDP-GCase 118.90 0.88 3.02 
Cerezyme 98.53 0.73 23.09 
 
Table 4.2: Comparison of GCase detected in GCKO mouse neuronal cell lysate 
following protein treatment with 12 µg/mL recombinant GCase.  RDP was not found 
to improve GCase binding and internalization.  Neither Tat nor RDP facilitated 
significantly better protein transduction efficiency compared to commercially available 
Cerezyme (Genzyme Corp).  For all enzyme assays, 20 µg lysate was added per 100 µL.    
 
4.4.5. Linker region design is critical to facilitate RDP-mediated neuronal delivery 
of glucocerebrosidase 
 Since we had thoroughly established that RDP-GFP preferentially binds neuronal 
cell types compared to Tat-GFP without a linker region, it was clear that while a linker 
region between RDP and the recombinant protein of interest is not required in all 
circumstances, it might be imperative for GCase.  The first attempt at relieving this 
hypothesized steric hindrance was to create RDP-GFP-GCase, where GFP would be 
utilized as the linker region.  While the eventual goal would have been to engineer a small 
peptide linker region, effective RDP-GFP delivery predicted that GFP would be an 
effective linker region to test the steric hindrance hypothesis.  However, since RDP-GFP-
GCase was expressed only in a truncated form (Table 4.1), the small peptide linker region 
design was attempted. 
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 The four linker regions inserted between the Thr-Gly two amino acid sequence and 
RDP were Tat, a flexible linker region (Flex), a linker region derived from the flexible 
hinge region of IgA (IgAh), and a highly alpha-helical linker region (Rigid).  The RDP-
Tat-GCase enzyme was created since Tat has the length of a typical linker region, 11 amino 
acids, and most importantly, there was a high degree of confidence that Tat would not 
interfere with protein expression.  The flexible linker region selected was GGGSGGGS.  
Although shorter than most flexible linkers, this 8-amino acid linker was used successfully 
in the construction of RDP-linked recombinant proteins (Fu et al., 2012).  The IgAh linker 
region is a typical example of proline-rich semi-rigid linker regions that are commonly 
used (Bhandari et al., 1986; Evans et al., 1986; Li et al., 2009; Low et al., 1976; Turner et 
al., 1993).  Finally, the rigid A(EAAK)4A 22 amino acid linker was selected for its highly 
alpha-helical structure, ensuring a known amount of space between RDP and GCase (Arai 
et al., 2001).   
 Along with Tat-GCase as the control, each of RDP-Tat-GCase, RDP-Flex-GCase, 
RDP-IgAh-GCase, and RDP-Rigid-GCase were expressed and purified.  Using production 
scheme #3 with four days of expression, all expressed well with final yields from ~40-70 
µg/mL.  All new RDP-linked enzymes had comparable specific activities ranging from 
1.78E4 to 2.53E4 U/mg (Table 4.1).       
 Duplicate wells containing GCKO mouse neuronal cells were treated with 
12µg/mL of purified Tat-GCase or one of the RDP-Linker-GCase enzymes for 18 hours at 
which time the cells were harvested, lysed, and protein content of the lysates was 
quantitated.  Identical quantities of lysate were added to MUG-containing assay buffer and 
4-methylumbelliferone fluorescence was compared.  Fluorescence from GCase-treated 
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samples was normalized using untreated GCKO cell lysate.  The percentage of wild-type 
activity delivered was calculated using untreated wild-type mouse neuronal cell line lysate.  
The concentration of GCase found in the lysate was calculated by preparing standard 
curves of each purified GCase.   
 The concentration of GCase detected in the cell lysate was compared for all RDP-
Linker-GCase enzymes (Figure 4.5).  RDP-IgAh-GCase performed the best, as 2.65X more 
RDP-IgAh-GCase was delivered to the GCKO neurons compared to Tat-GCase.  Tat-
GCase was bound/internalized better than both RDP-Flex-GCase and RDP-Rigid-GCase.  
Although RDP-IgAh-GCase is a less active enzyme than Tat-GCase, 2.52X more enzyme 
activity was delivered to the GCKO cells representing ~10% of wild-type activity.  This 









Figure 4.5: The impact of linker region on RDP-Linker-GCase binding and 
internalization in GCKO mouse neurons.  The concentrations of GCase detected in the 
cell lysates for each treatment condition were quantitated and subsequently normalized to 
Tat-GCase to facilitate comparison.  RDP-IgAh-GCase was internalized 2.65X more than 
Tat-GCase.  All bars in the above graph represent the average of duplicate treatment 
conditions.   
  





(Normalized to Tat-GCase) 
Percent WT 
Activity Delivered 
Percent WT Activity Delivered 
(Normalized to Tat-GCase) 
Tat-GCase 67.08 1.00 3.94 1.00 
RDP-Tat-GCase 106.71 1.59 5.89 1.50 
RDP-Flex-GCase 39.77 0.59 1.32 0.34 
RDP-IgAh-GCase 177.68 2.65 9.92 2.52 
RDP-Rigid-GCase 51.29 0.76 1.74 0.44 
     





(Normalized to Tat-GCase) 
Percent WT 
Activity Delivered 
Percent WT Activity Delivered 
(Normalized to Tat-GCase) 
Tat-GCase 29.75 1.00 1.87 1.00 
RDP-IgAh-GCase 66.18 2.22 4.45 2.38 
 
Table 4.3: Data compilation for the two independent experiments quantitating GCase 
activity in GCKO mouse neuronal cell lysate following a 18 hour protein treatment 
with 12µg/mL purified protein.  All data points in the above tables represent the average 




4.4.6. Reduction of glucosylsphingosine accumulation with Tat-GCase and RDP-
IgAh-GCase treatment 
 Production and purification processes were scaled up 4X to produce enough Tat-
GCase and RDP-IgAh-GCase to perform the substrate accumulation and reduction 
assessment.  Each scaled up production process was performed in duplicate to produce 8x 
the final protein typically generated.  This was accomplished; final protein concentrations 
and purity were similar to the smaller scale process.  Desalting and buffer exchange did 
not lead to any loss of purified enzyme however activity was reduced.  Although the 
reduction in activity was unexpected and unwanted, removal of the 250mM imidazole was 
necessary for treatments spanning multiple days.   
 The GCKO mouse neuronal cell line was expected to accumulate 
glucosylsphingosine but not glucosylceramide (W. Westbroek, personal communication).  
This expected result was confirmed; GCKO cells accumulated GlcSph ~60X more than 
WT cells while no accumulation of GlcCer or any GlcCer species was observed in the 
GCKO cells (Figure 4.6).  Treatment with both Tat-GCase and RDP-IgAh-GCase was 
found to reduce accumulated glucosylsphingosine to essentially wild-type levels (Figure 




Figure 4.6: Treatment of GCase-Knockout (GCKO) immortalized mouse neuronal 
cell line with Tat-GCase or RDP-IgAh-GCase dramatically reduces 
glucosylsphingosine (GlcSph) accumulation.  Duplicate sets of three wells were treated 
with 10µg/mL purified protein or fresh medium only for 72 hours with complete medium 
changes every 24 hours.  For each triplicate treatment condition, wells were pooled for 
analysis.  Accumulated GlcSph was quantitated using LC-MS/MS analysis and data was 
normalized to the total protein detected in the cell lysate.  Duplicate GlcSph data points 
presented in the table were averaged for graphical display.   
 
4.5. Discussion 
 The development of RDP-IgAh-GCase potentially represents a significant advance 
in recombinant protein therapeutics for neuronopathic Gaucher’s disease therapy.  In 
pursuit of developing an effective neuron-targeted recombinant GCase, seventeen different 
recombinant enzymes were designed and expressed.  Parameters that were varied in 
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recombinant protein design included the type of cell penetrating peptide or neuronal 
membrane binding vector, the presence of GFP, the order of the different functional 
domains N-terminus to C-terminus, and the type of linker region used between protein 
domains.  Recombinant proteins were designed in stages where results from each set where 
employed to optimize the design of subsequent sets of proteins.  There was enough overlap 
in the sequences of the recombinant enzymes to make a number of observations regarding 
recombinant GCase design and expression.  All of the recombinant GCase enzymes 
expressed and successfully purified had specific activities at least 3x lower than 
commercially available Cerezyme (Genzyme) using the in vitro activity assay with 
synthetic substrate 4-MUG.  Due to this difference in enzyme activity, all protein 
incubation conditions of cells were set up by enzyme concentration instead of enzyme 
activity, a treatment paradigm that has been used with some GCase delivery work (Lee et 
al., 2005).  It is highly likely that increasing the purity of our GCase would improve enzyme 
specific activity as protein aggregation would be reduced (Van Patten et al., 2007).  
Improving production yields and purity after protein purification are two important future 
goals in this work.   
 The second observation made was that the presence of cell-penetrating peptide Tat 
or cell-penetrating peptide-containing RDP improved protein expression.  The 
improvement of GCase expression with inclusion of CPPs Tat and VP22 has been 
previously observed (Jin et al., 2012; Lee et al., 2005; Vaags et al., 2005) although the 
mechanism involved is not currently known.  Comparing the production of the GFP-
containing recombinant GCase enzymes can provide insight on this observation.  
Interestingly, while Tat-GCase-GFP, Tat-Tet1-GCase-GFP, and RDP-GCase-GFP all 
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expressed well, Tet1-GCase-GFP did not.  Although Tet1 is similar to the size of the Tat 
peptide, it is not highly cationic.  In fact, Tat-Tet1-GCase-GFP was the only Tet1-
containing enzyme to be expressed at comparable levels to Tat-GCase-GFP or RDP-
GCase-GFP.  The only Tat or RDP-containing enzymes to express poorly also contained 
Tet1 (Table 4.1).  Wild-type GCase did not express nearly as well as any of the Tat-GCase 
or RDP-GCase enzymes.  Overall, at this time, it can only be concluded that a CPP N-
terminal to GCase improves production.  Although the absence of Tat or RDP at the N-
terminus leads to lower production, it does not lead to lower enzyme activity.  There does 
not appear to be any clear relationship between expression level and enzyme activity (Table 
4.1).   
 Many of the initial GCase expression vectors were designed with a GFP at the C-
terminus of the GCase sequence.  The motivation for this design was the desire to perform 
initial screening for cell binding with low concentrations of protein, using fluorescent 
microscopy before using more quantitative methods to assess binding and internalization.  
While initial screening was performed for the first set of variants (Figure 4.4), most 
subsequently designed enzymes were made without a GFP.  This decision was based on 
two observations: GFP-containing enzymes had lower expression levels compared to their 
counterparts without GFP and GFP-containing enzymes had lower specific activities than 
even predicted by their greater molecular weights.   
 While the initial evaluation of GCase binding and internalization via GFP 
fluorescence was not a perfect system, it was suitable for eliminating Tet1 from further 
evaluation for GCase delivery.  Qualitatively, Tet1-GCase-GFP was not delivered as well 
as Tat-GCase-GFP nor did the addition of Tet1 with Tat give any appreciable advantage 
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over Tat alone in either NPCs or iPSC-derived Gaucher neurons (Figure 4.4).  Furthermore, 
work in our lab using model protein GFP indicated that Tet1 could not facilitate delivery 
to NPCs as well as Tat, TTC, or RDP (Mello et al., in preparation).   
 While TTC-GCase-GFP did not appear to be bound or internalized better than Tat-
GCase-GFP in NPCs qualitatively, it did improve binding with the iPSC-derived Gaucher 
neurons.  While this was an interesting observation regarding the neuronal properties of 
NPCs, it did not make TTC our preferred delivery vector for GCase.  TTC-GCase-GFP is 
also potentially problematic for in vivo delivery due to the presence of highly immunogenic 
TTC.  Furthermore, TTC-GCase-GFP was not secreted during production.  While purifying 
the protein from soluble lysate was not an issue, we observed that proteins harvested from 
the soluble lysate were several kDa smaller than their secreted counterparts.  TTC-GCase-
GFP was by far the least active enzyme purified, possibly due to decreased post-
translational modification.  N-glycosylation at the first of the four occupied sites, at amino 
acid #19, is critical for full catalytic activity (Berg-Fussman et al., 1993).  
 RDP seemed to be the most promising protein delivery vector for the neuronal 
targeting of GCase on the basis of its small size, low potential antigenicity, and high level 
of neuronal binding.  Along with the published literature (Fu et al., 2012; Fu et al., 2013b), 
experience in our lab indicated that model protein RDP-GFP could be delivered to neural 
progenitor cells ~9X better than Tat-GFP and ~46X better than Tet1-GFP (Mello et al., in 
preparation).  Along with the promising pilot binding studies, expression of RDP-GCase 
was high, nearly identical to Tat-GCase.  However, our initial recombinant RDP-GCase 
was unexpectedly not bound or internalized preferentially to Tat-GCase (Table 4.2).  The 
first pTagRDP_GBA expression vector was constructed like the pTagTat_GBA, where the 
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RDP sequence replaced the Tat sequence with only a two amino acid linker region 
separating the delivery peptide from the GCase sequence.  We hypothesized that RDP was 
sterically hindered by GCase, and that introduction of a linker region would allow RDP to 
appropriately bind its receptor(s).  Four additional RDP-GCase enzymes were designed, 
each with a differently linker region.  The flexible, semi-rigid IgAh, and rigid linker regions 
were chosen based upon potential structure, while Tat was selected as a linker region to 
ensure that at least one of the RDP-Linker-GCase enzymes expressed well.  We were 
unsure what affect the addition of space between RDP and GCase would have on 
expression level.  Although expression levels did vary for the RDP-Linker-GCase variants, 
all expressed fairly well.  Enzyme activity was comparable for all variants ranging between 
1.78E4 – 2.53E4 U/mg (Table 4.1).  Linker region length did not appear to affect enzyme 
activity as RDP-IgAh-GCase and RDP-Rigid-GCase were the least and most active linker-
containing enzymes respectively.  Overall, RDP-IgAh-GCase was found to be bound and 
internalized preferentially compared to Tat-GCase and all the other RDP-Linker-GCase 
variants.  While there are review articles describing the effect of linker region on 
recombinant protein design (Chen et al., 2013; George et al., 2003; Zhang et al., 2009) this 
work with RDP-GCase is a rare description of the impact of a variety of linker region 
classes on enzyme functionality and delivery.  This work also indicates what while RDP 
has a lot of potential to mediate the neuronal targeting of cargo proteins, steric hindrance 
of RDP by the cargo protein is an issue.  While the IgAh linker could be useful for all RDP-
based delivery, it is possible that linker region will need to be evaluated on a protein-
specific basis.   
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 The 19 amino acid IgAh linker, PVPSTPPTPSPSTPPTPSM, was first used by 
Hallewell and colleagues in 1989 to link superoxide dismutase (SOD) subunits for the 
purpose of making functional polymers.  The IgAh linker was chosen in an attempt to 
reproduce the partially flexible linkage between Fab and Fc portions of IgA (Hallewell et 
al., 1989).  Our collaborators have used it previously to facilitate the expression of a 
recombinant TTC-GDNF in a baculovirus expression system (Li et al., 2009).  The IgAh 
linker closely mimics a class of relatively common proline-rich linker regions (Bhandari et 
al., 1986; Evans et al., 1986; Turner et al., 1993).  Proline has been found to be the most 
preferred amino acid in linkers during linker region analysis.  Proline-rich sequences adopt 
less secondary structure since proline does not hydrogen bond with other amino acids 
leading to a more extended confirmation (George et al., 2003). 
 The development of RDP-IgAh-GCase is the creation of the first recombinant 
glucocerebrosidase capable of effectively binding neurons with the potential to cross the 
blood brain barrier.  There have only been two publications describing the delivery of 
GCase using methods other than mannose-directed endocytosis.  As described, Lee et al. 
created GCase-Tat and demonstrated that it was delivered preferentially to type 1 and type 
2 Gaucher fibroblasts.  While it was suggested that GCase-Tat could be used for types 2 
and 3 GD therapy, delivery of GCase-Tat to neurons was not demonstrated.  This 
publication is the first to describe the binding and internalization of Tat-GCase in a 
neuronal cell type.  The well-known ability of Tat to move cargo proteins across the BBB 
makes Tat-GCase more promising for neuronopathic Gaucher’s disease therapy than 
mannose-terminal recombinant GCase (Schwarze et al., 1999).  However, results presented 
here indicate that Tat might not provide much of a binding advantage.  Besides the creation 
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of Tat-GCase, a receptor-dependent delivery strategy was employed for facilitating the 
passage of GCase across the BBB.  Apolipoproteins B and E capable of mediating 
lysosomal enzyme delivery across the BBB have been tested and compared to Tat 
(Böckenhoff et al., 2014; Spencer et al., 2007).  Specifically, ApoB has been used to deliver 
GCase across the BBB.  ApoB can bind the low-density lipoprotein receptor (LDLR) and 
mediate transcytosis of cargo protein across the BBB (Spencer et al., 2013).  While it can 
transport proteins across the BBB, it does not target the GCase to neurons once in the CNS.   
 RDP-IgAh-GCase has the potential to not only target neurons, but to transport 
GCase across the BBB.  The potential to cross the BBB adds a straightforward and non-
invasive treatment scheme in addition to direct infusion.  In an effort to improve delivery 
of enzyme to deep brain structures such as the basal ganglia, direct IC injection of GCase 
using the low pressure infusion parameters of convection enhanced delivery (CED) have 
been investigated in large animals.  This method results in high concentrations in brain 
regions adjacent to the infusion site; evidence of enzyme in a vesicular location was 
observed (Lonser et al., 2005; Lonser et al., 2007).  CED was employed to attempt to treat 
an infant with acute neuronopathic GD.  Although the patient tolerated the treatment with 
some degree of stabilization, distribution of the injectate suggested that multiple intra-
cerebral injections would be needed to for widespread brain treatment even using CED 
(Lonser et al., 2007).  In a small study, 3 patients with GD underwent intra-
cerebroventricular infusion of GCase.  As with intra-cerebral injection, failure of this 
therapy was due to lack of neuronal binding of this unmodified commercial enzyme 
(Erickson et al., 1997). 
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 The final goal of the presented work was to demonstrate that the active GCase we 
delivered to the GCase-knockout mouse neuronal cell line was functional and capable of 
reducing accumulated substrate.  While enzymatically active RDP-IgAh-GCase and Tat-
GCase were detected in cell lysate, we aimed to show that following receptor-mediated 
endocytosis, sufficient enzyme was trafficked to the lysosome to reduce GlcSph 
accumulation.  Proteins were treated for 72 hours, a treatment time chosen based on both 
in vitro and in vivo GCase treatment literature (Cabrera-Salazar et al., 2010; Panicker et 
al., 2012).  When the protein-treated and control cells were analyzed by LC-MS/MS to 
quantitate GlcSph, the GCKO neuronal cell line was found to accumulate ~60X more 
GlcSph than the WT cells and both RDP-IgAh-GCase and Tat-GCase treatment reduced 
GlcSph accumulation to essentially wild-type levels.  This result fully confirmed that we 
had delivered active, functional recombinant enzyme.  In 2010, Cabrera-Salazar and 
colleagues demonstrated that three consecutive daily intra-cerebroventicular injections of 
reformulated Cerezyme reduced GlcCer and GlcSph levels to wild-type concentrations in 
the neuronopathic Gaucher’s disease K14 mouse model (Cabrera-Salazar et al., 2010).  
Substrate reduction in vivo has the potential to be even more efficient with a neuron-
targeted recombinant GCase instead of one that is internalized via mannose-directed 
endocytosis.   
4.6. Conclusions 
Recombinant RDP-IgAh-GCase has exciting potential as a therapeutic for 
neuronopathic Gaucher’s disease due to both its neuron-targeting properties and potential 
to cross the BBB.  RDP-IgAh-GCase was bound/internalized ~2.5 fold over control protein 
Tat-GCase and both enzymes were found to reduce substrate glucosylsphingosine 
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concentrations to wild-type levels in a GCase-knockout mouse neuronal cell line.  In future 
work, both RDP-IgAh-GCase and Tat-GCase merit in vivo testing to determine their 
therapeutic potential in Gaucher’s disease animal models.  Additionally, while a transient 
expression system was invaluable for the production of multiple GCase variants in the work 
presented here, moving forward, improved production and purification processes will be 
pursued both to support in vivo testing and facilitate scale-up to meet increased protein 















Chapter 5: Conclusions 
5.1. Review of Findings 
 This thesis dissertation work aimed to develop novel protein therapeutics for 
neurological diseases including Parkinson’s disease and neuronopathic Gaucher’s disease.  
The two most important achievements of this research were the discovery and 
characterization of the Tat-TTC protein delivery vector and the development of RDP-IgAh-
GCase, the first neuron-targeted recombinant glucocerebrosidase with the potential to cross 
the BBB.  While our goal to develop a protein-treatment method for dopaminergic neuronal 
differentiation was not met, that research project generated a number of interesting results 
including the finding that a new in vitro translation system can express soluble transcription 
factors at a high level.   
 The motivation for Chapter 2 was to develop an improved neuron-specific protein 
delivery vector.  Although such a vector could have multiple uses, one particular idea and 
motivation for the work was to improve the delivery of transcription factors for the 
differentiation of NPCs.  The hypothesis was that because cell-penetrating peptide Tat and 
neuronal binding polypeptide TTC bind neuronal membranes through different 
mechanisms, the combination of the two could facilitate more efficient protein delivery 
than either Tat or TTC alone.  Model protein GFP was used since its fluorescence leads to 
straightforward methods of detection.  Tat-GFP, TTC-GFP, and Tat-TTC-GFP were 
delivered to NPCs, N18-RE-105 neuroblastoma cells, and 3T3 mouse fibroblasts to 
determine whether Tat-TTC-GFP was preferentially bound or internalized, and whether or 
not this binding was neuronal cell type-specific.  Binding and internalization was 
quantitated in NPCs using direct fluorimetry.  After 18 hours of 20 µg/mL protein 
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treatment, cells were lysed and protein found in the lysate was quantitated.  Tat-TTC-GFP 
fluorescence was easily detected while Tat-GFP and TTC-GFP fluorescence was below the 
limit of detection.  Using conservative estimates and assuming the maximum amount of 
Tat-GFP and TTC-GFP were in the lysate, below the limit of detection, Tat-TTC-GFP was 
found to be bound or internalized at least 83 fold better than Tat-GFP and at least 33 fold 
better than TTC-GFP.  This result was confirmed using fluorescent image quantitation.  In 
NPCs and N18-RE-105 neuroblastoma cells, Tat-TTC-GFP was taken up at least an order 
of magnitude better than Tat-GFP or TTC-GFP where as in 3T3 cells, no preferential 
binding was observed.  This result indicated that Tat-TTC-GFP is both an improved protein 
delivery vector and neuronal cell type-specific.   
 Future plans for our protein delivery vectors, including Tat-TTC, included a variety 
of intracellular compartments.  The protein delivery vectors were taken up by endocytosis 
and the majority of delivered cargo was retained in endosomes following uptake.  Although 
this is fine for lysosomal protein delivery, to deliver cargo to cytosolic or nuclear targets, 
we needed to find a way to facilitate cargo redistribution.  Using the TPPS2a photosensitizer 
and light delivered by the 4X objective of a Zeiss fluorescent microscope, PCI was 
mediated leading to clear release of GFP into the cytosol.  Some cytotoxicity was expected 
with PCI because it involved the rupture of membranes, therefore, LDH assays were 
performed to ensure that PCI could be mediated with reasonable cytoxicity.  While full 
endosomal rupture was too cytotoxic, a substantial quantity of protein could be released 
without excessive cell death.   
 Chapter 3 covered the attempt to produce functional transcription factors to mediate 
dopaminergic neuronal differentiation.  The long-term plan for this project was to develop 
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a library of reprogramming factors that could be used with a variety of source cells.  To 
start, we chose to produce Mash1, Lmx1a, and Nurr1 based on a paper that used lentiviral 
delivery of these three factors to transdifferentiate human fibroblasts to dopaminergic 
neurons (Caiazzo et al., 2011).   A number of technologies developed in the Tat-TTC 
project were utilized in Chapter 3.  Since our initial goal was to deliver recombinant factors 
to fibroblasts, the Tat delivery vector was chosen over Tat-TTC.  Furthermore, since the 
intracellular target was the nucleus, PCI was used to redistribute endocytosed cargo from 
the endosomes.   
 Both Tat-Nurr1 and Tat-Nurr1-GFP expressed at very low levels; the quantity of 
protein produced was insufficient for any experimentation.  Unpublished attempts in the 
Fishman Lab to express Nurr1 were unsuccessful, so our issues with Nurr1 expression in 
mammalian cells were not unexpected.  Tat-Mash1, Tat-Mash1-GFP, Tat-Lmx1a, and Tat-
Lmx1a-GFP were all expressed, and the majority of the protein was found in the insoluble 
lysate.  Proteins were purified and shown to be taken up by NPCs via protein transduction.  
Using PCI, Tat-Lmx1a-GFP was delivered to the nucleus while for Tat-Mash1-GFP, 
nuclear delivery results were inconsistent.  Promoter-reporter vectors were utilized to show 
transcription factor functionality.  Only Tat-Mash1 was shown to be functional with co-
transfection of 3T3 fibroblasts, but all factors increased luciferase expression in SK-N-
BE(2)C cells.  This indicated that Tat-Mash1-GFP was less active than Tat-Mash1 and the 
Lmx1a reporter vector is cell type-specific.  Two protein treatment paradigms were 
attempted to demonstrate Tat-Mash1 protein functionality following reporter gene 
transfection.  While no increase in luciferase expression was observed following 1 µg/mL 
purified protein treatment, small increases were observed when Tat-Mash1-containing 
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soluble lysate was added.  This finding called the functionality of the resolubliized 
transcription factors into question.  Following this result, our efforts shifted to identifying 
a method to produce soluble transcription factor.  I identified the Pierce one-step HeLa in 
vitro translation kit as the best option; it was able to produce high concentrations of soluble 
Tat-Mash1 and Tat-Mash1-GFP.  This method will be critical for future work as it has the 
potential to address the two main roadblocks that limited the work in Chapter 3: the yield 
of soluble transcription factor produced and consequently, the dose that was given.   
 My work with protein delivery of transcription factors gave me an appreciation for 
the attributes of a recombinant protein that would be best for therapeutic delivery.  If a 
protein could be expressed in a soluble form, required endosomal/lysosomal targeting, and 
had a clear functional output, it would lend itself well to delivery using many of the protein 
delivery vectors I had either developed or gained experience with in the lab.  An interesting 
candidate for neuronal-targeted protein delivery emerged from an interest in developing 
PD therapeutics.  Mutations for the GBA1 gene encoding the enzyme glucocerebrosidase 
are the greatest genetic risk factor for PD.  Furthermore, many individuals with GBA1 
mutations have GCase deficiencies that lead to Gaucher’s disease.  While there are multiple 
FDA-approved large and small molecule therapeutics for the non-neuronopathic type 1 
GD, there is currently no therapy for types 2 and 3 with nervous system involvement.  As 
a result, I aimed to develop the first neuron-targeted GCase that would have potential for 
neuronopathic GD therapy.   
 Tat-GCase had previously been shown to be internalized by Gaucher fibroblasts 
several fold better than commercially available Cerezyme (Lee et al., 2005).  However, this 
result had never been shown in neuronal cell types.  In Chapter 4, I demonstrated that Tat-
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GCase was not bound or internalized by a GCase-knockout neuronal cell line much better 
than Cerezyme.  Numerous GCase-variants were produced before I identified and 
developed RDP-IgAh-GCase, a GCase variant that was found to be internalized ~2.5x 
more than Tat-GCase in the GCKO neuronal cells.  A 19 amino acid linker from the flexible 
hinge region of IgA was found to be critical to relieve steric hindrance of RDP by GCase 
itself.  Both Tat-GCase and RDP-IgAh-GCase were shown to reduce glucosylsphingosine 
accumulation in the GCKO neurons to wild-type levels.  RDP has been shown the ability 
to cross the BBB (Fu et al., 2012).  Moving forward, RDP-IgAh-GCase has considerable 
potential as a protein treatment for neuronopathic types 2 and 3 GD, and has the potential 
to be delivered non-invasively because the protein would be predicted to cross the BBB. 
5.2. Future Work 
5.2.1. Tat-TTC protein delivery vector 
 Research presented in Chapter 2 and in Gramlich et al., 2013 demonstrated that 
Tat-TTC is one of the highest capacity neuron-specific protein delivery vectors that has 
been described in the literature.  However, since TTC is highly immunogenic, Tat-TTC is 
limited to future in vitro applications.  Tat-TTC warrants consideration for in vitro protein 
delivery where the maximum intracellular dose is desired.  Although the larger size of Tat-
TTC may limit its protein expression, its dramatically improved binding would make its 
evaluation in any in vitro setting worthwhile.  There has already been a fair amount of 
interest in Tat-TTC from other labs for protein delivery, and other applications.  Recently, 
the lab of Jeffrey Friedman at Rockefeller University contacted the Fishman Lab for the 
plasmid DNA so they can use Tat-TTC’s improved binding for neuronal mapping.   
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 Tat-TTC could be modified in the future to enable it to be used as an in vivo protein 
delivery vector.  The most straightforward way to do this would be to substitute the 51 kDa 
C-terminal fragment of the heavy chain of Botulinum toxin for TTC.  While this 51 kDa 
fragment is still large and potentially immunogenic, individuals are not vaccinated against 
Botulinum toxin, a fact that makes TTC a non-starter for in vivo work.  The better option 
for in vivo delivery is likely RDP, a rabies-derived peptide that we have worked with 
extensively in this thesis research.  As it is a combination of a virus-derived neuronal 
binding domain and a polyarginine cell-penetrating peptide, RDP functions analogously to 
Tat-TTC except that RDP is much smaller and likely far less immunogenic than TTC.  The 
combination of a cell-type specific peptide and a receptor-independent cell-penetrating 
peptide is likely a promising formula for construction of cell type-specific protein delivery 
vectors for many cell types.   
5.2.2. Neuronal differentiation using protein delivery of transcription factors 
 As discussed at length in chapter 3, I was not successful in expressing and purifying 
recombinant transcription factors capable of reproducing the reporter gene induction 
observed with traditional co-transfection.  In chapter 3, I concluded that this was likely the 
direct result of not having a method to produce sufficient quantities of soluble transcription 
factor, and therefore, treating cells with only low protein doses.  Indeed, when I treated 
reporter-transfected 3T3 fibroblasts with Tat-Mash1 and Tat-Mash1-GFP containing 
soluble producer cell lysate, there was a small increase in reporter gene expression.  Future 
work mediating neuronal differentiation with purified recombinant factors must start with 
an expression system capable of high levels of soluble protein production.  In this thesis, I 
identified a mammalian in vitro translation system with the potential to meet this distinct 
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need.  While cell-free expression systems have limited scalability, they would be sufficient 
to support the development of protein-based neuronal differentiation technology.  Besides 
needing high concentrations of soluble transcription factor, the efficiency of differentiation 
is a critical issue.  Even if a protein-based differentiation procedure was developed, if it 
was too inefficient, it would not be able to generate the large number of cells needed for 
cell replacement therapy.   
 Two months before the completion of this thesis, the first paper describing a form 
of neuronal differentiation using recombinant transcription factors was published 
(Mirakhori et al., 2015).  In this article, a complex cocktail of small molecules, along with 
recombinant Tat-Sox2 and Tat-Lmx1a, was utilized to transdifferentiate human foreskin 
fibroblasts to dopaminergic progenitor cells capable of expanding and spontaneously 
differentiating into dopaminergic neurons.  This article, while extremely interesting, did 
have a few limitations.  First, there was no information given regarding efficiency, likely 
indicating efficiency was very low.  It is possible that this was due to limited functionality 
of their resolubilized transcription factors.  Second, the method was complex and involved 
a cocktail of small molecules as well.   
 The ideal method to generate replacement neurons or specialized dopaminergic 
neurons would be efficient, straightforward, and lead to high concentrations of fully 
differentiated neurons that would be safe for transplantation.  Two methods described in 
Chapter 3 have the potential to improve process efficiency: the in vitro translation system, 
and PCI to improve the nuclear delivery of the transcription factors following endocytosis.  
The feasibility of these two methods has been demonstrated in this thesis, but significant 
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work will need to be required to use them to develop an efficient protein-based 
differentiation scheme.   
5.2.3. The potential of RDP-IgAh-GCase as a therapy for neuronopathic Gaucher’s 
disease 
 RDP-IgAh-GCase is the first neuron-targeted recombinant GCase ever developed, 
and as a result, the enzyme has significant potential for use in enzyme replacement therapy 
for neuronopathic GD.  Chapter 4 described the preferential delivery and in vitro 
functionality of the enzyme.  Future work can facilitate the continued development of RDP-
IgAh-GCase including improving the production and purification schemes and 
demonstrating in vivo functionality.   
 The first goal of this work is to finish the in vitro characterization of RDP-IgAh-
GCase delivery.  One interesting result from the substrate reduction work is that both Tat-
GCase and RDP-IgAh-GCase reduced glucosylsphingosine accumulation to 
approximately wild-type levels.  Since I have reproducibly shown that RDP-IgAh-GCase 
treatment delivers more GCase and enzyme activity intracellularly, this result likely 
indicates that we delivered more Tat-GCase or RDP-IgAh-GCase than was necessary.  The 
GCKO mouse neuronal cell line needs to be treated with several concentrations of either 
Tat-GCase or RDP-IgAh-GCase to generate dose response curves.  The expected and 
probable result will be that a lower RDP-IgAh-GCase dose can clear the 
glucosylsphingosine substrate.   
 After the in vitro delivery work is completed and dose-response curves are 
generated, the next major goal of the project will be to evaluate the therapeutic effects of 
RDP-IgAh-GCase in neuronopathic GD mouse models.  Before the in vivo effects can be 
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evaluated, improved production and purification methods need to be developed.  As is done 
in the biopharmaceutical industry, I would propose that a stable mammalian cell line 
expressing high levels of RDP-IgAh-GCase be generated to maximize secreted protein 
production.  With a stable cell line, production could be scaled up and traditional 
bioprocess techniques could be utilized to considerably improve enzyme yields.  With 
higher yields, multiple purification steps could be performed to improve final product 
purity, and as a result, improve final product activity (Van Patten et al., 2007).  When the 
purified RDP-IgAh-GCase and Tat-GCase stocks were desalted, protein was not lost but 
activity was.  With higher yield and purity, purification schemes that do not reduce activity 
could be developed.  The design of the RDP-IgAh-GCase could be further optimized as 
well.  The Fishman Lab has shown that RDP can enhance GFP internalization ~9x more 
than Tat, indicating that perhaps the potential of RDP-mediated binding with GCase has 
not been fully realized (Mello et al., in preparation). 
 With more pure and higher RDP-IgAh-GCase yields, in vivo evaluation of RDP-
IgAh-GCase’s therapeutic potential could be performed.  The ideal mouse model for in 
vivo evaluation is the 4L;C* neuronopathic mouse GD model that has homozygous V394L 
GBA1 mutation and is null for GCase activator saposin C.  This mouse model was 
generated by our collaborator Dr. Ying Sun.  This mouse model has 4-10% of wild-type 
GCase activity that is particularly unstable due to the lack of saposin C.  The mice develop 
neurological symptoms at day 30 and die by day 48 (Sun et al., 2011).  Although their 
lifespan seems relatively short, it is considerably longer than the neuronopathic K14 GD 
model that has been used in phenotype correction research (Cabrera-Salazar et al., 2010; 
Cabrera-Salazar et al., 2012).  The 4L;C* model accumulates both glucosylceramide and 
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glucosylsphingosine and will allow the assessment of substrate reduction.  It will be critical 
to test multiple dosing strategies.  Intravenous delivery will need to be assessed since RDP 
has the potential to cross the BBB.  Also, direct brain infusion that has been performed 
with mannose-terminal GCase (Lonser et al., 2005), should be attempted.  It would be 
interesting to test whether RDP-IgAh-GCase therapeutic effects could be enhanced with 
the addition of small molecules therapies that were described at length in Chapter 1.  It has 
been suggested that small molecule therapies may be most effective in combination with 
some sort of enzyme replacement therapy (Cabrera-Salazar et al., 2012).   
 The final future direction for the RDP-IgAh-GCase work is to investigate alternate 
delivery strategies that still take advantage of the enhanced neuronal binding of the 
enzyme.  Work has already begun in the Fishman Lab in pursuit of this goal.  With the IgK 
signal peptide, the RDP-IgAh-GCase expression vector could be transfected into neuronal 
cells, secreted by producer cells, and taken up by a large proportion of surrounding cells 
due to the presence of RDP.  To this end, we have already constructed a third generation 
lentiviral expression system to test the feasibility of this idea.  The pursuit of genetic 
techniques to deliver RDP-IgAh-GCase does not mean that the protein delivery approach 
is not feasible or valuable.  RDP-IgAh-GCase has great potential for neuronopathic GD 
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 Assessed HCV protein NS3 function using site-directed mutagenesis and novel assays 
 
Pugh Laboratory, Pennsylvania State Univ. 
Undergraduate Researcher 
University Park, PA 
August 2002-May 2005 
 Performed undergraduate research in yeast transcriptional regulation 
o Created haploid Mot1 mutants for microarray analysis 
 Evaluated the effect of physical and chemical stresses on yeast strain survival 
 
 
Industry Research Experience: 
 
Merck & Co., Inc. 
Schering-Plough Corp. 
Assistant Scientist, Bioprocess Development 
Union, NJ 
October 2006-August 2010 
 Developed and optimized novel mammalian and bacterial cell culture production processes 
 Evaluated and selected CHO clones for high-yield and stable production of recombinant 
proteins including monoclonal antibodies 
 Scaled-up mammalian production processes from shake flasks to 2L bioreactors and 
subsequently to wave bioreactors and 500L bioreactors for preclinical production 
 Evaluated CHO cell line production stability and medium stability 
 Supported novel base and feed medium development using the Hitachi HPLC Amino Acid 
Analyzer 
 Collaborated with cell line development, purification, and bioanalytical groups to improve 
processes  




Johns Hopkins University 
Teaching Assistant, Transport Phenomena I 
Baltimore, MD 
Spring 2012 & Spring 2013
 Managed numerous responsibilities including planning and running the recitation sections, 
teaching class when the instructor was unavailable, grading all exams, and meeting students 
for extra instruction 
 
Huntington Learning Center 
SAT Math and Chemistry Tutor 
Doylestown, PA 
February 2006-September 2006 
 Tutored students using the HLC SAT Math lesson plans and served as the learning center’s 
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Professional Training Courses: 
 
Cellular Bioprocess Technology, University of Minnesota, 2008 
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